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ABSTRACT 
Biomimetic Porogen Freeform Fabrication and Biopolymer  
Injection Methods for Bone Tissue Scaffolds 
Lin Lu 
Jack G. Zhou, Supervisor, Ph.D. 
 
This research has explored and proved a novel structured porogen-based fabrication 
method for design and manufacture of bone scaffolds and replacements. This method has 
demonstrated highly efficient and reproducible fabrication of porous scaffolds and 
structured bone. In the materials study, molten Poly (ε-caprolactone) (PCL) and its 
composite of PCL with Calcium Phosphate (CaP) were selected as injected biomaterials 
for the scaffolds fabrication process.  By incorporating bioactive CaP into the scaffolds, 
the mechanical integrity and bioactivity of the scaffolds have been improved significantly.  
In the manufacturing system study, three Solid Freeform (SFF) systems (Drop on 
Demand Printing (DDP) system, Three Dimensional Printing system (3-DP) and a self-
designed biomaterial SFF system) were used to test the feasibility of the structured 
porogen method for bone scaffolds fabrication. Using the structured porogen method, the 
resolution of our fabricated scaffolds can be improved 2 to 4 fold compared to directly 
built method. This fabrication method allows us to use multiple biomaterials for injection 
molding with a single ubiquitous porogen. The structured porogen method can also 
provide the ability to make complex structures which mimic human bone tissue with 
sufficient mechanical strength. By combining this novel fabrication method with newly 
developed bio-composite materials, the tissue manufacturing technology can be highly 
advanced. 
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Specifically, by using the DDP system the mechanical properties of PCL and PCL-
CaP composite materials and their scaffolds were characterized; and cytocompatibility 
has been tested for both PCL and PCL–CaP scaffolds in vitro. It has been found that 
using 3-DP system gave us more flexibility to make various scaffolds with more material 
selections since the porogen materials used in the system has high melting point. By 
using 3-DP system, the cell-scaffold interaction was investigated; the degradation 
behavior of the PCL and PCL-CaP composite materials has been studied using weight 
loss measurement and High Performance Liquid Chromatography (HPLC); and the post-
degradation mechanical properties have also been examined. In the self-designed 
biomaterial SFF system, three kinds of nozzles were tested on the fabrication system. The 
final selected nozzle was then set to further variable study on flow rate and the strut 
diameter. The dominant factors for controlling the quality of the fabricated scaffolds have 
been determined. PCL scaffolds have been fabricated and tested using the newly 
developed SFF machine. In addition, endothelial hybridoma cells (EAhy 926) and 
osteoblasts (7F2) have been cultured on the fabricated PCL scaffolds for validating the 
biocompatibility of the scaffolds.  Cell viability studies have proven that the fabricated 
scaffolds are able to maintain the EAhy 926 and 7F2 cells in a healthy proliferating state. 
These results have demonstrated that the structured porogen fabrication method is 
capable to manufacture biocompatible, biodegradable and complicated porous bone tissue 
scaffolds efficiently and economically. 
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CHAPTER 1: INTRODUCTION 
1.1 From Tradational Bone Scaffold Replacement to Tissue Engineering  
Non-healing bone fractures are a major health concern in the United States because of 
a large aging population and increased occurrence of sport-related injuries. The rate of 
usage of bone grafting is increasing dramatically. Bone substitutes are playing a major 
role in repairing or replacing damaged or diseased tissue resulting from trauma, 
pathological degradation, congenital deformation, cancer and cosmetics [Yang, Hillas, 
Baez, Nokelainen and Balan, 2004; Cuckler, 2004 and Bock, Goode and Novartis, 2003].  
It was reported that over 1 million bone grafts implanted annually in US and Europe 
[Kelly, 2000] and over 500,000 bone-grafting procedures performed annually in the 
United States alone [Cutter and Babak, 2006].  
Two traditional ways used in bone disease treatment are autografting and allografting. 
The autograft, which is a section of bone taken from a patient’s own body, has been used 
for decades to supplement host repair, while an allograft is tissue harvested from one 
individual and implanted into another individual of the same species, usually taken from 
cadaver. Bone graft provides the structural stability and natural osteogenic behavior for 
patients, but both autograft and allograft failed to provide the optimum therapy and they 
have limitations [Giannoudis, Dinopoulos and Tsiridis, 2005 and Laurencin and 
Ambrosio, 1999].  
Autograft is expensive and the remaining tissue at the harvest site damaged by the 
removal of the graft, which often leads to donor site morbidity and raise problems of 
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restricted availability [Silber, Anderson and Duffner, 2003]. And there is limited amount 
of bone available for harvesting, besides that the characteristics in resorption of the graft 
cannot be easily predicted. Allograft often provokes an immunogenic response, can be 
rejected by the host and often need autograft tissue to initiate osteogenesis. Furthermore it 
may transmit disease. Although these methods are successful in some aspects, 
shortcomings are encountered with their usage [Gadzag, Lane, Glaster and Forster, 1995]. 
The main problem when using those standard treatments is the shortage of donor tissue 
limits the number of people who receive bone transplantations.  
To overcome the limitations, alternative methods have been developed to fabricate 
synthetic bone graft substituates which promote regeneration of feasible healthy bone, but 
till now no method has yet provided a satisfactory solution. As a result, researchers are 
turning toward the promising field of tissue engineering to develop new methods of bone 
regeneration. Tissue engineering is an interdisciplinary field that draws from materials 
science, cell biology, and biotechnology to synthesize effective strategies for repair or 
replacement of damaged or diseased tissues [Langer and Vacanti, 1993]. In tissue 
engineering, cultured cells and biomaterials can reproduce new tissues.Typically, in vitro 
bone tissue engineering uses engineered 3-D scaffolds [Mistry and Mikos, 2005], made 
of synthetic biodegradable polymers [Thomson, Mikos, Beahm, Satterfield, Aufdemorte 
and Miller, 1999] or bioceramics [de Groot, 1984; Ohgushi, Miyake and Tateishi 2003], 
as substrates for 3-D culture of osteoblasts or other applicable cell types. 
Today’s tissue engineering research and development could be done by providing a 
synthetic porous scaffold that mimics aspects of the body’s own extra cellular matrix 
(ECM), onto which cells attach, migrate, proliferate and function [Freyman, Yannas and 
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Gibson, 2001]. Typically, the donor tissue is harvested from the patient, then, the tissue is 
dissociated into individual cells. The cells are then seeded into a porous scaffold in a cell 
culture medium in vitro. The diseased or damaged tissue is removed and the scaffold with 
attached cells is implanted. Over time, the synthetic scaffold degrades into the body and 
the cells produce their own natural ECM [Chapekar, 2000; Freyman et al., 2001]. 
For bone tissue engineering, a scaffold is used to either induce formation of bone 
from the surrounding tissue or act as a carrier or template for implanted bone cells or 
other agents [Burg, Porter and Kellam, 2000]. Bone regeneration generally involves few 
critical components: a morphogenetic signal, host cells that will respond to the signal, a 
template of this signal that can deliver it to the damaged tissue then serve as a scaffold for 
the growth of the host cells, and a feasible, well vascularized host bed [Geiger, 2001]. 
Bone morphogenetic protein (BMP), a group of proteins responsible for a variety of 
events in embryogenesis and in postnatal skeleton, acts as the morphogenetic signal 
[Burg et al., 2000]. BMP causes pluripotential cells to differentiate into osteoblast, bone-
generating cells. The scaffold servers as a carrier of BMP or functions as a template for 
implanted bone cells or other agents, and it also supports ingrowth of capillaries and cells 
from the host into 3-D substrate to form bone [Coelho, 2005 and Saito, 2003]. Some 
scaffolds degrade at a controlled rate that is compatible with tissue ingrowth rate; the 
degradation products can be easily metabolized or excreted. At the end a new, completely 
natural bone tissue is formed in the place of scaffold [Burg et al. 2000, Klawitter and 
Hulbert. 1971]. 
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1.2 Basic Concept of Bone Tissue Engineering and Required Characteristics of Bone 
Scaffold 
The bone scaffold must meet certain requirements. The ideal bone scaffold should be 
biocompatible and osteoconductive, contain osteoinductive factors to enhance new bone 
ingrowth, and contain osteogenic cells to begin secreting new ECM. In general, the 
required characteristics of bone scaffold can be classified into four related aspects: 
1. Biological properties: The scaffold material must be biocompatible and promote 
cell adhesion, migration, and ingrowth. As the cells produce their own ECM, the 
synthetic matrix should degrade into nontoxic components that can be eliminated 
from the body [Freyman et al., 2001]. 
2. Internal porous structure: Both cell seeding and bone ingrowth normally are well 
developed with high porosity, typically among 50-90%. In general, the pore size 
falls within a certain critical range to promote cell seeding and ingrowth [Freyman 
et al, 2001 and LeGeros, Parsons, Decals, Driessen, Lee, Leu and Metger, 1988]. 
Both upper and lower bounds are computed by different factors. Cell size controls 
the lower bound; the specific surface area via the availability of binding sites 
decides the upper bound. Klawitter et al’s study showed that the optimal pore size 
for bone ingrowth is in the range of 100-250 μm [Klawitter et al., 1971]. Cell 
ingrowth and nutrients transporation are interconnected with the porosities. 
3. Mechanical properties: The primary bone tissue has relative high compressive 
strength that supports the body weight. So the scaffold must provide mechanical 
support during the reconstruction process. Mechanical integrity for the scaffold 
design has to be sufficient to resist handling during implantation and in vivo 
loading.  An ideal scaffold would be biomechanically similar to the type of bone 
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being replaced in order to function quickly as a synthetic bone replacement. The 
compressive modulus is in the range of 0.01 to 2.0 GPa for trabecular bone, and 
14 to 18 GPa for cortical bone [Athanasiou, Zhu and Wang, 2000]. The scaffold 
should be able to maintain sufficient mechanical properties until newly formed 
bone can assume a structural role and then the scaffold can be degraded and 
resorbed in the process of bone regeneration. Numerous studies have 
demonstrated profound effects of mechanical forces (strain) on cells using in vivo 
and in vitro models. Chen, Yannas and Spector [1995] found that the mechanical 
properties of the substrate are significant factors affecting biological response, as 
the mechanical environment of the contained cell is determined by these 
properties.  
4. Precise three-dimensional shape: The scaffold must be manufactured to an 
arbitrary complex 3-D shape which can match that of the tissue to be replaced, at 
both the microscopic and macroscopic levels.  
1.3 Current Needs in Tissue Scaffold Manufacturing  
From the perspective of length scale, bone has a complex varied hierarchical structure 
Bone is classified into different types at the macrostructure level: cortical bone (or 
compact bone) and cancellous bone (or trabecular bone).  At the microstructure level, in 
the scale of 10 to 500μm, there are Haversian systems, osteons and single trabeculae; and 
in the scale of 1 to 10μm there are sub-microstructure lamellae. Fibrilar collagen and 
embedded mineral are the nano-structural components at the scale of a few hundred 
nanometers to 1μm. Subnanostructures with size below a few hundred nanometers 
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consist of molecular structure of constituent elements such as mineral collagen and non-
collagenous organic proteins [Rho, Liisa and Zioupos, 1998; Mehta, 1995; Weiner and 
Traub, 1992 and Weiner and Wagner, 1998].  
Figure 1.1 illustrates the basic architecture of the bone [Rho et al., 1998]. The 
collagen fibers run parallel to each other to form laminae or lamellae. The lamellae can 
be arranged in concentric cylindrical layers in osteons, or parallel in the interstitial 
lamellae, outer circumferential lamellae or inner circumferential lamellae. Haversian 
systems and osteons constitute the main portion of compact bone, originated from a 
process of erosion initiated from the vascular channel towards the periphery and followed 
by a later centripetal deposition of concentric lamellar bone. Osteons are surrounded by a 
cement line as the result of bone resorption. The vascular channel of the center of the 
osteon is called a Haversian channel, and its diameter varies depending on the amount of 
lamellar bone deposited. Different osteons are mutually connected by radially oriented 
Volkmann channels. Blood vessels run inside the Haversian and Volkmann channels 
[Rho et al., 1998; Mehta, 1995; Weiner et al., 1992 and 1998].  
 The various scale structures perform various functions, i.e., mechanical, biological 
and chemical. In bone tissue engineering, the scaffold with biomimetic microstructures 
can be made in different bone types, such as trabecular or compact bone, however the 
structures at sub-micron and even smaller scales are the results of human body’s 
biological and chemical processing, and we don’t need and also cannot fabricate them. 
The artificial scaffold acts only as temporary ECM, and will be resorbed and remodeled 
by biological and chemical processes of human body to achieve completely natural bone 
tissue at the end of the recovery. Since the high mechanical strength requirement for 
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artificial cortical bone is difficult to reach for most biomaterials, our target tissue in this 
proposed research will be the highly porous non-load bearing trabecular bone.  
 
Figure 1.1 Basic architecture of bone [Rho et al., 1998]  
Because the porosity of the bone scaffold is very important, many manufacturing 
techniques and biomaterials were being used to control the pore size and porosity rate. 
New biocompatible materials and a number of fabrication technologies have been 
explored and developed to create synthetic bone grafts, which process biodegradable and 
biocompatible materials into a 3-D scaffold with high porosity and surface area 
[Hutmacher, 2000]. These technologies include Porogen Leaching, Fiber Bonding, Gas 
Foaming, Gel Casting, Solution Casting and Emulsion Freeze-Drying [Gadzag et al., 
1995; Chapekar, 2000; Mikos, Bao, Cima, Ingber and Vacanti, 1993; Harris, Kim and 
Mooney, 1998; Coombes and Heckman, 1992; Singhal, Agrawal and Athannasiou, 1996 
and Mooney, Baldwin, Suh, Vacanti and Langer, 1996]. In the above mentioned methods, 
although researchers have achieved significant progresses in making a porous scaffold for 
bone tissue engineering, many difficulties remain. Most of the above-mentioned methods 
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for fabricating 3D scaffolds are mainly used for laboratory testing purpose and are not 
computer controlled production process, placing substantial limitations on manufacturing. 
Consequently, the control of scaffold architecture, such as pore size, shape, porosity, and 
interconnectivity, using these fabrication techniques is still highly process driven, not 
design driven [Lee, Ryu, Lee, Hong, Chang and Lee, 2005]. And most of the above-
mentioned processes involve organic solvent or high temperature melting and sintering, 
which may denature bioactive factors such as BMP. In most methods, an internal porous 
structure generated by randomly packed porogen cannot be controlled precisely and 
flexibly. For example, the pore size and porosity at different sections of the scaffold 
should be different in many cases, and all the pores should be interconnected; however, 
these requirements cannot be obtained or guaranteed. Furthermore, most of the 
scaffolds/organs made through these processes have relatively low mechanical strength, 
which may lead to problems with implant failure and stress overloading. It is hard for the 
above mentioned techniques to produce the functional structure with defined morphology 
which is important for the regenerative tissue. A current limitation of commercializing 
scaffolds for bone repair is the lack of a manufacturing system capable of producing 
defined structures with a high degree of reproducibility [Gadzag et al., 1995 and 
Chapekar, 2000]. 
Solid freeform fabrication (SFF), also known as rapid prototyping (RP), is a new 
manufacturing technology that is capable of producing complex freeform parts directly 
from a computer aided design (CAD) model of an object. Recently, SFF has been used in 
direct fabrication of porous scaffold for tissue engineering [Geng, Feng, Hutmacher, 
Wong, Loh, Fuh, 2005; Taboas, Maddox, Krebsbach, and Hollister, 2003; Williams, 
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Adewunmi, Schek, Flanagan, Krebsbach and Feinberg, 2005; Hollister and Maddox, 
2002]. However SFF techniques still present various problems in materials, processing 
methods, and bionic requirements when making bone scaffolds. The main difficulty is to 
make highly porous parts with delicate internal structure, sufficient mechanical strength, 
and integrity. Some commonly used bone making materials, such as Hydroxyapatite (HA) 
and Calcium Phosphate Cement (CPC) are difficult to use directly with SFF methods, due 
to their low fluidity, poor strength, high processing temperature and long degradation 
time. In addition the usage of SFF to manufacturing scaffolds for tissue engineering is 
limited by the fact that SFF machines must be adapted to the fluid mechanical properties 
of each biomaterial under consideration. In most of SFF methods, the machine 
parameters must match the physical properties of the build material, such as viscosity and 
surface tension. These properties vary greatly amongst different biomaterials, precluding 
the use of a single machine for direct fabrication of scaffolds from multiple biomaterials, 
requiring more complicated multi-nozzle designs. Therefore, it is desirable to develop 
SFF fabrication processes in which a single, universal porogen material is used to build 
porogens (a negative pattern of bone and bone ECM) that may then be injected with a 
wide range of biomaterials.  
There were few researchers have worked on the porous scaffold making in the last 
decade using so called porogen method[Gadzag et al., 1995; Harris et al., 1998; Coombes 
and Heckman, 1992 and Mooney et al., 1996]. Most of them just used simple molds and 
injected with biomaterial, then used salt leaching, gel casting or gas forming to create the 
randomly packed pores. To distinguish with other researchers previously mentioned, our 
proposed structured porogen method uses SFF technique to fabricate structured porogen. 
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The porogen can be precisely designed by directly reconstruct CT and MRI images or 
CAD model. Then the porogen with complicated external shape and interconnected 
delicate internal structure can be manufactured using SFF techniques. Following the 
fabrication of the porogen, the biomaterials can be injected. After removal of the porogen, 
the scaffolds can be made. This proposed study can overcame the existing limitations to 
fabricate improved bone scaffold, by combining the advantages of SFF method, 
structured porogen design, and reverse injection of bioactive composite materials to 
establish an innovative bone and tissue manufacturing system. 
1.4 Objectives  
Currently a commercially available bone scaffold fabrication system for tissue 
engineering has not yet been developed. Even though SFF is a suitable fabrication 
method to generate bone scaffold, more investigations need to be carried on. The overall 
goal of this research is to prove a new general porogen mold method for tissue/scaffold 
fabrication and further to build a porogen-making machine for three-dimensional bone 
scaffold fabrication using biomaterials to study the effect of the processing, materials and 
structural design on the scaffold formation. The specific aims are: 
• To find a novel structured porogen method to generate tissue engineering 
scaffolds for bone in which  it utilizes SFF technique to build bone scaffold 
porogen and then use inject molding technique to extrude and cast the bio-
composite into the porogen to form bone scaffolds with predefined structures and 
sufficient mechanical strength. 
• To meet the materials needs for propogen method, we will conduct material 
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studies on the bio-composite material as a bone scaffold material in its 
solidification, mechanical properties, biodegradability, biocompatibility, and 
ability to support cell ingrowth to fit different porogen fabrication systems.  
• To conduct extensive biotesting for our structured porogen method fabricated 
PCL, PCL-CaP, CPC scaffolds on their biocompatibility, biodegradation and cell 
proliferation.  
• To solve the porogen making material’s biocompatibility, bioresorbability, 
manufacturability and fluidity problems, a sucrose porogen making machine will 
be invented and built in this research.  
1.5 Proposed Porogen Mold Method and Its Technical Advantages 
Briefly, the complete porogen mold bone fabrication method (Figure 1.2) consists of 
four steps.  1) Based on multi-planar images obtained from computed tomography (CT) 
or magnetic resonance imaging (MRI), the 3-D CAD model of bone tissue can be 
reconstructed. 2) Based on the CAD model of bone structure, a structured porogen can be 
designed and fabricated using SFF technology in stacking biocompatible sucrose or other 
materials. 3) A melted PCL (or other biopolymer) and CaP composite or liquid-like gel of 
calcium phosphate cement is then injected into the negative skeleton to form the desired 
bone scaffold. 4) The negative skeleton is removed by immersing the assembly of the 
composite and skeleton into water or other solvent, and then the skeleton is dissolved, 
leaving the bone scaffold.  
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Figure 1.2: Diagram of the main processes in the bone scaffold and tissue 
manufacturing system 
 
   
                        (a)              (b)     (c) 
Figure 1.3: A simplified illustration of structured porogen method for bone scaffold 
fabrication (note: for easy illustration a square shape is used): (a) structured 
porogen takes the majority of the volume; (b) biopolymer composite injected into 
the skeleton cavity; (c) after removing the porogen a thin wall fine structure scaffold 
is formed. 
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The porogen mold bone tissue fabrication method has the following uniqueness and 
advantages:  
1. Comparing with traditional bone treatments, our structured porogen method is 
more convenient to use, which allows for the use of a single building material in 
the SFF machine to fabricate multiple biomaterial scaffolds without recalibrating 
the SFF machine. 
2. Up to now, mechanical strength is a major drawback of artificial bone scaffold.  
The use of composites to improve the scaffold strength has been studied and 
recognized. By using composite materials, the composition of the composite 
scaffold can be adjusted to fit different requirements such as biodegradation rate 
and mechanical strength. In this research, composites of ceramics and polymer are 
selected as filling materials. Therefore the mechanical properties can be improved.  
3. The precise shape of the bone substitute scaffold is reconstructed through reverse 
engineering based on the CT or MRI images. The unique manufacturing 
capability of SFF enables us to make the negative skeleton with both the external 
shape and internal porous structure of the bone scaffold accurately, including 
spatial gradients in microstructure. 
4. The bone scaffold is required to be of high porosity. Such high porosity is very 
difficult to achieve by using SFF technology directly, because the fabricated part 
must have a solid-to-void ratio less than 10%, and the built porous structure 
cannot hold shape. Conversely, it is much easier to make an inverse-porous 
structure with the solid-to-void ratio of over 90%, in other words, to make the 
porogen of ECM. In this study, the porogen of bone ECM will be fabricated first, 
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then the CPC and biopolymer composite will be injected into the interconnected 
cavities to form the scaffold, and then the negative pattern will be removed to 
create porous structure (Figure 1.3). 
In this study, PCL and Calcium Phosphate (CaP) were chosen as the injective 
biomaterials. The innate rigidity of PCL makes this material well suited for the 
fabrication of tissue engineering scaffolds, mainly for orthopedic applications [Shin, 
Yoshimoto and Vacanti, 2004; Chen, Bei and Wang, 2000 and Rohner, Hutmacher, 
Cheng, Oberholzer and Hammer, 2003]. PCL was attractive also due to its low cost and 
sustained biodegradability although it is not bioactive [Kim, Knowles and Kim, 2003]. 
Calcium phosphate, a major constituent of native extracellular matrix in bone, has been 
widely used as a bone substitute or as coatings on metal implants in orthopedic and dental 
applications to accelerate bone reconstruction or skeletal fixation [Albee, 1920; Ruhe, 
Hedberg, Padron, Spauwen, Jansen and Mikos, 2003; Xu and Simon, 2004; Xu, Quinn, 
Takagi and Chow, 2004and Barralet, Grover, Gaunt, Wright and Gibson, 2002]. CaP is 
bioactive, so the osteoblasts can successfully attach with biological hard tissue. However, 
because it has relatively poor mechanical properties (it is a brittle material) CaP is not 
suitable for load-bearing sites or large bony defects. Incorporation of CaP into PCL 
would overcome the shortcoming of hydrophobicity of the PCL and the brittleness of the 
ceramic CaP. In our research CaP microparticles will be hybridized with PCL melting 
solution to make the PCL-CaP composite scaffolds.  With alteration in the CaP/PCL ratio, 
the morphology, mechanical properties, and biodegradation behavior were investigated.  
This process is able to design a bone scaffold that has the exact shape and similar internal 
structure of the bone tissue, and sufficient mechanical strength.  
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1.6 Thesis Outline 
The first chapter is a general introduction. The existing problems of current bone 
manufacturing techniques have been discussed. The proposed research has been 
introduced.  
 The second chapter of this thesis presents an overall review of the current available 
manufacturing methods on bone tissue scaffold fabrication; biomaterials used for tissue 
engineering applications, especially PCL, CaP and CPC; and indirect build method for 
bone fabrication. The reviews provided guidelines for development of the new structured 
porogen method for bone scaffolds fabrication.  
A study on structured porogen method for bone scaffolds fabrication using drop on 
demand printing (DDP) system is presented in chapter three. In this chapter the DDP 
system is introduced. To characterize the attainable resolution and to compare the 
structured porogen method with direct building method, a calibration block has been 
designed and studied. Design and fabrication of porogen and scaffolds are been presented.  
Porosity of the scaffolds has been analyzed using micro CT. The mechanical properties of 
composite materials and scaffolds have been tested and the obtained results have been 
compared with other researchers’ results. The biocompatibility of the scaffolds has also 
been studied.  
Chapter 4 focuses on the study of structured porogen method using a three 
dimensional printer (3DP). In this chapter, first the 3DP is introduced, and then the 
design and fabrication of porogen is presented. The fabrication of bone scaffold and a 
complex human femoral head are discussed. The biocompatibility of the fabricated 
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scaffolds has been tested and biodegradation tests of the composite materials have been 
performed.  
The fifth chapter introduces the development of a new fabrication system to fabricate 
our own developed sucrose porogen material, including the system configuration, motion 
control system and nozzle deposition system. In this chapter, the sucrose material has 
been studied including the rheological property, manufacturability and melting point. The 
flow rate of the micronozzle has been measured. The variable analysis of flow rate and 
strut size has been done. The design and fabrication of the sucrose porogen and 
biomaterial scaffolds are presented. The biocompatibility test of fabricated scaffolds has 
also been performed.  
The conclusions, recommendations and the future work of this thesis are presented in 
Chapter 6. 
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CHAPTER 2: LITERATURE REVIEW 
Bone tissue engineering is a rapidly growing interdisciplinary field which offers a 
promising new approach for bone repair [Liu and Ma, 2004].  One approach is to use 3-D 
porous, degradable, polymeric scaffolds, which serve as substrate for tissue regeneration 
and provide support while allowing the ingrowth of new tissue as the scaffolds degrade 
[Laurencin and Ambrosio, 1999 and Kneser, Schaefer, Polykandriotis and Horch, 2006]. 
In the reconstruction of bone tissue, various types of biomaterials and techniques are used.  
Compared to traditional autograft and allograft treatments, bone tissue engineering may 
help to overcome the problems related to donor site morbidity and size limitations and 
may also eliminate immune rejection [Liu and Ma, 2004; Kneser et al., 2006]. 
2.1 Bone Scaffold Fabrication Technologies 
2.1.1 Existing Processes for 3-D Bone Scaffold Fabrication 
Porogen leaching gives a microstructure similar to foam. This popular fabrication 
procedure is widely used to fabricate porous scaffold using biodegradable polymers. In a 
typical application, micro-spheres of mold (salt or gelatin) and polymer powder such as 
PLA (poly lactic acid) or PGA (poly glycolic acid) are mixed together, and then cast into 
a compression mold and sintered at certain temperature. At the above melting 
temperature of polymer, the remaining solid is then heated and the polymer particles are 
distributed more uniformly [Heijkants, Tienen, de Groot, Pennings and Buma, 2006 and 
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Freyman et al., 2001]. The porogen is then leached away by placing the prototyped part 
in water to form porous structure (NaCI is insoluble in PLA or PGA). By varying the 
composition and the size of porogen sphere, different foam with different porosity and 
pore size can be achieved [Ishaug and Grane, 1999]. Porosities in the range of 20-93% 
and pore sizes in the range of 30-120μm have been achieved with this technique. 
However, the pore shape is limited to the crystal shape of porogen such as the cubic 
crystal shape of salt, and the pores are always randomly distributed, in addition, the 
interconnectivity of the pores is always a question.   
The method of Fiber bonding has been applied to make matrices for attachment of 
liver cells (hepatocytes) [Mikos et al., 1993]. A non-woven mesh of PGA fibers was 
immersed in a chloroform solution of PLLA (poly-L-lactide, which is not a solvent for 
PGA) [Mikos et al., 1993]. After the solvent is evaporated, a PLLA and PGA network is 
formed.  The resulting PLLA-PGA composite is then heated at the temperatures above its 
melting point of PGA (at least 195°C for 90 minutes) to bond the fibers at their junctions. 
A porous scaffold of PGA is developed with the PLLA dissolved in methylene chloride. 
PGA is insoluble in these solvents to dissolve PLLA [Mikos et al., 1993].  
Gas foaming can be used to create a porous structure. In this method, carbon dioxide 
gas is dissolved in polymer under high pressure (800 psi) at room temperature, then 
depressurized and expanded to form bubbles. Scaffold with porosity of 93% and pore size 
of roughly 100μm have been made by gas foaming [Harris and Kim, 1998].     
Gel casting: In this method, polymer is first dissolved in a solvent such as acetone; 
and the solution is poured into a mold, and then allowed to cool at room temperature until 
it forms a gel [Agrawal et al., 1997 and 2001]. The gel is extracted by solvent exchange 
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in mixtures of acetone, ethanol and water to make microporous solid implant materials. 
These implant materials may also incorporate growth factors in the starting solution 
[Agrawal et al., 1997 and 2001]. 
Solution casting process for producing polymers comprises the following two steps:  
dissolve polymers in organic solvents and mold them into different shapes. In a typical 
application, a 50:50 copolymer of PLGA was dissolved in chloroform, precipitated with 
the addition of methanol, and combined with demineralized freeze-dried bone. The molds 
are kept at the temperatures of 45-48°C for up to 24 hours after the doughy composite 
material was forced into them. Meanwhile, the initial percent porosity of these implants 
was limited from 40 to 50 [Agrawal and Athanasiou, 1997]. 
Emulsion freeze-drying method dissolves biopolymer in methylene chloride or other 
organic solvent, to which deionized water was added, forming two immiscible layers. 
These layers were homogenized to form an emulsion with water as the dispersed phase 
and the polymer/solvent as the continuous phase. The emulsion was prepared in a copper 
mold and quenched quickly by putting it into a copper container maintained at near liquid 
nitrogen temperature. Once frozen, the sample was free-dried, and then placed in vacuum 
desiccator at room temperature for one week. With effects of varying processing 
parameters, such as water volume fraction (or percent), weight percent and molecular 
weight of polymer, polymer foam with different pore size and porosity had been achieved. 
The porosity was in the range of 90-99%, median pore diameters ranged from 13~35μm 
with larger pore diameters greater than 200μm, and the specific pore area was in the 
range 58~102m2g-1   [Mooney et al., 1996]. 
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Floating self-assembly method is employed by Liu et al. to prepare 3D colloidal 
crystals from polystyrene particles of various diameters (10-240 µm) [Liu, Wang, Lee 
and Kotov, 2005]. With ethylene glycol as the solvent, polymer colloidal particles are 
floating at the surface of ethylene glycol and self-assemble into a hexagonal crystal 
lattice structure. Solvent-free 3D colloidal crystals are formed after ethylene glycol is 
slowly evaporating. Human hepatocellular carcinoma HEP G2 and human bone marrow 
HS-5 cell have been cultured on the scaffolds to test the biocompatibility [Liu et al., 
2005].  
There are some other conventional scaffold fabrication methods, which are also 
investigated, such as injection molding, textile woven and so on.  In the above-introduced 
methods, although researchers have accomplished distinct progresses, there are still many 
problems in the bone scaffold fabrication. The internal porous structure cannot be 
controlled precisely due to the characteristics of the current processes. Most of the 
processes use organic solvent or high temperature injecting, which may modify the 
bioactive factors. In addition, most of the scaffold made through these processes does not 
have sufficient mechanical strength for the load bearing application. 
2.1.2 Solid Freeform Fabrication Used for Bone Scaffold Manufacturing 
Rapid prototyping (RP) and solid freeform fabrication (SFF) technologies employed  
for bone repair scaffolds construction as replacements for autografts and allografts has 
been receiving greater interest in the past few years [Geng et al., 2005; Starly, Fang, Sun 
and Regli, 2005; Williams et al, 2005; Taboas, 2003; Roy, Simon, Ricci, Rekow, 
Thompson and Parsons, 2003; Hollister et al., 2002]. As a new manufacturing technology, 
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SFF is able to produce freeform parts directly from a CAD model without part-specific 
fixturing or tooling. The CAD model can be designed using a large range of powerful 
CAD software or obtained through reverse engineering to reconstruct three dimension 
models from the data of CT, MRI or 3-D coordination measuring machine. This model is 
then transferred into STL file, using sets of triangles to represent the model surface. The 
STL model is sliced layer by layer with certain interval to get the profile of every section; 
the profiles of every section are further segregated into series of scanning lines or dots; 
based on this, numerical control codes are generated to control the machine [Yan, Wu, 
Zhang, Xiong and Lin, 2003]. 
SFF technology possesses several unique advantages that make it a powerful 
manufacturing tool for three dimension bone scaffolds. Firstly the 3-D CAD model of the 
bone tissue can be reconstructed precisely by reverse engineering software based on the 
data of computed topography (CT) and magnetic resonance imaging (MRI) system. The 
SFF machine can subsequently make the scaffold with any complex geometry in very 
high accuracy. This will significantly eliminate the problems caused by the mismatch 
between implant and remaining host tissue. Secondly, SFF technology makes parts in an 
additive fashion through layer-by-layer process. In each layer, materials can be added line 
by line, even dot by dot, so the internal structure of the porous scaffold can be controlled 
directly and precisely to meet any special requirements. For example, the arrangement of 
pores can be controlled to make gradient structure according to the biological 
requirements through CAD; the interconnectivity of the pores can be guaranteed through 
porous network design, which is critical for cell and vascular tissue ingrowths and 
nutrients supply. Thirdly, many different materials are available to make bones and 
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tissues by using SFF technology. The versatility of materials makes it possible to 
fabricate bone scaffold with biocompatible and bioresorbable materials. Lastly, SFF 
technology can be combined with other manufacturing technologies, such as powder 
metallurgy processes, casting processes or plastic injection modeling etc. that make the 
technology even more flexible to meet various bionic requirements.  
Because of the above-mentioned features of SFF technology, efforts have been made 
towards medical applications from the very beginning of the emergence of SFF 
technologies.  At the early stage, the medical applications of SFF technology ranged from 
design and building of medical implants and devices to preoperative plan tools for 
surgeons.  
2.1.2.1 Direct SFF Method  
Different SFF techniques have been used in the direct fabrication to construct porous 
bone scaffolds for skeletal part replacement [Sodian, 2000; Lange and Bhavnani, 1994; 
Porter, Pilliar and Grynpas, 2001].In the University of Texas at Austin, Carl Deckard and 
Joe Beaman used Selective Laser sintering process (SLS) to make customer artificial 
limb component [Sodian, 2000]. This method uses the laser as the energy source and 
selectively sinters the powder biomaterial layer by layer. The advantages of this 
technology include no extra support is needed and the finished part has good mechanical 
properties. The disadvantage is that the part is not accurate; especially it is hard to control 
the accuracy in z-direction.  
The stereolighography Apparatus (SLA) process uses a layer by layer solidification 
of resin to fabricate a part. In the University of Toronto, Canada, researchers fabricated 
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porous calcium polyphosphate (CPP) implants using SLA process, and evaluated the in 
vitro degradation characteristics of the scaffold. In their research, fine CPP powder were 
added to an UV curable monomer at solid loading of 25%(v/v), after the part had been 
made, it was sintered to remove the binder producing porous amorphous samples with 
average porosity of 27.7±2%, and further sintering produced crystalline samples with 
average porosity of 22.9±1.3%. In this research the porosity of the parts is too low for 
bone scaffold, and the remaining UV curable monomer will be a big problem [Porter et 
al., 2001]. 
In the National University of Singapore, efforts had been undertaken to make 3-D 
scaffolds of bioresorbable polymer using FDM process (Fused Deposition Modeling) 
[Hutmacher, 2000]. Polycaprolactone (PCL) or PCL/ hydroxyapatite (HA) filament with 
diameter of about 1.78mm fed into a temperature controlled extrusion head. The filament 
was heated to a semi-liquid state and thin line of fused polymer was extruded and 
deposited to form a 3-D part layer by layer. Parts with different lay-down pattern and 
various porosity as well as different pore geometry had been made with the porosity 
reaching as high as 75% [Hutmacher, 2000]. 
A Precision Extruding Deposition (PED) system, developed at Drexel University was 
used for fabrication of the bone tissue scaffolds [Shor, Gordon, An, Güçeri and Sun, 2006 
and Wang, Shor, Darling, Khalil, Sun, Güçeri and Lau, 2004]. The PED system utilizes 
the SFF technique. First bulk materials fed into a heated chamber are melted. The 
material in the chamber is forced down and out through the tip of the nozzle by the 
pressure from a rotating screw. After the hot melted material exits the extruder, the 
liquid-state material begins solidifying to form small diameter filaments. The extruder is 
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then moved up a layer thickness on the z direction and another layer is formed onto the 
previously completed layer. Polycaprolactone (PCL) and Hydroxyapatite (HA) composite 
tissue scaffold with 300 μm pores 65% porosity was directly fabricated using this system 
[Shor et al., 2006 and Wang et al., 2004].  
3-D Printing process (3DP) is also reportedly used to fabricate three-dimensional 
scaffold [Freyman et al. 2001; Park, Wu and Griffith, 1998]. This method spread a mixed 
powder of PLA or PGA into a powder bed with NaCl particulates and hydroxyapatite 
powder if needed. A single head nozzle then prints chloroform solvent over the powder 
layer. The chloroform serves as a binder by partially dissolving the polymer in the 
solvent. After the part is finished, the remaining chloroform is removed by drying and the 
salt is leached out by immersion in water. The porosity can reach up to 95%, and the pore 
size, controlled by the size of salt particles, is typically 100μm. Hydroxyapatite powder 
can also be possibly used in bone regeneration as a scaffold if it is incorporated into the 
initial mixture. However, this method has some limitations.  All solvents which can 
dissolve aliphatic polymer are highly toxic, such as chloroform, methylene chloride etc; 
therefore, non-toxic solvent need to be explored; the mechanical strength of this kind of 
parts are very low; the pore size by salt particles and the interconnectivity of pores is 
hardly controlled, and it is very difficult to get delicate internal structures [Park et al., 
1998].  
All of the above mentioned direct SFF techniques used for bone scaffold 
manufacturing are still in their initial developing stages and none is mature enough to be 
commercialized. They are all facing various problems in materials, processing methods, 
bionic requirements when making bone scaffolds. The desired porosity of bone scaffold 
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is at least 90%. However under this porosity, the mechanical strength will decrease 
dramatically, and it is difficult to make such porous and fine inner structures by directly 
stacking materials. In above-mentioned several SFF techniques, organic or inorganic 
binders are involved, which are usually toxic and not suitable for biological purpose. In 
some SFF processes such as SLS and SLA, laser beam heating and sintering are used, 
where the biomaterials are subject to high temperature damage or degradation.  
2.1.2.2 Indirect SFF Method 
SFF method has been also indirectly used for bone manufacturing by few research 
groups [Taboas et al., 2003; Limpanuphap and Derby, 2002; Manjubala, Woesz, Christin, 
Rumpler, Fratzl-Zelman, Roschger, Stampel and Frztzl, 2005; Chu and Halloran, 2000, 
Chu, Halloran, Hollister and Feinberg, 2001, Chu, Hollister, Halloran, Feinberg and 
Orton, 2002]. Chu et al. have developed an indirect building technology to produce HA 
based porous scaffolds [Chu, 2000, 2001, 2002].  A suspension of HA in acrylate was 
prepared first and the HA slurry was then poured into a mold fabricated using 
stereolithography. The injected mold was thermally cured. Then the mold was burned and 
the scaffold was sintered under high temperature [Chu, 2000, 2001, 2002]. The problems 
associated with this indirect method are: the resin mold was highly toxic; removal of the 
mold involves high temperature which will destroy the bioactive components in the 
scaffold.  
Limpanuphap and Derby fabricated tricalcium phosphate (TCP) scaffolds using the so 
called lost mold technique [Limpanuphap and Derby, 2002]. First a gel suspension of 
TCP in diacrylate cross-linking monomers was prepared. Then a mold was made using 
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Solidscape DDP system. The scaffolds were made by selective dissolution of the mold in 
acetone. They were heat treated for removal of the acrylic binder followed by sintering. 
In their study, toxic acetone solvent was used. The mechanical strength of the fabricated 
scaffolds was low, which can only be used for soft tissue or low load bearing purpose. 
The later heat treatment limits the usage of bioactive components in the scaffolds. And 
the scaffolds shrunk about 22%. The scaffolds were also distorted because of excessive 
heat evolution from the gelling suspension.  
Manjubala et al. also indirectly fabricated chitosan and hydroxyapatite scaffolds using 
the same Solidscape DDP system [Manjubala et al., 2005]. Chitosan was dissolved in 1% 
acetic acid and the HA powder was added in. Then the slurry was cast into molds and 
rapidly transferred into a freezer at -80°C to solidify the slurry. After that 10% alcoholic 
sodium hydroxide solution was used to dissolve the filled mold. Afterwards, scaffolds 
were then critical point dried with liquid carbon dioxide using a critical point dryer. Their 
pore size is around 500µm [Manjubala et al., 2005] and the mechanical strength of 
fabricated scaffolds is low.   
Taboas et al. have developed an indirect building fabrication method to produce PLA 
scaffolds [Taboas et al., 2003].  First premolds with defined global pores were made 
using Solidscape system. Followed by the ceramic/polymer casting, a ceramic/cement 
mold with global pore was fabricated. Then PLA in chloroform with NaCl or PLA melt 
grains were cast into the ceramic mold.  The solvent evaporated and the PLA melt was 
cooled. PLA scaffolds have been fabricated following the removal of the mold via acid. 
However, their fabrication process to make the scaffolds was very complicate and it is 
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not suitable for production. Toxic organic solvent and high temperature melt was 
involved. 
In the above mentioned indirect building techniques, although researchers have 
achieved significant progresses in making a porous scaffold for bone tissue engineering, 
many difficulties remain, for example, some biopolymers can be only dissolved in highly 
toxic solvent such as chloroform, methylene chloride etc; the mechanical strength is low; 
high temperature is involved; the distortion and shrinkage of the scaffolds and 
complicated fabrication method etc. 
2.2 Material Used for Bone Scaffold 
An important issue with regard to bone scaffolds is the choice of suitable material. 
Numerous materials have been used to replace injured bones. These materials include 
metals, ceramics, natural and synthetic polymers and their combinations [Ellisseeff, 
Puleo, Yang and Sharma, 2005]. Engineering alloys such as cobalt-chromium alloys, 
stainless steel and titanium alloy have been extensively used in bone replacement. 
Titanium knee and hip implants and poly lactic-co-glycolic acid (PLGA) screws have 
shown good success [Weiler, windhagen, Raschke, Laumeyer and Hoffmann, 1998 and 
Barber, Elrod, McGuire and Paulos, 2000]. Implants made of metals are quite sturdy, so 
they readily support the body’s load-bearing mechanisms. The benefits of using metals 
ensure their significant future use as orthopedic biomaterials [Wang, 2003]. But since 
they are much stronger than bone, metallic implants tend to stress shield bone, which 
leads to the erosion of the surrounding native bone. Over time, the implant loosens due to 
mechanical mismatch and stress shielding, and causes pain and suffering for the patient. 
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The multiple surgeries may be needed for metal implant [Mooney et al., 1996; Weiler et 
al., 1998 and Barber et al., 2000]]. 
Pharmaceutical and biomedical applications of biodegradable polymers have been 
popularized and widely extended recently in research and development [Weiler et al., 
1998; Freyman et al., 2001; Burg et al., 2000; Klawitter and Hulbert, 1971 and 
Athanasiou et al., 2000]. The advantage about these applications is that, as long as their 
intended purposes are fulfilled, surgical removal is not required [Blacka and Saunders, 
2005; Evans and Hunt, 2002; Shikinami and Okuno, 2001 and Rupp, Seil, Schneider and 
Kohn, 1999].  
Using bioactive materials can enhance bone growth. Guided bone tissue regeneration 
can occur due to the osteoconductive characteristics of certain ceramics, ceramic-glasses, 
and bioactive glasses. These bio-ceramics and glasses extend from being biologically 
stable to the bioactive and the bioresorbable, but their fragile nature restricts their uses. 
Ceramics lack the strength and flexibility of polymers, whose characteristics can change 
greatly simply by changing the polymer’s structure. Generally, synthetic polymers are 
biologically stable or bioresorbable, but not osteoconductive. An effort to obtain stiff yet 
osteoconductive material has been made by creating composites that contain both 
ceramics and polymers [Kellomäki, Niiranen, Puumanen, Ashmmakhi, Waris and 
Törmälä, 2000; Seal and Otero, 2001]. 
2.2.1 Ceramic Materials 
Calcium phosphate ceramics is one prominent class of biomaterials. Hydroxyapatite 
(HA), crystallized from calcium phosphate ceramics, is the major component of hard 
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tissue and bone. Those kind of biomaterials are biocompatible and osteoconductive. 
Plaster of Paris was first used as bone cement in 1892, and since that time, while various 
bone ceramic cements have been explored, ceramics with CaP have been used to repair 
bone fractures or plug bone defects [Reis and Cohn, 2002 and de Groot, 1984].  They 
promote bone ingrowth, are biocompatible and harden in situ. The most common types of 
calcium phosphate ceramics, hydroxyapatite (HA, Ca10 (PO4)6(OH) 2) and 
tricalciumphosphate (TCP, Ca3 (PO4)2) have different characteristics in vivo. In general, 
HA was found to be more osteogenic, while TCP was degraded much faster [Kokubo, 
Kim and Kawashita, 2003; Agrawal and Ray, 2001; Peter, Nolley, Widmer, Merwin, 
Yaszemski, Yasko, Engel and Mikos, 1997; Peter, Miller, Yasko, Yaszemski and Mikos, 
1998; Burg et al., 2000 and Wang, 2003]. 
2.2.1.1 HA 
One alternative for non-load bearing orthopedic functions is to utilize synthetic HA 
as filler [Ural, Kesenci, Fambri, Migliaresi and Piskin, 2000]. In contact with bone, 
synthetic HA often develops a mechanically tight bond with bone, which may be of 
chemical nature. Due to its biocompatible and osteoconductive behaviors, synthetic HA 
is widely used in the clinic as a bioactive material [Wang, 2003].  However, the most 
publicized success of HA is its use as a bioactive coating on total hip prostheses 
[Temenoff and Mikos, 2000; Laurencin, Attawia, Lu, Borden, Lu, Gorum and Lieberman, 
2001; and Chen et al., 1995]. HA scaffolds implanted into bone are gradually substituted 
with bone by an osteoconductive process; however, they are rigid yet fragile, so they 
have been found unsuitable to operate as different structural forms [Ural et al., 2000].  
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Some consideration has lately been given to combining HA with polymers in order to 
create composites that have better handling and retention properties and to overcome the 
problem of brittleness associated with ceramic bone repair implants by using the 
polymers as binders for particulate bio-ceramics [Ural et al., 2000; Kokubo and Kim, 
2003; Burg and Porter, 2000 and Wang, 2003].  
2.2.1.2 Bioglass 
Bioglass and A-W glass-ceramic are also bioactive bio-ceramic that have been 
successfully used for tissue replacement [Peter et al., 1998; Burg and Porter, 2000 and 
Wang, 2003]. Bioglass is a family of bioactive glasses that contain SiO2, Na2O, CaO and 
P2O5 in specific proportions. Bioglass has the capacity to bond to both hard and soft 
tissues, but its major inadequacy is mechanical weakness along with a low fracture 
toughness, which is caused by an amorphous two-dimensional glass network [Wang, 
2003]. Generally, bioglass is not appropriate for major load-bearing functions since its 
bending strength is 40-60 MPa. Glass can be made into a glass-crystal composite by 
being treated with heat; such a composite would have a crystalline phase of controlled 
sizes and contents, along with acceptable mechanical properties. A-W glass ceramic has 
much higher bioactivity than does sintered HA. The outstanding mechanical 
characteristics of A-W glass–ceramic has allowed it to be utilized clinically for both iliac 
and vertebrae prostheses, as well as intervertebral spacers [Wang, 2003]. 
2.2.1.3 CPC 
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CPCs has been successfully used as a bone substitute materials, especially widely 
used in orthopedic, reconstructive, and oral surgery because they promote bone-healing. 
In 1987, Brown and Chow reported the first CPC. Since then, both researchers and 
clinicians have explored CPCs, with some CPCs offered commercially [Klein, 1983 and 
Chow and Takagi, 2001] and are identified as an excellent biomaterial for osseous 
augmentation because of the unique osteoconductive, biocompatible and moldable 
behaviors. The Food and Drug Administration (FDA) approved CPC to repair human 
cranial defects in July 1996, making it the first such substance allowed to be used 
clinically [Chow and Takagi, 2001]. Continuing improvements in the technological 
properties of cement and better understanding of material-tissue interactions lead to the 
development of different CPC formulations [ACA, 2001]. 
CPCs are more attractive than other bone cements, because of their non-toxicity 
[Komath et al., 2000]. CPC is more attractive than hydroxyapatite ceramic because, 
within CPC’s setting period, it is possible to mold it and shape it into any complicated 
geometry; in that time, it can also be packed into any complicate cavity. And they can be 
made into an injectable form, which simplifies the bone repair procedures. CPC induces 
bone ingrowth since it presents good fixation along with excellent tissue-biomaterial 
contact [Komath, Verma and Sivakumar, 2000]. Furthermore they show excellent in vivo 
resorption and negligible shrinkage [Ruhe, Henriette, Kroese-Deutman and Wolke, 2004]. 
CPCs are developed based upon the cementing action between acidic and basic 
calcium phosphate compounds on wetting with an aqueous medium. The cement is 
formulated in two parts— dry and wet [Komath and Varma, 2003]. 
• Dry - a powder mix contains dry calcium phosphate particles and; 
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• Wet - a wetting medium prepared with distilled water or other aqueous 
medium. 
 Mixing of these in appropriate proportion gives a self-setting slurry. The setting time 
can be adjusted by adding adequate phosphates to the wetting medium. CPCs have been 
used successfully in assorted surgical procedures in both animal and clinical studies 
[Komath at al., 2003 and Wang, 2003]. 
CPC was used in putty form to apply the mix to easily reachable bony defects for 
nearly all of the surgical applications, but the putty form causes problems in clinical 
practice when sites are not easily reachable or the defects are narrow. Serious problems 
occur since, in putty form, CPC does not have viscous flow or a cohesive property, 
making it difficult to deliver with syringes. While it is possible to make the cement a 
loose paste by raising the wetting ratio, this creates additional problems. Increasing the 
wetting ratio radically increases the setting time; in addition, the particulate mass tends to 
remain in the syringe while the liquid is pushed through the needle. In an aqueous 
environment, such as blood or bodily fluids, the unset cement can be washed out since it 
lacks cohesive property. While some researchers have attempted to inject CPC as a paste, 
future researchers will have a large obstacle to create a fully injectable CPC formula 
[Komath et al., 2003; Hutmacher, 2000 and Ruhe et al., 2003]. 
Although these ceramic materials have been successfully used to fill bony defect, 
they have some disadvantages when used to make bone scaffold such as insufficient 
biodegradation and their inherent brittleness limit their use. The main disadvantage is its 
weak mechanical strength of porous ceramic scaffolds. Ceramics are brittle materials, and 
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its mechanical strength decreases rapidly with the pore size and porosity increase [Ruhe 
et al., 2004 and Porter, Pillar and Grynpas, 2001]. 
2.2.2 Polymeric Materials 
There are several distinct advantages offered by polymers over ceramic materials. 
Polymers are injectable and harden in situ as ceramics, but their mechanical properties 
and degradation times can be more easily tailored than bio-ceramics [Temenoff and 
Mikos, 2000]. Reis and others believe that polymers provide the additional possibility of 
functionalization to interact specifically with certain cell types. However, compared to 
ceramics, polymers have less biocompatibility and more difficulty to sterilize without 
damage because of the polymer formulation [Reis, 2002]. 
The following synthetic polymers are labeled as biocompatible materials : 
polyethylene (PE), polypropylene (PP), polymethylmethacrylate (PMMA), 
polytetrafluoroethylene (PTFE), polyurethane (PU), poly(vinyl chloride) (PVC), 
polyamides (PA), polyacetal, polycarbonate (PC), poly(-ethylene terephthalate) (PET), 
polyethylene glycol (PEG),  and polysulfone (PSU) [Wang, 2003]. These polymers are 
also considered as biostable in the human body and have found wide applications in the 
medical field. The interest of tissue engineering research and development has recently 
shifted into biodegradable polymers which include poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA), poly (ε-caprolactone) (PCL), and a few other polymers that can be 
used to fabricate biodegradable scaffolds. [Peter et al., 1998 and Wang, 2003]. 
2.2.2.1 PLA/PGA and their copolymers 
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The well known polymers used for bone scaffold fabrication are polyesters such as 
polyglycolic acid (PGA), polylactic acid (PLA) and especially their copolymer poly 
lactic-co-glycolic acid (PLGA) [Ella, Kellomakim and Tormala, 2005; Kolybaba, Tabil, 
Panigrahi, Grerar, Powell and Wang, 2003; Huh, Cho and Park, 2003]. PLGA have been 
extensively investigated for use in a wide range of applications based on their unique 
properties, including good mechanical properties, versatile degradation kinetics, non-
toxicity, and biocompatibility [Huh et al., 2003; Ouyang, Goh, Mob, Teoh and Lee, 2002; 
Panyam, Dali, Sahoo, Ma, Chakravarthi, Amidon and Levy, 2003 and Zhang, Cui, Bei 
and Wang, 2006]. They have a long history of use (over 20 years in surgical sutures) and 
favorable clinical records. They have been extensively used in implantable materials, 
controlled drug delivery systems, and tissue engineering scaffolds because of a wide 
range of physical properties, degradation rate and delivery time can be achieved by 
varying the ratio of PGA and PLA for specific applications requiring specific degradation 
kinetics ranging from weeks to months [Graysona, Michael and Langer, 2005; Huh et al., 
2003; Oh, Kang and Lee, 2006; Ouyang et al., 2002; Panyam et al., 2003 and Zhang et al., 
2006;]. Their degradation is influenced by various factors like the polymer chain length, 
lactic to glycolic ratio (PLA: PGA) and characteristic of the surrounding medium. 
PLA and PGA are aliphatic polyesters and belong to the α-hydroxy group. High 
molecular weight PLA and PGA are often synthesized by ring-opening polymerization 
process [Agrawal, Niederauer and Athanasiou, 1995]. The methyl pendant group in PLA 
results in the only difference between the structures of PLA and PGA, and it leads to 
different features in their degradation kinetics.  Therefore, the rate of their copolymer 
PLGA degradation is related with the ratio of PLA and PGA in the polymer [Agrawal 
 35
 
and Ray, 2001]. As a highly crystalline polymer, PGA is the most hydrophilic material of 
PLA, PGA and their copolymers. So PGA loses its mechanical strength quickly about 
50% in 2 weeks and is absorbed very well within 4 weeks after grafting and would be 
fully absorbed within 4–6 months [Yang, Leong, Du and Chua, 2001]. Obviously, the 
degradation rate of PLA is much lower than that of PGA.  The degradation of PLGA 
through random hydrolysis causes no damage to physiological metabolites [Simon, 
Khatri, Wight and Wang, 2006].  
PLA, PGA and PLGA can be well dissolved in Pyridine, Dioxane, Chloroform as 
well as other organic solvents, and their solubility can reach up to 40%. By selecting 
polymer and solvent, adjusting the concentration of polymer solution, the viscosity and 
fluidity can be changed. The scaffolds made of those biomaterials are biocompatible and 
biodegradable, and have oseteoconductivity. PLGA functions as delivery medium of 
bioactive molecules after blending into microparticles. Transforming growth factor-β1 
(TGF-β1), recombinant human bone morphogenetic protein-2 (rhBMP-2), and other 
molecules are evaluated with comprehensive study of PLGA microparticles as delivery 
vehicles [Ruhe et al., 2003]. Brekke and Toth used a porous PLGA filled with 750,000 
molecular weight hyaluronic acid (HyA) and bone morphogenic protein-2 (BMP-2). 
PLGA filled many of the architectural requirements of the material by mimicking 
cancellous bone microstructure, while the HyA provided a viscous scaffold for cell 
ingrowth, vascular ingrowth and stimulation, and growth factor storage. The BMP-2 
acted as a stimulant for bone regeneration and was osteoconductive [Brekke and Toth, 
1998 and Park et al., 1998]. However, these scaffolds also have some disadvantages, for 
example, the reduction of the local pH value caused by the degradable products may 
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speed up the polymer degradation and induce an inflammatory reaction [Agrawal and 
Athanasiou, 1997 and Martin, Winet and Bao, 1996].  
2.2.2.2 PMMA 
A good bone fixation is essential for the final success of arthroplasties. Currently, 
autopolymerizing polymethylmethacrylate (PMMA) bone cement is used for the 
anchoring of arthroplasties to bones. Two main drawbacks of PMMA are that it is non-
degradable and its high curing temperatures causes necrosis of the tissue surrounding the 
implant site [Reis, 2002]. Acrylic (PMMA) based cements pose the risk of monomer 
toxicity, glass-ionomer cements have the problem of metallic component leach out and 
bioactive bone cements have the drawback of poor bio-degradability [Kokubo et al., 2003; 
Agrawal and Ray, 2001; Wang, 2003]. 
2.2.2.3 Poly (ε-caprolactone) (PCL) 
PCL is one of the most promising candidates for bone tissue engineering due to its 
availability, biodegradability, non-toxicity and biocompatibility with stable structure and 
reduced sensitivity to environmental conditions. PCL has been used on biomedical and 
pharmaceutical applications extensively because of its high permeability to drugs. The 
mechanical properties and biocompatibility of PCL have been tested in many applications 
[Marletta, ciapetti, Satriano, Perut, Salerno and Baldini, 2007].  The ring-opening 
polymerization of ε-caprolactone yields a semicrystalline polymer with a melting point of 
58–63°C and a glass transition temperature of -60°C. Domb et al. (1997) listed five non-
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polar methylene groups and a single relatively polar ester group found in the repeating 
molecular structure of PCL homopolymer. This kind of structure makes PCL a unique 
polymer. It is similar to polyolefin because of its high olefinic content. Meanwhile, with 
hydrolytically unstable aliphatic-ester linkage, the PCL polymer is easily biodegradable. 
Because of its biocompatibility, PCL has been used as a suture material [Domb, Kost and 
Wiseman, 1997]. Due to the PCL material’s degradation period, of the order of 2 years, 
composites of PCL have been made to reach a faster bioabsorption rate. For example, 
copolymers of ε-caprolactone with D, L-lactide have yielded materials with more rapid 
degradation rates [Chen et al., 2000; Sun, Mei, Song, Cui and Wang, 2006; Ali, Zhong 
and Doherty, 1993; Rai, Teoh, Ho, Hutmacher, Cao, Chen and Yacob, 2004 and Nottelet, 
Coudane and Vert, 2006]. Extended in vitro and in vivo research was done by 
Hutmacher’s group on PCL-based scaffold [Hutmacher, 2001]. In vivo the scaffolds 
showed new bone growth, remodeling of bone with rapid vascularization [Rai et al., 
2004]. 
2.2.3 Bioactive Composites   
In order to obtain the top properties of its component parts, metal and ceramic have 
been used along with polymers to construct bioactive composites scaffolds for hard tissue 
replacement. Both metal composites and ceramic composites have their advantages and 
shortcomings as grafting materials [Wang, 2003]. Bonfield created a bone graft using 
hydroxyapatite (HA) as the bioactive and reinforcing phase in high density polyethylene; 
since then, researchers have explored many composites with bioceramics and 
biopolymers [Bonfield, Grynpas, Tully, Bowman and Abram, 1981; Wang, 2003; 
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Wolfgang, Fabian and Wolfgan, 2001; Laurencin et al., 2001; Peter et al., 1997 and Ruhe 
et al., 2003].  
Poly (propylene fumarate) (PPF), which can be injected into irregularly shaped voids, 
offers mechanical stability and has been shown to have osteoconductive property in vivo 
when used as a composite bone scaffold [Porter, Oldham, He and Zobitz, 2000 and Peter 
et al., 1997].In 1995, Smith & Nephew Richards Inc. launched a Hydroxyapatite 
reinforced high density polyethylene (HA/HDPE) composite imitating the structure and 
match properties of bone, the first bioactive ceramic-polymer to do so [Wang, 2003].   
Other than PE, there are several other biopolymers used for making composite bone 
scaffold. Since Polysulfone (PSU) possesses higher strength and modulus than HDPE’s, 
it is likely a better alternative for the matrix of a composite as it offers superior 
mechanical properties for composites [Wang, 2003]. Other favorable properties of PSU 
include low creep rate, resistance to oxidation, excellent resistance to hydrolysis or 
reduction of molecular weight, stability in aqueous inorganic solvent such as acids, 
alkalis and salt solutions etc. Furthermore, PSU can be steam-sterilized. As a result, 
HA/PSU composite, whose mechanical properties are within the lower bound for cortical 
bone, is regarded as a new hard tissue grafting substance [Wang, 2003].  In biaxial 
fatigue testing, the torsional stress greatly reduced the fatigue life of HA/PSU composite, 
which was similar to HA/HDPE composites [Wang, 2002].  
Bioglass or A-W glass-ceramic may possibly be used as the bioactive phase in 
composites as long as they are more bioactive than HA, which will create a more robust 
bond between the implant and the surrounding tissue in a shorter time [Wang, 2003]. 
After implantation, bioglasss implants can evoke specific physiological responses at 
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interfaces with tissues, thus providing high bioactivity and conditions for building a 
strong tissue-implant bond. In fact, the composite’s bioglass particles indicated superior 
biocompatibility and bioactivity [Wang, 2003]. In  vitro experiments using simulated 
body fluid, it was found that it took a shorter time for bone-like apatite to form on 
Bioglass/HDPE composite surfaces than on HA/ HDPE composite surfaces, indicating 
higher bioactivity of the Bioglass/HDPE composite [Wang, 2003].  
PLGA as composite material has been used in many bone scaffolding applications 
along with other biomaterials such as calcium phosphate cement, Poly(ethylene glycol) 
and hydroxyapatite [Habraken, Wolke, Mikos and Jansen, 2006; Huh et al., 2003; Ruhe 
et al., 2003, 2005, 2006 and Laurencin et al., 2001]. Using chitin or poly (L-lactic acid) 
(PLLA) as the matrix polymer, composite scaffolds containing plasma sprayed HA 
particles can be produced. By using porosifier particles of various sizes, it might be 
possible to control the pore size of the scaffolds [Wang, 2003].   
Bone tissues in the human body are natural composite materials and they serve as 
templates in the development of grafting materials [Wang, 2003]. During the past twenty 
years various bioactive materials have been utilized for bone tissue replacement. Each of 
these biomaterials has its own advantages and may be used in specific clinical situations. 
The successful clinical use of biomaterials promoted further developing of biomaterials 
for various clinical applications. With new knowledge being gained of bone tissue and 
the progress of composite science, newer and better composite materials will become 
available for damaged bone replacement. Much work remains to be undertaken in 
development of biomaterials for bone tissue engineering, especially with regard to their 
interaction with cell ingrowth and differentiation.  
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CHAPTER 3: STRUCTURED POROGEN METHOD FOR BONE SCAFFOLDS 
FABRICATION USING DROP ON DEMAND RP MACHINE 
At present, SFF is the best way to generate defined porous structures. SFF technology 
combined with 3D reconstruction based on CT and MRI data is able to form high 
precision, realistic models. The use of SFF technology to manufacture scaffolds for tissue 
engineering applications is limited by the fact that SFF machines must be calibrated for 
each material used. The machine parameters must match the physical properties of the 
building material. These properties vary greatly in biomaterials, making the use of a 
single machine for fabrication with multiple biomaterials difficult. The structured 
porogen-based bone fabrication method allows for the use of a single building material in 
the SFF machine and the flexibility to use any biomaterial or composite that can be 
injection molded. In addition, the use of a porogen allows for the fabrication of structures 
with features<100 µm, while direct building methods have lower resolution.  
3.1 Introduction of Drop on Demand RP Machine 
In this part of study a commercial drop on demand RP machine (Solidscape Model 
Maker II) uses thermal phase change ink jetting technology has been used to test our 
structured porogen method for bone scaffolds fabrication. Figure 3.1 shows a schematic 
view of Solidscape machine (Merrimack, NH). This technology deposits melted build 
material onto substrate which cools to form solid on impact. 3-D CAD design first was 
converted to STL representation. Then it can be imported into Solidscape’s ModelWorks 
control software for orientation and build configuration selection. ModelWorks then 
 41
 
automatically slices the STL file and converts it to a binary file to drive the nozzles.  
There are two moveable inkjet heads (Figure 3.2A), both depositing a kind of material. 
One head deposits a green thermoplastic build material - similar to an investment casting 
wax. The other deposits a red wax that serves as a sacrificial support material for the 
support of undercuts and overhanging features and is dissolved in a solvent after the 
model is complete. These materials are solid at room temperature, but they are stored in a 
molten liquid state at an elevated temperature in reservoirs which are located at the back 
of the system, and fed to the individual jetting heads through thermally insulated tubing. 
The inkjet heads deposit micro-droplets of the materials as they are moved side to side on 
the build platform following the cross-section geometry to form a layer of the model. The 
inkjet heads are controlled and only deposit droplets where they are needed. The 
materials solidify due to rapidly drop in temperature after they are printed. After an entire 
layer has been formed, a milling head is passed over the layer making it a uniform 
thickness assuring great precision. The excess material is collected by a vacuum system 
and captured in a filter. The build platform is then moved down a layer thickness and the 
subsequent layers built in the same manner. The operation of the nozzles is checked after 
each layer has been finished by printing a line of each material on a drum and reading the 
result optically. If all goes well, the building table is moved down a layer thickness and 
the next layer is begun.  If a clog is detected, a jet cleaning process is performed.  If the 
clog is cleared, the problematic layer is cut off and then reprinted. It gives us the ability 
to correct mistakes resulting from a failure of the inkjet. When the model is finished, the 
wax support material is either melted or dissolved away.  
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Figure 3.1: Schematic view of Solidscape system. 
     
Figure 3.2: Digital photograph of (A) Inkjet print heads; (B) Solidscape 
Modelmaker II RP machine. 
3.2 Calibration Block  
In order to characterize the attainable resolution using structured porogen method by 
Solidscape MMII RP machine and compare it to direct building method, calibration 
blocks were designed and fabricated.  
A B 
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As shown in Figure 3.3, the design of calibration block has three different types of 
graduations. Each type of graduation was designed to test a specific aspect of machine 
resolution. The first set of graduations (Section A) determines what wall thickness the 
machine can produce with reasonable quality. The thickness of these graduations ranged 
from 400 to 800µm and protruded 1000µm from the base of the block. The second set of 
graduations (section B) tested how close adjacent features can be without any of the 
thermoplastic building materials being interconnected. The gap between the graduations 
was gradually reduced from 800µm to 200µm. The third set of graduations (section C) 
represented groups of equally spaced and equally thick protrusions to measure the actual 
shape resulting from a 90º corner design. Figure 3.4 showed the detailed dimensions of 
the calibration block. 
 
 
 
Figure 3.3: Computer model of calibration block used to characterize machine 
resolution. 
A 
B 
C 
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Figure 3.4: Dimensions of calibration block (in mm) 
The attainable resolution varies with the machines used in the fabrication process. To 
test the resolution of our DDP machine, the designed calibration block has been imported 
to Modelwork software and sliced. First Modelwork software was used instead of 
building the real porogen. Figure 3.5 shows a digital image of the tool path for the 
calibration block. The build material is shown in green and the red areas represent a 
support material that holds up the part while it is built. We started the test by scaling 
down the calibration block from 700µm to 100µm. In Figure 3.5(A) only the red support 
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material can be seen without any green material, which tells us that the 100µm channels 
can not be directly built. The software cannot recongnize the 100µm features in the sliced 
file. We gradually scaled down the 700µm channels to 200µm and 300µm.The digital 
images of sliced 200µm channels are all the same as seen in Figure 3.5 (A). Until we 
scaled the channels to 300µm, we can see the build material and support material at the 
same time as shown in Figure 3.5(B), therefore the resolution of direct build is 300 µm.  
 
(A)                                                (B) 
Figure 3.5: Generating the calibration block (A) The RP machine can not directly 
build 100µm channels.  (B) The RP machine least directly built channel is 300µm 
After the resolution test of the direct build, the sliced calibration block with the 
original design (without any scale up and down) has been sent to the host computer and 
built with the layer thickness setting to 12.7 µm.  After the part has finished, Bioact 
solution (Solidscape) was used to dissolve the red support material. Then the calibration 
block was washed using deionized (DI) water. Following that, the calibration block was 
stained with 0.1 % fluorescein solution in distilled water.  An epifluorescence microscope 
was used to characterize the calibration block, and followed by scanning electron 
microscopy (SEM).  The calibration block was prepared according to standard protocol 
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[Li, Mondrinos, Gandhi, Ko, Weiss and Lelkes, 2005]. Briefly, it was air-dried and 
sputter coated with Au/Pd for a period of 120 seconds. Then the sputter coated calibration 
block was examined with a SEM (XL-30 Environmental SEM-FEG), using an 
acceleration voltage of 10.0 kV. 
The test results are shown in Figures 3.6 and 3.7.  Figure 3.6 shows the direct built 
700µm and 900µm channels (section C).  Figure 3.7 shows the indirectly built 200µm 
gap (section B). After achieving the indirect built 200µm gap, to further test the 
resolution of indirect build, a new calibration block was designed which is shown in 
Figure 3.8. This new calibration block has indirectly built gaps size from 800µm to 
100µm, each gap is 50µm apart. Figure 3.9 shows the achieved indirect built 100µm gap.  
The black debris is undissolved fluorescein that stuck to the wax surface despite repeated 
washes. The results demonstrated that the indirect (porogen volume space) resolution 
limit of the machine is as low as 100µm. The RP machine least directly built channel is 
300µm which suggested that the indirect porogen technique can improve the resolution of 
SFF system at least by 3 times as compared to directly built in fabrication.  
 
 
Figure 3.6: Epifluorescence images of calibration blocks: (A) The directly built 
700µm channel. (B) The directly built 900µm channel (Images were taken from top 
view) 
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Figure 3.7:  Indirectly built 200µm gap, front view 
 
Figure 3.8: Design of a calibration block with gaps from 800 to 100 µm 
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Figure 3.9: (A) Fluorescent micrograph illuminated 100µm channel. (B) SEM image 
of 100µm channel (images were taken from the front view). 
3.3 Reconstruction of Bone  
3.3.1 Reconstruction of Trabecular Bone 
MicroCT images segmented (by Mark Mondrinos from laboratory of Tissue and 
cellular engineering) by thresholding with ImageJ software to separate bone from non-
bone material were used in reconstruction of CAD models. Amira 3.0 software was 
utilized to generate three dimensional surface models based on the multi-planar microCT 
images (Figure 3.10). The higher the resolution of the images, the more information will 
be retained. Therefore, images of the highest resolution possible are a necessity to avoid 
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loss of crucial structural information during the image segmentation process 
(thresholding). After the selection of threshold, the trabecular bone was reconstructed 
(Figure 3.11A and B). An STL file has been generated and imported to Pro/EngineerTM. 
Then the negative of the trabecular bone-porogen has been created (Figure 3.11 C and D). 
The voxel-based images of the trabecular bone and the mold have been fabricated using 
the DDP RP machine ((Figure 3.11 E and F). 
 
Figure 3.10: 3-D reconstructions of trabecular bone structure from microCT data. 
(A)Injectable porogen model (B) Direct build scaffold model  
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Figure 3.11: (A) Front view of reconstructed trabecular bone (B)Side view of 
trabecular bone (C) Voxel-based image of trabecular bone (D) Voxel-based image of 
trabecular bone porogen (E)  Fabricated trabecular structure  (F) Fabricated 
trabecular bone porogen 
A B
C D
E F
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3.3.2 3-D Reconstruction of Femur Head 
3.3.2.1 Femur head reconstruction 
CT images of a proximal femur bone obtained from MIMICS software (Materialise) 
medical image database were reconstructed using MIMICS. In all, 34 sliced images were 
obtained, each of 2mm slices, therefore a total length of 68 mm of the proximal femur 
bone. Once the images were loaded, the region of interest was identified and a 3-D voxel 
model of the bone can made. An appropriate threshold number of 211 was found that 
could best capture the relevant information contained in the femur. Using this threshold 
number, the set of all pixels within this range was grown to a color mask and by using 
region-growing techniques in MIMICS. First the whole hip was grown into one single 
color mask. Some necessary mask editing was done to make sure the whole hip is 
connected together. Then the edited mask was calculated to a 3-D object and a STL file 
was generated. Then the femur has been segmented and reconstructed and an STL file 
was generated. This STL file can then be imported into Geomagic software package for 
surface refinement and surface generation. The resulting smoother femur CAD file (IGES 
file) then can be imported to Pro/E. Figures 3.12 showed the reconstructed two ends of 
femur.   
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Figure 3.12: Reconstructed femur heads: (A) Upper end of the femur (B) Lower end 
of the femur 
3.3.2.2 Porogen design for femur head 
The creation of our femur head began with mold design and mixing of materials.  
After importing the IGES femur head file, the surfaces of the femur head were solidified 
using Pro/E. A mold for later injection designed by Pro/E is shown in Figure 3.13. This 
mold has an open top for injection of the biomaterial and two small vents on the bottom 
to let the air come out from the mold.   
 
A B 
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Figure 3.13: Femur head mold design from Pro/E 
3.3.2.3 Fabrication of femur head 
Once the design was complete, mold was fabricated using the Solidscape MMII 
prototyping machine.  The individual mold was then cleared of support material by 
soaking it in a warm Bioact (Solidscape) solution and prepared for injection. Following 
fabrication of the thermoplastic mold, the Poly (ε-caprolactone) (PCL) femur head was 
generated by injection molding. PCL (Sigma-Aldrich) is a semicrystalline polymer used 
as a biomaterial due to its good mechanical properties and a low melting point (around 
55°C); in addition, it is biodegradable and bioresorbable. Prior to the injection process, 
PCL pellets were melted in a vacuum oven (VWR 1410) at 72ºC. Meanwhile the mold 
was also preheated to 72ºC. Next, a half hour prior to scheduled injection, the molten 
 54
 
PCL was subjected to a vacuum in order to minimize air pockets in our fabricated femur 
head. Then material was poured from the beaker quickly and filled the mold. The filled 
PCL mold was placed in the vacuum oven for degassing for another 30 minutes until 
there were no air bubbles coming out from the injected mold. Following degassing, the 
injected femur head mold was removed from the oven and allowed to air cool to room 
temperature for solidification. In order to separate the thermoplastic mold from the femur 
head structure after PCL solidification, the filled femur mold was immersed into 75% 
ethanol (Fisher) in a big beaker.  The thermoplastic material was completely dissolved by 
repeated changes of the ethanol. After mold removal, the femur head was then allowed to 
air-dry at room temperature. Figure 3.14 shows the injected mold and the fabricated 
femur head. 
 
Figure 3.14: (A) PCL injected mold and (B, C, and D) Fabricated femur head in 
different views  
B 
C D 
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Figure 3.15: Fabricated porogen structure 
3.4 Porogen Design and Fabrication   
3.4.1 CAD Designs of Porogen 
Pro/E software package was used to design porogens and then transfer the design into 
STL format which is required by Modelwork software to run the RP machine. In order to 
simulate the global pore structure present in bone tissue, those porogens were designed 
with fully interconnected voids. They had different design with different size, varying 
porosity and internal architectures. Figure 3.15 shows a fabricated porogen design, its 
CAD model is shown in Figure 3.16 (B). After fabrication and injection tests, considering 
the uniformity and ease in making the porogens we finalized our design which is shown 
in Figure 3.16 (G). In this design, each void of the square scaffold is in the shape of a 
cube and is separated from adjacent voids by struts on four of its sides. Hence the 
resulting structure of the scaffold was a series of rods with rectangular cross-sections 
connected to one another. The dimensions of the voids and the rod cross sections were 
equal and constant throughout the scaffold volume. The overall scaffold volume was 
cube in shape that is easy for the machine to make. Scaffold designs were created for a 
constant pore size of 600µm, 400µm, 300µm, and 200µm.  
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Figure 3.16: CAD models of designed porogen 
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Figure 3.17: Computer generated models of the porogen illustrating key features of 
the injection molding process. A: Injectable porogen with cylindrical basin for 
loading molten biomaterial that is injected through the single injection gate using a 
syringe plunger; B: Overhead view shows the single injection gate equal to the 
largest sized feature in the porogen (250, 300, 400 or 600 µm); C: Cut-out view of 
resultant scaffold; D:  Molten biomaterial injection; E: Theoretical model of 
resultant scaffold consisting of pores with the void volume corresponding to the 
porogen gate dimension (250 - 600 µm) 
A 
B C
D E
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In order to minimize air entrapment and weld line formation, the porogen was 
designed such that molten biomaterial would flow into the cavities of the porogen 
through a single injection gate (Figure 3.17B). The dimensions of the gate’s cross-section 
were equal to the pore size of the particular scaffold being injected (e.g. the gate was 
600×600 µm2 for 600 µm-wide pores), except for the fabrication of 200 µm pore 
scaffolds, which required an opening of 250×250 µm2. Therefore, a transition region was 
needed to go from a relatively large basin where molten material could be deposited 
down to the gate dimension corresponding to the desired pore size of the scaffold being 
fabricated (Figure 3.17B). The interior diameter of the basin was designed such that the 
plunger of a standard plastic 1ml syringe could be used to force the molten biomaterial 
into the cavities of the porogen (Figure 3.17A). By using a syringe, a pressure could be 
applied to the scaffold material to help overcome the frictional forces resisting material 
flow through the porogen. To accommodate using a syringe for injection, one end of the 
porogen had a basin and a hole through the wall of the porogen. The basin allows a flow 
front of the material being injected to develop in a direction parallel to the porogen 
surface containing voids. As a result, the scaffold material begins filling the first row of 
voids at approximately the same time. Therefore, the porogen fills more uniformly and 
the time required to fill the porogen is reduced.  A cutout view model of the desired 
resultant scaffold geometry following porogen injection and subsequent removal is 
shown in Figure 3.17C. In order to empirically determine the minimum porogen basin 
wall thickness and maximum biomaterial injection temperature for which thermoplastic 
porogens would consistently maintain structural integrity, simple destructive testing was 
conducted. Based on these preliminary experiments, a 3.18mm wall thickness and a 
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biomaterial injection temperature of 72 °C were selected. Then the designed porogen was 
imported to the Modelwork software and sliced with the setting layer thickness of 38.1 
µm.  Following the same procedures mentioned before, the porogens were fabricated. 
 
Figure 3.18: (A) Air trap (B) Welding Line 
3.4.2 Moldflow Simulation 
The designed porogen was imported to Moldflow software package to check whether 
the porogen can be injected and the quality of resultant scaffolds such as the air trap, 
welding lines, confidence of fill, quality prediction etc. Figure 3.18 shows the possible 
locations where air may be trapped and weld line may be formed in the scaffolds. The Air 
Trap (Figure 3.18A) result shows the regions where the melt stops at a convergence of at 
least 2 flow fronts or at the last point of fill, where a bubble of air becomes trapped. The 
regions highlighted in the result are positions of possible air traps. The weld line result 
(Figure 3.18B) indicates the presence and location of weld and meld lines in the filled 
part model. These are places where two flow fronts have converged. The presence of 
weld and meld lines may indicate a weakness or blemish. 
A B
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Figure 3.19: Mold flow simulation results: (A) Flow front temperature (B) 
confidence of fill (C) fill time (D) injection pressure (E) pressure drop (F) sink mark 
estimate (G) quality prediction 
C 
A B
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FE 
G
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The flow front temperature result (Figure 3.19A) uses a range of colors to indicate the 
region of lowest temperature (colored blue) through to the region of highest temperature 
(colored red). The colors represent the material temperature at each point as that point 
was filled. The result shows the changes in the temperature of the flow front during 
filling. The confidence of fill result (Figure 3.19B) displays the probability of a region 
within the cavity filling with injected PCL which suggested the red colored region is hard 
to fill during the injection and may cause future defects. The fill time result (Figure 3.19C) 
shows the flow path of the injected PCL through the part by plotting contours which join 
regions filling at the same time. These contours are displayed in a range of colors from 
red, to indicate the first region to fill, through to blue to indicate the last region to fill. By 
plotting these contours in time sequence, the impression is given of plastic actually 
flowing into the mold. The injection pressure result (Figure 3.19D) uses a range of colors 
to indicate the region of lowest pressure (colored blue) through to the region of highest 
pressure (colored red). The color at each place on the model represents the pressure at 
that place on the model, at the moment the part is filled completely. This shows the 
pressure through the whole part at the end of fill. The pressure drop result (Figure 3.19E) 
uses a range of colors to indicate the region of highest pressure drop (colored red) 
through to the region of lowest pressure drop (colored blue). The color at each place on 
the model represents the drop in pressure from the injection location to that place on the 
model, at the moment that place was filled. That is, the pressure required to force material 
to flow to that point which tells us the maximum pressure required to fill the scaffold is 
0.65MPa. The sink mark result (Figure 3.19F) indicates the presence and location of Sink 
Marks (and voids). The highlighted region shows where we may have severe quality 
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defects. The quality prediction result estimates the expected quality of the scaffold's 
appearance, and its mechanical properties (Figure 3.19G), which tells us with the current 
design we may get a scaffolds with acceptable quality.  
3.5 Scaffold Fabrication Using Structured Porogen Method 
In previous studies, generation of biocompatible scaffolds using injectable porogens 
has been accomplished by polymer solution casting [Taboas et al., 2003; Ren, Ren, Zhao, 
Huang and Pan, 2007]. However, most of the solvents which are commonly used to 
solubilize synthetic biopolymers, such as dimethyl formamide (DMF), chloroform, and 
dioxane, are highly cytotoxic and will also dissolve the proprietary thermoplastic material 
used with the Solidscape machine, making solution casting difficult to implement in our 
process. Therefore, in order to use the parts fabricated by the machine without any 
secondary processing, we chose to inject molten biopolymers into the porogen. 
After the fabrication of structured thermoplastic porogens, scaffolds were generated 
by injection molding as described below. The overall process is illustrated in Figure 
3.17A. The fabrication process for three biomaterials (PCL, CaP and CPC), as well as 
their composites (PCL/CaP) has been developed and tested using the thermoplastic 
porogen system. The resultant scaffolds demonstrate the defined porous structure 
designed into the thermoplastic porogens (Figure 3.17E). These scaffolds demonstrate an 
interconnected porous structure that might be suitable for tissue engineering applications. 
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3.5.1 PCL Scaffolds Fabrication 
PCL pellets were melted in an oven (VWR 1410) at 72ºC. Concomitantly, the 
porogens were also preheated to 72ºC. Heating of the porogens prior to injection with 
PCL allowed for complete penetration throughout the porogen structure. Attempts were 
also made at filling unheated porogens. The depth at which the PCL injected into the 
porogen was a function of pore size and temperature of molten PCL. In unheated 
porogens the molten PCL solidified in the voids before reaching the other end of the 
porogen. The smallest pore size in unheated porogens which allowed 72ºC molten PCL to 
reach the opposite end of the porogen was 600µm. For smaller pore sizes, the molten 
PCL solidified in the pores before reaching the other end of the porogen. Fill tests were 
also conducted for various temperatures of PCL while the porogen temperature was held 
at room temperature. During heating the PCL was occasionally mechanically agitated by 
hand and visually inspected for solid particles. A half hour prior to scheduled injection, 
the molten PCL was subjected to a vacuum in order to minimize air bubbles in the 
scaffolds. Molten PCL was drawn into a 1 ml syringe (Fisher). The flat tip of the syringe 
was placed into the basin, thus allowing the plunger to advance from the syringe body 
into the cylindrical basin of the porogen (Figure 3.17A). The syringe was emptied 
quickly and the filled porogen was allowed to cool to room temperature. After solidifying, 
excess PCL was trimmed using razor blade.  
A number of reagents and techniques were used to separate the thermoplastic porogen 
material from the biomaterial scaffolds after biomaterial solidification, after series of tests 
ethanol was selected and used through the remainder of this part of study.  First the 
injected porogens were immersed into 99% ethanol (Fisher) in a 50ml test tube. The 
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ethanol in the tube was removed and replenished with new ethanol for a minimum of 
three times. The tube was shaken vigorously and the solvent replaced every 3-5 minutes, 
until all porogen material was dissolved, as evaluated by the colorless appearance of the 
solvent. Using this method, most of the porogen material was removed in 10 min, with 
soaking for no more than 1 h to remove residual thermoplastic from the scaffold center. 
After porogen removal, the scaffolds were then allowed to air-dry at room temperature 
and stored dry as long as needed prior to cell culture and mechanical testing. A cutout 
view of the scaffold structure corresponding to the porogen design is shown in Figure 
3.17C. PCL scaffolds with a void size of 600µm (Figure 3.20), 400µm, 300µm and 
200µm (Figure 3.21) were successfullyf fabricated. 
3.5.2 PCL-CaP Composite Scaffolds Fabrication 
PCL-CaP composite scaffolds were fabricated in the same fashion as the PCL 
scaffolds, with the additional step of preparing the PCL-CaP composite. For that, dry 
PCL pellets and CaP powders (Fisher Scientific, calcium phosphate tribasic) were 
weighed using a standard balance (VWR) and mixed at the desired ratios in beaker. After 
melting at 72ºC, the mixture was homogenized using an ultrasonic probe, and reheated as 
necessary; total mixing time was approximately 30 minutes. Scaffolds were made with 
ratios (w/w) of 90% PCL to 10% CaP and 80% PLC to 20 % CaP. PCL-CaP composite 
scaffolds with a void size of 600 and 400µm were successfully fabricated (see Figure 
3.22).  
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3.5.3 CPC Scaffolds Fabrication 
CPC (Shanghai Rebone Biomaterials) scaffolds were fabricated in four distinct steps. 
The first step involved preparing the CPC putty by mixing 3.8 g of CPC powder with 
2.66ml of sterilized water. Mixing was performed manually with a spatula and was 
completed in less than 5 minutes. For the second step, the putty was quickly packed into a 
syringe and injected into the porogen. Excess CPC which had extruded out from the 
voids in the opposite end of the porogen was removed using the spatula. Next the 
material was allowed to cure at room temperature for 30 minutes. Finally the porogen 
thermoplastic material was separated from the CPC by submersing the filled porogen into 
a 99% reagent alcohol bath. The alcohol in the bath was removed and replenished with 
new alcohol a minimum of three times. CPC scaffolds with a void size of 600µm and 
400µm were successfully fabricated (Figure 3.23).  
 
 
Figure 3.20: SEM micrograph demonstrating global pore structure of injection 
molded PCL scaffold. 
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Figure 3.21: SEM micrograph of (A) 200 micron pores in an injection molded PCL 
scaffold (B) single pore ~ 200 micron. 
 
Figure 3.22: Digital photograph of 90/10 PCL-CaP scaffold (size: 4.2×4.2×5.4mm, 
pore: 600 μm).  
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Figure 3.23: (A) SEM image of the central region of a CPC scaffold fabricated using 
the thermoplastic porogen method. (B) SEM image of single 400 micron pore in 
injection molded CPC scaffold. 
3.5.4 Design of Injection Design 
There are two ways to fabricate bone scaffold: single injection and batch production. 
The previously described injection process in sections 3.5.1-3.5.3 is single injection. To 
batch produce scaffolds, an injection device was designed and manufactured (Figure 3. 
24). This injection device has a material reservoir in the back of the device which has an 
open top. The central plate is moveable and can be slid back and forth to help lock the 
porogens into position. The bottom part of the porogens was sitting in the pockets and the 
head of the porogen was placed in the holes on the central plate. An O-ring was installed 
between the pocket and the porogen to prevent the air leakage. Three acme threaded rods 
were installed on the central plate to move the central plate by adjusting the knob. PTFE 
(polytetrafluoroethylene) gasket tape was installed on the whole system. The font cover 
plate was made of polycarbonate, so the injection process can be carefully monitored. A 
vacuum port was drilled on the front plate. A vacuum was connected through it to the 
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injection device. The whole system can be put into an oven. The oven’s temperature was 
set to 72°C. When the injection process started, the molten biomaterial was drawn into 
the injection chamber through the holes on the reservoir. Then the scaffolds can be 
injected.  
 
 
 
 
Figure 3.24:  Injection device (A) CAD design (B) Digital images 
Reservoir
Central Plate
Adjustable Knob 
Porogen Pocket   
Front Plate 
Vacuum Port
A 
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3.5.5 Pore Size Evaluation of Fabricated Scaffolds 
To understand the manufacturing capability and accuracy and pore size distribution, 
the microporous architecture of fabricated scaffolds, and in some cases thermoplastic 
porogens, was further assessed by SEM as described previously (section 3.2). An SEM 
micrograph of a 400µm thermoplastic porogen and an 80/20 PCL–CaP composite 
scaffold fabricated using a 600µm porogen are shown in Figure 3.25A and B, 
respectively. The measured pore sizes of our scaffolds, as evaluated from SEM 
micrographs, confirmed well to the predicted sizes, based on the designs of the porogens. 
The measured pore sizes of pure PCL scaffolds fabricated using 400 and 600µm 
thermoplastic porogens were 396.740µm (n≥6) and 607.712µm (n≥6). In attempting to 
reproducibly fabricate PCL scaffolds with 200µm pore diameters, we found that 
porogens with pore diameters of 250µm yielded scaffolds with rectangular shaped pores 
with an average pore size of 198.738µm (n≥3) (Figure 3.25C). An example of these pores 
is shown at higher magnification in Figure 3.25D. When using porogens with 250µm 
pores, the porogens either did not completely fill or we obtained scaffolds with irregular-
shaped pores in the regions that maintained any structural integrity, indicating the current 
limitations of this scaffold manufacturing process with this DDP machine. 
We note that other SFF systems have been able to generate structures with features of 
200µm or less using direct building methods with PCL [Darling and Sun, 2004; Zein, 
Hutmacher, Tan and Teoh, 2002 and Vozzi, Previti, De Rossi and Ahluwalia, 2002]. For 
example, using a solution casting approach, Vozzi et al. (2002) developed a microsyringe 
deposition system capable of depositing 2-D lines with widths as low as 20µm using a 
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2.5% poly L-lactic acid (PLLA)/20% PCL solution. However, the manufacturing process 
reported by these authors was limited by the fact that it did not allow for the effective 
fabrication of macroscopic 3-D scaffolds. The pore sizes in our scaffolds are comparable 
with some of the highest resolution SFF systems capable of fabricating 3-D macroscopic 
scaffolds reported in the literature. For example, Geng et al. (2005) reported pore sizes of 
200–500µm using a direct printing system with the polysaccharide chitosan. Darling and 
Sun (2004) used precision extrusion deposition of CAD models to fabricate PCL 
scaffolds with pore sizes and strut widths of 200–300µm. Similarly, Zein et al. (2002) 
used fused deposition modeling to fabricate PCL scaffolds with struts of 260–370µm in 
diameter and pore sizes of 160–700µm, which is similar to the smallest pore sizes seen in 
our scaffolds (Fig 3.25D). All direct build SFF methods cited above are limited by the 
fact that the manufacturing process must be re-configured for each material used. By 
contrast, our approach is more versatile; the machine must be configured only once for 
the ubiquitous porogen which may then be filled with any biomaterial having a melting 
temperature below 75°C. Taboas et al. (2003) used an indirect thermoplastic porogen 
approach comparable to our process. However, their process is complicated by the fact 
that an additional step of casting ceramic into the thermoplastic is required. Thus, upon 
dissolution of the thermoplastic, Taboas et al. injection-molded poly lactic acid (PLA) 
into the ceramic to generate scaffolds with macropore sizes of 500µm and an internal 
microporous structure on the order of 50–100µm produced by salt leaching. Our process, 
which intrinsically is simpler than that of Taboas et al., is easily amenable to the 
introduction of salt leaching approaches; it would require an additional leaching step in 
aqueous medium following thermoplastic porogen removal. 
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Figure 3.25: Scanning electron microscopy of representative thermoplastic porogen 
and scaffolds. A: Thermoplastic porogen used for fabrication of 400μm PCL and 
PCL-CaP scaffolds; B: 80/20 PCL-CaP composite scaffold fabricated using 600μm 
porogen; C: PCL scaffold fabricated from 250μm porogen; D: High magnification 
SEM micrograph of PCL scaffold fabricated from 250μm porogen, example pore 
size measurements used for quantification are shown. Magnification and/or scale 
bar indicated in images. 
3.6 Porosity and Voids Analysis Using Micro CT 
Since the porosity is very critical to bone ingrowth, nutration and waste transport,  
nine scaffolds with 600µm pores made of pure PCL, 90/10 and 80/20 PCL–CaP (n≥3 for 
A B
C D
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each material) were scanned using a SkyScan 1072 Microtomograph (µCT) scanner 
(Micro Photonics) to evaluate the porosity of fabricated scaffolds. This is a compact, 
desktop X-ray system for non-destructive 3-D microscopy with 5µm resolution and 2µm 
detectability operating at 100 kV, yielding transmission images which can be used to 
reconstruct cross sections or the complete 3-D internal microstructure. The image pixel 
size was set at 6.1µm in this study. The output format for each specimen was 976 serial 
1024×1024 bitmap images. These slice images were viewed in SkyScan’s TView 
software and reconstructed by CT Analyzer software.  
3.6.1 Porosity Analysis  
By selecting darker thresholds, the struts of a specimen may be reconstructed. 
Conversely, by selecting the white levels of the bitmap images, the pores in the specimen 
can be visualized. Thresholds of the gray scale images were inverted to allow 
measurement of the volume of all pore spaces. The ratio of pore volume to total volume 
was then calculated to determine the porosity. µCT analysis based views of an 80/20 
PCL–CaP composite scaffold fabricated using a 600µm porogen are shown in Figure 
3.26. Pore corners in the horizontal build plane (x–y directions) were quite sharp (Figure 
3.26A and B), whereas rounding of the scaffold pore corners was observed in the vertical 
build plane (z-axis, Figure 3.26C). The porosity of our 600µm scaffolds was determined 
for each of the materials by volumetric analysis of 3-D reconstructions from µCT data 
(see Figure 3.27). For the 600µm scaffolds, the theoretical porosity based on the porogen 
design was 59.9%, while measured values were 52.6% for pure PCL, 57.2% and 58.2% 
for 90/10 and 80/20 PCL–CaP composites, respectively. These data conform fairly well 
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(within< 5% for 90/10 and 80/20 PCL–CaP) to the theoretically calculated porosity. The 
somewhat higher porosities observed for the PCL–CaP composites vs. pure PCL may be 
due to resistance to flow within the porogen caused by the solid CaP particles, whereas 
the pure PCL melt flows more freely during injection molding, thus more completely 
filling and compressing the porogen. From Figure 3.27, we can also see that increasing 
the CaP to PCL ratio made the scaffolds rough due to the large amount of CaP particles.  
 
    
Figure 3.26:  µCT analysis of 80/20 PCL-CaP composite scaffolds. A: View of 
horizontal build plane (looking down the longest dimension), note the sharp square 
pores; B: View of horizontal build plane (looking down shortest dimension), note the 
sharp square pores; C: View of vertical build plane, note the rounded pores  
   
Figure 3.27: 3-D reconstruction from µCT data (A) pure PCL scaffold (B) 90/10 
scaffold (C) 80/20 scaffold 
A B C 
A 
B 
C 
A C 
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3.6.2 Air Traped Voids Effect and Its Relation with Materials 
Another important endpoint measured by this µCT analysis is the presence of air 
traped voids in the struts resulting from the injection molding process which reduced the 
measured mechanical properties of our scaffolds. The contribution of void space to the 
strut volume was determined by calculating the ratio of strut internal void volume to total 
strut volume.µCT analysis indicated that for pure PCL scaffolds only 0.06% of the strut 
volume was contributed by voids, whereas the value rose to 0.42 and 0.77% in the case of 
90/10 and 80/20 PCL–CaP scaffolds, presumably due to mixing artifacts in the slurry-like, 
particle-containing polymer melt.  
3.7 Mechanical Testing 
Mechanical properties such as compressive strength, tensile strength and elastic 
modulus of the scaffolds is critical to bone scaffolds and they are also a weak point of 
most biomaterial artificial scaffolds.  To find out the mechanical integraty of our 
structured porogen method fabricated scaffolds, we have conducted a series of 
mechanical testings on our composited materials as well as the scaffolds. 
3.7.1 Compression Test 
Compression tests of solid rods made of PCL and PCL-CaP composite were 
performed for specifying the properties of the composite as well as validating the 
properties of pure PCL, on an Instron 5543 uniaxial testing system using 1KN load cell. 
1cc disposable syringes were used to make the testing specimens. First the degassed 
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molten PCL and PCL-CaP composite materials were drawn into the syringe.  Then filled 
syringe was solidified at room temperature. The two ends of the syringe were cut and the 
center part was left and cut to certain length (15.24 mm, D=4.8mm).   Five specimens of 
each material were tested according to the guidelines specified in ASTM D695-02a. In 
addition, compression testing was done on 600µm pore pure PCL, 90/10 and 80/20 
scaffolds (n=6) at a compression rate of 1mm/min using the same system described above 
with a 100N load cell and compression to failure. Effective stress was computed based on 
the scaffold cross-sectional area. The ultimate compressive strength (UCS) as well as the 
compression modulus (CM) was calculated from the effective stress-strain diagrams. And 
the average UCS and CM are plotted as a function of composition.  
As seen in Figure 3.28 the increase in CaP content of the composite significantly 
raised the CM and UCS as well as stiffness of the material of the samples (P<0.002). This 
is particularly advantageous for making scaffolds for application in hard tissue 
engineering. But as the fraction of the composite increases the structure becomes brittle. 
Scaffold stress–strain curves show multiple failure points due to failure of the weakest 
strut, prior to collapse of the entire scaffold structure (Figure 3.29). In order to assess 
potential mechanical effects of the porogen leaching and sterilization by EtOH, we 
conducted preliminary mechanical tests of cylinders soaked in EtOH for 5 days. While 
specimen integrity was not affected by EtOH exposure, we noted a reduction in the CM 
and UCS (Figure 3.30). The decrease in CM is 31.8% for pure PCL, 34.3% for 90/10 and 
42.5% for 80/20 PCL-CaP composite materials. The decrease in UCS is 60.1% for pure 
PCL, 58.9% for 90/10 and 56.4% for 80/20 PCL-CaP composite materials.  These results 
suggest that care should be taken to minimize EtOH exposure time during manufacturing. 
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Figure 3.28: Compressive mechanical properties of PCL-CaP composites. A: 
Comparison of the compressive modulus of 100% PCL, 90:10 and 80:20 PCL-CaP 
cylinders; B: Comparison of the ultimate compressive strength with different 
concentrations of CaP. Statistical analysis indicates that the material properties are 
significantly different (p < 0.002) for different concentrations of CaP.  
 
Figure 3.29: Stress-strain curve for a 600 µm 100% PCL scaffold. Multiple failures 
seen in the figure are due to the failure of weakest strut among the struts. 
A B
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Figure 3.30: Effect of EtOH exposure on (A) UM (B) UCS 
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ANOVA test for independent variables was used to check for differences between 
results obtained for different materials. Pure PCL cylinders had average UCS of 12.4MPa 
and CM of 275MPa. Cylinders with 90% PCL and 10%CaP had average UCS of 
19.5MPa and CM of 341MPa, where as cylinders with 80% PCL and 20%CaP had 
average UCS of 24.8MPa and CM of 425MPa (See Table A-1 in Appendix for detailed 
data). Increasing stiffness of the material, under compression loading, with the increase 
of percentage of CaP has been found by the statistical analysis. The UCS increased 
57.3% from pure PCL to 90/10 PCL-CaP composite material and 100% from PCL to 
80/20 PCL-CaP composite material while the CM increased 24% from pure PCL to 90/10 
PCL-CaP composite material and 54.5% from PCL to 80/20 PCL-CaP composite 
material. The 600µm pure PCL scaffolds had UCS values of 2.777±0.26MPa and a CM 
of 43.97±3.15MPa while the 90/10 PCL-CaP scaffolds had UCS value of 3.21±0.53MPa, 
CM of 46.6±6.49MPa and 80/20 had UCS of 3.702±0.207MPa, CM of 61.4±3.44MPa 
( See Table A-2 in Appendix for detailed data). Figure 3.31 summarized our compressive 
testing results for scaffolds with 600µm pores. We noticed the same trend as the cylinders: 
with the increasing CaP contents, the mechanical performance of scaffolds improved. 
Our compressive strength results of the scaffolds with 600µm pores is in line with 
reported values for trabecular bone from human mandibles ranging from 0.22 to 
10.44MPa [Misch, Qu and Bidez, 1999]. We note that the compressive strength of 
trabecular bone varies greatly with anatomical location and individual factors such as 
bone density, volume fraction of the sample being measured, and strain rate [Cater and 
Hayes, 1976]. Our scaffolds are considerably less stiff than and hence not suitable for 
replacing cortical bone, for which UCS values of over 200MPa have been reported 
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[Carter and Hayes, 1976]. The small standard deviation (<10% coefficient of variation) 
for CM and UCS of the solid cylinders as well as scaffolds (except 90/10 scaffolds) 
demonstrates the reproducibility (in a range of 84-96%) of the mechanical properties 
achieved using this process. The standard deviation results for compression specimens as 
well as scaffolds had clearly shown the repeatability of mechanical properties of the 
products manufactured by this process.  
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Figure 3.31: Compressive mechanical properties of PCL-CaP composites scaffolds. 
A: Comparison of the compressive modulus of 100% PCL, 90:10 and 80:20 PCL-
CaP scaffolds; B: Comparison of the ultimate compressive strength with different 
concentrations of CaP.  
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To double check the accuracy of previous compressive tests and to further 
characterize material properties, we performed compressive and tensile tests using Tinius 
Olsen H25KT (Figure 3.32) single column materials testing machine. This machine has 
rapid changed Z beam load cells with digital encoding for automatic recognition and 
scaling feature (25 KN, 10KN, 5 KN, 2.5KN, 1kN, 500N, 250N, 100N, 50N, 10N, 5N) 
with load measurement accuracy +/- 1% of applied load.  
The cylindrical specimens of compression test were prepared using injection molding. 
A three piece mold was designed to make the testing specimens. The mold (Figure 3.33) 
was designed following the ASTM standard D695-02a. The height of the mold was more 
than two times of the diameter of the mold. First the degassed molten PCL and PCL-CaP 
composite materials were injected into the mold using syringes in the oven with setting 
temperature of 72°C.  Then the vacuum was turned on to get the air bubbles out of the 
injected mold.   After half an hour vacuuming, the oven was turned off and the mold was 
cooled. Then the solidified specimens (15.24 mm, D=4.8mm) were taken out from the 
mold. The two ends of the specimens were cut and the center part of the specimens was 
left to test.   Following by this the specimens were tested following the ASTM D695-02a. 
As seen in Figure 3.34 the same trend can be observed that the increase in CaP 
content of the composite significantly raised the compressive modulus (CM) and UCS as 
well as stiffness of the material. In addition to testing the mechanical properties of solid 
cylinders made of the diverse scaffold materials, we tested the compressive strength of 
scaffolds made of 3 different materials with 600µm pore size using the same system 
applying load cell at a crosshead speed 1mm/min in ambient conditions until the final 
failure or densification occurred. The porous scaffolds with a dimension of ~ 
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4.2×4.2×5.4mm3 were used. The stress-strain curve obtained was used to determine 
mechanical properties. The compressive strength and elastic modulus was determined 
from the maximum load recorded and from the slope at the initial stage (<2% strain), 
respectively. Three specimens were tested for each condition.    
  
Figure 3.32: Tinius Olsen H25KT mechanical testing machine 
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Figure 3.33: Mold design of cylindrical specimens prepared for compression test (A) 
Font and back pieces (B) Middle piece (C) 3 piece mold assembly  
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Figure 3.34: Compressive mechanical properties of PCL-CaP composites. A: 
Comparison of the compressive modulus of 100% PCL, 90:10 and 80:20 PCL-CaP 
cylinders; B: Comparison of the ultimate compressive strength with different 
concentrations of CaP.  
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Figure 3.35: Compressive mechanical properties of PCL-CaP composite scaffolds. A: 
Comparison of the compressive modulus of 100% PCL, 90:10 and 80:20 PCL-CaP 
scaffolds; B: Comparison of the ultimate compressive strength with different 
concentrations of CaP. Bars represent mean ± standard deviation.  
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Figure 3.35 shows comparision of the compressive modulus and ultimate 
compressive strength of PCL, 90/10 and 80/20 PCL-CaP scaffolds (Detailed data was 
summerized in Table A-3 which can be see in Appendix). Statistical analysis indicates 
that the CM is significantly different (p < 0.002, t-Test, one-tail: assuming Unequal 
Variances) for different concentrations of CaP while UCS is not significant different due 
to the big standard deviations. With the composite materials, the mechanical properties, 
such as compressive strength, compressive modulus and yield strength were improved.  
We note the slight difference between the results using Tinius Olsen and Instron, but they 
are in line with the results we tested previously using Instron.  
The compressive test results can be compared to scaffold mechanical properties 
reported by others for PCL scaffolds of similar porosity (Table 3.1). CM was slightly 
higher than Hutmacher et al. (2001), in the range reported by Zein et al. (2002), and 
slightly lower than reported by Williams et al. (2005). UCS is essentially equal to 0.2% 
offset yield stress in our experiments, due to the brittle failure mode of most samples. The 
mean UCS of our scaffolds was at the high end of the reported range for PCL scaffold 
yield stress in the literature [Hutmacher et al., 2001; Zein et al., 2002 and Williams et al., 
2005]. The CM and mean UCS for 90/10 and 80/20 PCL-CaP composite scaffolds were 
all higher than reported for PCL scaffolds in the literature [Hutmacher et al., 2001; Zein 
et al., 2002 and Williams et al., 2005]. 
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Table 3.1: Porosity and compressive mechanical properties of PCL scaffolds 
fabricated by various SFF techniques 
 Porosity Compressive Strength or Yield Stress (MPa) 
Compressive Modulus 
(MPa) 
Hutmacher et al. 
2001* 61.1 % 2.0 – 3.1 21.5 – 41.9 
Zein et al. 2002+ 48 – 77 % 0.4 – 3.6 4 – 77 
Williams et al. 2005+ 63 – 79 % 2.0 – 3.2 52 – 67 
Our results 52.5 % 3.15 + 0.157 45.672 + 3.798 
 
*:Range of mechanical properties reported reflects differences between two strut lay-
down patterns (constant porosity) in either dry condition or wet in saline. 
+: Range of mechanical properties reported reflects the dependence on porosity, in both 
cases the compressive mechanical properties increased with decreasing porosity. 
 
3.7.2 Tensile Test 
  
 
Most of bone scaffold testing is based on compression test, main reason is it’s a 
traditional way to evaluate the mechanical properties of bone scaffolds. But the tesile 
strength is equally important for bone scaffolds. From our knowledge there is no 
available data for bone scaffolds tensile testing, one reseaon is that the testing mechanism 
is difficult for micro-porous structures. So in our study we also tested the tensile strength 
of the diverse scaffold materials. Followed ASTM standard D638-03 dogbone tensile 
bars, with wide ends and a narrow middle, which are commonly used in tensile test, were 
designed. The grips of the testing setup hold the specimen tightly at the wide ends. The 
midsection of the sample has a narrower width than the grip section. This concentrates 
the stress in the test area, so that fracture and most of the strain occur here. To make the 
dogbone tensile specimens, a three piece mold was designed (Figure 3.36).  Using this 
mold testing specimens were prepared by injection molding, then follow by the 
machining operations to assure all surfaces are free of visible flaws, scratches.  Numbers 
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of specimens (n≥6) have been tested for each material. Tensile modulus was measured at 
a tension rate of 5mm/min following the ASTM standard. To find out the literal 
deformation properties of the various materials, we also conducted Passion ratio test for 
PCL, PCL/CaP composite materials. Before testing general purpose strain gages (Vishay 
micro-measurements & SR-4) were mounted on each specimen to measure the Poisson’s 
ratio. Since the strain gauge is an extremely sensitive device and any small imperfection 
in the bond can affect the performance, extra caution was taken when installing the gauge 
onto specimens. During the tests, the specimens that broke at some flaw, or that broke 
outside of the narrow cross-sectional test section were discarded. The width and thickness 
of the flat specimens at the center of each specimen have been measured and recorded 
before test. Then the specimens have been placed in the grips of the testing machine. The 
grips have been tightened evenly and firmly to prevent slippage of the specimen during 
the tests.  Tensile strength and tensile modulus were computed as the slope of the stress-
strain curve. Figure 3.37 shows a typical tensile stress-strain curve for 90/10 PCL-CaP 
dogbone specimen. As seen in Figure 3.38 the increase in CaP content of the composite 
significantly raised the tensile modulus (TM) and UTS as well as stiffness of the material 
of the samples (P<0.002).  It’s approximately 8% of increase in UTS from pure PCL to 
90/10 PCL-CaP composite material and 52.6% of increase in UTS from pure PCL to 
80/20 PCL-CaP composite while the TM increased 11.4% from pure PCL to 90/10 PCL-
CaP composite material and 22.9% from pure PCL to 80/20 PCL-CaP composite material. 
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Figure 3.36: CAD design of dogbone mold: (A) Central dogbone cavity plate (B) Top 
and bottom cover plate 
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Figure 3.37: Tensile stress-strain curve for a 90/10 PCL-CaP dogbone specimen 
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Figure 3.38: Tensile mechanical properties of PCL-CaP composites (n≥6). A: 
Comparison of the tensile modulus of 100% PCL, 90:10 and 80:20 PCL-CaP 
scaffolds; B: Comparison of the ultimate tensile strength with different 
concentrations of CaP.  
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Figure 3.39:  Poisson’s ratio measurement results 
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Figure 3.40: Tensile stress-strain curve for a PCL scaffold with 600µm pores 
ANOVA test for independent variables was used to check for differences between 
results obtained for different materials. Pure PCL dogbones had average UTS of 
1.90±0.19MPa and TM of 105±15.4MPa. Dogbones with 90% PCL and 10%CaP had 
average UTS of 2.05±0.35MPa and TM of 117±17.8MPa, where as dogbones with 80% 
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PCL and 20%CaP had average UTS of 2.90±0.31MPa and TM of 129±17.8MPa. It has 
been fund statistically that by increasing percentage of CaP the tensile strength of the 
material increased. 
Poisson’s ratio was calculated using the recorded transverse contraction strain to 
longitudinal extension strain. The results were summarized in Figure 3.39. The Poisson’s 
ratio behavior of the various materials under tension showed a general trend of decrease 
with increasing CaP content. The testing results were within the range for silicone and 
some polymers such as acrylic and polycarbonate. 
In addition to testing the tensile properties of dogbone specimens made of the diverse 
scaffold materials, we also tested the tensile strength of pure PCL scaffolds with 600µm 
pore size using the same testing machine. The reason of why we only performed one 
material tensile testing for scaffolds is that the standard tensile testing procedure is very 
hard to follow, the scaffold fixtures are very difficult to fulfill and the time limitation.  
Three specimens were used for testing and they were pulled to failure.  Figure 3.40 
showes a typical tensile stress–strain curve for PCL PCL-CaP scaffolds. In order to test 
tensile properties of the scaffolds, a fixture with two ends has been designed (Figure 3.41) 
which has a narrow bar session for the griper to easily grip. Epoxy was used to glue the 
scaffolds onto the fixture one day prior to the test. The epoxy has to have enough strength 
to withhold the load and the viscosity can not be too low so it won’t block the pores.  So 
the strength and capillary effect of the epoxy has been tested before tensile tests.  An 
acceptable epoxy was selected (Epoxy adhesive 300, Rosco laboratories Inc). Porous 
scaffolds with a dimension of ~ 6.6×6.6×13.8mm3 were used (Figure 3.42A).  A porogen 
(Figure 3.42B) has been designed to make the longer scaffolds for tensile tests followed 
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the aforementioned injection method. The 600µm pure PCL scaffolds had UTS values of 
1.43±0.35MPa and a TM of 25.70±0.47MPa. We noted that the tensile properties of the 
materials and scaffolds are slightly lower than the compressive properties.  
 
Figure 3.41: Designed fixture for tensile testing: (A) Two ends of the scaffold holder 
(Front view) (B) Two ends of the scaffold holder (Side view) to show two narrow 
rectangular bar for the tesile machine griper to grip (C) Top view of single scaffold 
holder to show the cavity for mounting the scaffold (D) Complete side view of single 
scaffold holder 
A B 
C D 
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Figure 3.42:  (A) PCL scaffold for tensile testing (B) CAD design of porogen to make 
long scaffold for tensile testing 
3.8 Biocompatibility Test 
To test the cytocompatibility of the scaffolds made by our structured porogen method 
using DDP system human embryonic palatal mesenchymal (HEPM) cells (ATCC, CRL-
1486) were used in this part of study. 
3.8.1 Testing Protocols  
HEPM cells are routinely maintained in Eagles’ minimum essential medium (MEM) 
with Earles’ salts supplemented with 10% fetal bovine serum (Hyclone), 2.0mM L-
glutamine, 1.0mM sodium pyruvate, 0.1 mM non-essential amino acids, and 1.5 g/L 
sodium bicarbonate at 37°C in a 5% CO2 incubator [Li et al. 2005]. For cell culture 
studies, the fabricated scaffolds were sterilized with 70% ethanol for 1 hour at room 
A B
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temperature, and washed 3 times with sterile phosphate buffered saline (PBS). The 
scaffolds were then incubated with a mixture of 30µg/ml collagen type I (BD Biosciences) 
and Matrigel™ (BD Biosciences, diluted 1:30) in MEM for 1 hour at 37°C to facilitate 
ECM protein adsorption and enhanced cellular attachment. Scaffolds were then seeded 
with a suspension of 1 million HEPM cells/ml overnight on an orbital shaker (Belly 
Dancer, Stovall). Following seeding, scaffolds were transferred to 24-well plates, allowed 
to equilibrate for 2 hours in the described cell culture medium and the initial level of cell 
seeding was assessed by the Alamar BlueTM (Biosource) assay [Li et al. 2005]which 
incorporates a fluorometric/colourimetric growth indicator that both fluoresces and 
changes color in response to chemical reduction of growth medium resulting from cell 
growth based on detection of metabolic activity.  In order to evaluate cell proliferation on 
the various scaffolds the Alamar BlueTM assay was performed again on the same samples 
at day 4 post-seeding. Subsequently, the samples were fixed in 10% buffered formalin 
(Fisher) for 1 hour at room temperature and stored in PBS at 4°C until cytological 
staining. For staining, the samples were washed once more with PBS and incubated with 
PBS containing 2µg/mL Hoechst 33258 (Bisbenzimide, Sigma), a nuclear stain. 
3.8.2 Results and Findings of Biocompatability Testing for PCL and PCL-CaP 
Scaffolds 
HEPM cells growing on the scaffolds are visualized by fluorescent staining of cell 
nuclei, and SEM. In the case of 3-D scaffolds of PCL and 80/20 PCL–CaP, HEPM cells 
were able to attach as evidenced by fluorescent nuclear staining with Hoechst 33258 
(Figure 3.43). These images indicate attachment onto the struts of both PCL (Figure 
3.43A) and 80/20 PCL–CaP composite scaffolds (Figure 3.43B). Based on the Alamar 
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BlueTM data, the initial seeding efficacy was not significantly different for the materials 
used (data not shown). 
This similar level of HEPM cell attachment to all materials used was probably due to 
the fact that all scaffolds were pre-coated with a mixture of MatrigelTM, a reconstituted 
extracellular matrix, and collagen type I solution. Without this coating, cellular 
attachment to the synthetic surfaces was minimal only (data not shown). Once attached, 
HEPM cells proliferated on all types of 3D scaffolds, as assessed from the Alamar 
BlueTM (AB) fluorescence data (Figure 3.44), with some differences between materials. 
The normalized cell proliferation data indicated an identical cell proliferation on pure 
PCL and 90/10 PCL–CaP scaffolds. By contrast, cell growth on the 80/20 scaffolds was 
significantly enhanced (p<0.05). The AB data was validated qualitatively by the observed 
increase in the density of Hoechst 33258–stained nuclei following 4 days of post-seeding 
culture in vitro on the various scaffolds (Figure 3.45). We note that at this time point, 
cells were visibly growing both on the struts (Figure 3.45A and C), as well as in the 
interior pore structures of all scaffolds investigated (Figure 3.45B and D). For further 
confirmation of cellular ingrowth into the scaffold center, the scaffolds were cut into 
segments using a scalpel. The presence of cells on all interior surfaces was visualized by 
nuclear staining (Figure 3.45E).  
The morphology of HEPM cells growing on PCL and 80/20 PCL–CaP composite 
scaffolds was assessed by SEM. As seen in Figure 3.46A the cells flattened on the rather 
smooth PCL surface. By contrast, on the 80/20 PCL–CaP the cells seemed to form 
multilayer assemblies (Fig. 3.46B), which further corroborates the increased density of 
nuclear staining (Figures 3.43 and 3.45) and significantly higher level of cell proliferation 
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(Figure 3.44) as compared to 100% PCL. In summary, these cytocompatibility tests 
clearly indicate that all structured porogen scaffolds when coated with suitable ECM 
proteins facilitate attachment and support proliferation of HEPM cells in vitro. In 
addition, our data suggest that the presence of CaP in the PCL–CaP composite enhances 
the proliferation of HEPM cells and reduces their spreading in favor of multi-layer 
assembly. 
 
  
Figure 3.43: Bisbenzimide nuclear staining of adherent HEPM cells following 24 
hours of orbital shaker seeding on PCL (Panel A, 200x) and 80/20 PCL-CaP 
composite (Panel B, 100x) scaffolds, 600 μm pore sizes. Images are captured by 
imaging the surface of a strut on the outside of the scaffold 
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Figure 3.44: Normalized increase in Alamar Blue™ readings over the 4 day in vitro 
culture period following the initial 24 hour seeding period for 600 μm pore size pure 
PCL, 90/10 and 80/20 PCL-CaP scaffolds. Metabolic activity as measured by 
Alamar Blue™ at 96 hours post-seeding was normalized to the Alamar Blue™ 
readings taken immediately following the 24 hour seeding period. Y-error bars 
represent the standard deviation from the mean for each sample (n = 5). * = 
Statistically significant differences (P < 0.05) compared to 100% PCL by one-way 
ANOVA with Tukey-Cramer post-tests for multiple comparisons. 
 
 
 
 
 
 
 
 
 
 98
 
B
D
E
  
 
 
 
 
 
 
 
 
 
 
        
 
Figure 3.45: Bisbenzimide staining of HEPM cells cultured on PCL (Panels A and B) 
and 80:20 PCL-CaP composite (Panels C and D) scaffolds for 5 days. A: HEPM cells 
on the surface struts of a 600 µm pore size PCL scaffold (50x); B: HEPM cells 
growing around and into a pore on the same scaffold imaged in panel A (100x); C: 
HEPM cells on the surface struts of a 600 µm pore size 80:20 PCL-CaP composite 
scaffold (200x), note the increased density of nuclear staining relative to the PCL 
scaffold; D: HEPM cells colonizing a pore in the scaffold imaged in panel C (original 
magnification 50x); E: HEPM cells growing on a strut from the scaffold center 
(100x). 
C 
B A 
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Figure 3.46: Scanning electron micrographs of HEPM cells cultured on 600 μm pore 
size PCL and 80/20 PCL-CaP scaffolds for 5 days. A: Flattened HEPM cells on PCL 
scaffold, Scale bar = 50 μm; B: Multilayered HEPM cells on 80/20 PCL-CaP 
scaffold, scale bar = 20 μm. 
Biocompatibility has been demonstrated for PCL, PCL-CaP scaffolds fabricated using 
the structured porogen method by DDP.  Our findings are in line with previous reports 
showing that PCL scaffolds fabricated using various manufacturing processes display 
good cytocompatibility in vitro [ Darling and Sun, 2004 and Hutmacher et al., 2001] and 
are biocompatible in vivo [Williams et al., 2005]. For example, Williams et al. (2005) 
used SLS to fabricate PCL scaffolds which were then seeded with human gingival 
fibroblasts genetically modified to express bone morphogenetic protein-7 (BMP-7) and 
implanted into subcutaneous pockets of immunocompromised mice. These scaffolds 
supported the development of new bone over a 4-week period, as evidenced by μCT 
detection of mineralized tissue [Williams et al., 2005]. Darling and Sun (2004) reported 
that precision extrusion-deposited PCL scaffolds supported the proliferation of cultured 
rat cardiomyoblasts, however detailed analysis of cellular metabolism, proliferation, and 
morphology were not provided. Hutmacher et al. (2001) used primary human fibroblasts 
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and human osteoprogenitor cells to demonstrate the biocompatibility of PCL scaffolds 
fabricated by fused deposition modeling, although the capacity of these scaffolds to 
induce bone formation was not addressed. 
Diverse scaffolds fabricated from CaP and diverse CaP composites also display in 
vitro [Wang, Tian, Liu, Cheng, Liao and Lin, 2005 and Xu and Simon, 2005] and in vivo 
[Ruhe, Hedberg, pardon, Spauwen, Jansen, Mikos, 2005] biocompatibility. For example, 
Wang et al. [Wang et al., 2005] demonstrated that biomimetic nano-structured CaP 
scaffolds, fabricated by gel lamination technology, supported osteogenic differentiation, 
as evidenced by alkaline phosphatase expression. Xu et al. (2005) used a murine 
osteoblast cell line to demonstrate biocompatibility of CaP–chitosan composites with 
amorphous architecture and pore sizes of 165–270 µm. These scaffolds were fabricated 
by preparing a water-soluble mannitol—CaP–chitosan mixture and subsequent removal 
of mannitol to create the pore structure. Amorphous poly (lactic-co-glycolic acid) PLGA– 
CaP scaffolds of various weight ratios, fabricated by admixing PLGA microparticles into 
Ca-P cement and implanted into subcutaneous and cranial defects in rats, facilitated 
fibrovascular and bone tissue development over a 12-week period, respectively [Ruhe et 
al., 2005]. Compared to these amorphous CaP scaffolds, the primary advantage of our 
fabricated scaffolds by structed porogen method is that they are comprised of precisely 
generated structures which allow for reproducible scaffold fabrication and control of 
mechanical properties. 
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3.9 Conclusion 
In this part of study, we established a thermoplastic structured porogen injection 
molding manufacturing process and demonstrated efficient, reproducible fabrication of 
porous PCL and PCL–CaP composite scaffolds with pore sizes as small as 200µm. With 
their interconnected porous structure, these scaffolds will be suitable for specific tissue 
engineering applications, such as replacement of trabecular bone, etc. 
 The mechanical testing for diverse materials and their scaffolds has been performed. 
The results gave us the obvious trend that with the increasing CaP content the mechanical 
performance of the materials and scaffolds has been improved, which is in the high end 
of PCL scaffolds with similar porosity. In vitro cytocompatibility has been demonstrated 
for both our PCL and PCL–CaP scaffolds. Those results are in good agreement with 
several other in vitro studies which showed the incorporation of calcium phosphate 
components into the artificial bone scaffolds resulted in more cell growth and also 
showed their mechanical effectiveness in the resultant scaffolds [Hong, Park, Kim, Lee, 
Ryu, Park and Kim, 2006; Schnettler, Ctahl, Alt, Pavlidis, Dingeldein and Wenisch, 2004; 
Flautre, Anselme, Delecourt, Lu and Hardouin, 1999 and Ruhe, Hedberg, Padron, 
Spauwen, Jansen and Mikos, 2006].  
 The primary advantage of this structured porogen method is the ability to use multiple 
biomaterials for injection molding with a single ubiquitous porogen. As an added 
advantage, the structured porogen method can improve the resolution of our 3-D SFF 
system by at least 2-fold as compared to directly built scaffolds using the same SFF 
machine. 
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CHAPTER 4: POROGEN- BASED METHOD STUDY USING THREE 
DIMENSIONAL PRINTING 
The melting point of wax building material of previously used DDP system is low 
(75°C), so the biomaterials can be melt caste into the desingned porogens are limited. 
And the machine’s production speed is relatively low (it takes approximately 15 hours to 
build a 20×20 mm porogen). Also to expend the usage of this proposed structured 
porogen fabrication method on other commercially available SFF machines and to test if 
this proposed structured porogen fabrication method can be a universal method on multi 
SFF machines, three dimensional printing (3DP) system was used to test our porogen 
method in this study.  Since it uses plaster composite material as building material which 
has very high melting temperature (in the range of 1400-1500°C) and the building speed 
of this 3DP system is relatively high ((it takes approximately 1 hour to build a 20×20 mm 
porogen). 
4.1 Introduction of Three Dimensional Printing (3-DP) 
3DP was developed at MIT (Massachusetts Institute of Technology). It is often used 
as a direct manufacturing process as well as for rapid prototyping. 3DP creates 3-D object 
by inkjet printing liquid adhesive to join loose powder, which allows parts to be built 
very quickly and inexpensively. This technology uses ink-jet based process. The 
multichannel print head deposits liquid adhesive binder onto the top of a bed of powder 
object material. The powder is bonded together in the areas where the adhesive is printed. 
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The material used in this application is calcium sulfate hemihydrate plaster based 
composite powder (ZP 130) and water-based binder (ZB 58). The designed 3-D porogen 
model was first converted to a general STL format and input into the 3D printing control 
software for fabrication.  
 
Figure 4.1: Schematic overview of three dimensional printer 
A 3-D printer is shown schematically in Figure 4.1. The system consists of the 
following parts: feed piston, build piston, spreading apparatus (roller) and multi-channel 
print head. The feed piston is used to measure and dispense powder that is spread across 
the build piston by means of a roller. The building process starts by spreading a layer of 
powder object material at the top of a fabrication chamber. Once the initial layer is spread, 
the lowest cross section of the part is subsequently printed by depositing a liquid adhesive 
binder solution on the powder substrate which becomes bonded in the areas where the 
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adhesive is deposited, to form a layer of the object by means of a multi-channel jetting 
head on the print head gantry in a 2-D pattern. Once a layer is completed the build piston 
moves down and the feed piston moves up one layer thickness to supply powder for the 
process. The roller then spreads and compresses the powder at the top of the building 
chamber. The process is repeated until the whole object is completed. Once the part has 
been completed and the part has been allowed to dry sufficiently, then the part can be 
removed and excess powder can be brushed off of the part. No support material is needed 
because the surrounding powder in the build chamber acts as support structure during 
fabrication. Once the part is de-powdered, infiltration can be used to increase part 
strength and achieve a desirable finish.  
4.2 Porogen Design and Fabrication 
4.2.1 Porogen Design 
Porogen with small voids were designed using Pro/E CAD design software and 
constructed to evaluate the resolution of 3-DP porogen approach. This inkjet 3-D printing 
technique allows the designing and fabrication of porogens of various lay-down patterns, 
pore sizes, and porosity. In this part of the study, rectangular and round shaped 
honeycomb-like porogens were fabricated with a perpendicular lay-down pattern (0/90°). 
A 0/60°/120° pattern was also designed in this study. However, in the late test, only a 
0/90° pattern was used. Figure 4.2 shows the schematic architectures of the porogens. 
The strut size ranges from 200 to 400 µm.  To estimate the resolution of the porogen 3-
DP approach, first a porogen with 200µm struts spaced 800µm apart was designed. After 
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fabrication, we noticed that the 200µm struts can not be fabricated. Then we increased 
the strut size to 300µm, we observed that the porogen can be manufactured, but they were 
too weak to hold any force. With further increasing the strut size to 400µm, good 
porogens with acceptable quality were produced.  A longer porogen was designed at the 
beginning, but the excess powder was very hard to clean completely. So a final porogen 
with 400µm struts, 800µm voids and overall dimension of 10.4×10.4×6.2 mm was 
designed.  
4.2.2 Porogen Fabrication 
Once the design was completed, the STL file was imported into the 3-D printer and 
sliced into layers. A commercially available 3-D printer (Z310 plus, Zcorp, Figure 4.3) 
was used to print each layer sequentially.  The ZPrinter functions by selectively gluing 
layers of powder together. During fabrication, the liquid adhesive was selectively printed 
on an 89µm thick layer of plaster powder to form the 2-D pattern. This process was 
repeated until the porogen was completely printed.  
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 Figure 4.2: The designed porogens: (A) Square porogen with 200µm struts spaced 
800µm apart (B) 0/60°/120° lay down pattern (C) Round porogen with 300µm struts 
spaced 800µm apart (D) Round porogen with 400 µm struts spaced 800µm apart (E) 
Square long porogen with 400µm struts spaced 800µm apart  (F)Square short  
porogen  
 
E F 
D C 
A B 
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Figure 4.3: The digital image of Zprinter 310 plus 
 
Following the printing stage, the individual porogens were removed and then cleared 
of excess powder which filled into the pores, using pressurized air blower, and prepared 
for injection. To help the biomaterial injection, a hollow cylindrical injection tool with 
400 μm opening on the top and a basin with 10.4mm internal diameter was designed and 
fabricated separately which allows the plunger of a standard plastic 1ml syringed could 
be used to inject the molten biomaterials into the pores of the porogen. The porogens and 
the injection tool were sintered at 275°F for 30 minutes. Following sintering, the 
porogens were infiltrated with alginate or polyethylene glycol (PEG, Sigma) to 
strengthen the porogens and to fill the small surface pores. 3% (W/V) alginate was 
prepared prior to infiltration by using alginate acid salt (Sigma) and 1% acetic acid. 20% 
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and 40% (W/V) PEG were also prepared by using PEG pellet and DI water. The reason 
to choose alginate and PEG as infiltration materials is because they all are biocompatible 
and PEG is water soluble biomaterial. The solvent we used to remove the plaster can 
remove plaster and alginate, so there will be no any infiltration residul left on the 
fabricated scaffold. All solutions were made and stirred for 60 minutes at room 
temperature. The porogens were dipped into the solutions for 2 seconds and quickly 
removed from the solutions.  The infiltrated porogens were air dried at room temperature 
and collected into a capped tube.  The coated porogens were compared. Half of the pores 
of the alginate infiltrated porogens were clogged by alginate. The alginate did not 
penetrate to the plaster porogens, so alginate is not a good choice for infiltration. The 
resultant 20% PEG infiltrated porogens were much better, the capillary effect helped the 
PEG solution to fill the micropores on the wall, but still left the macropores open. The 
only problem with 20% PEG was the water contents were too high, so it was very easy to 
destroy the porous structure. The 40% PEG infiltrated porogens were the best, not only 
because the small microspores on the surface were all filled, but also because the 
structural integrity of the whole porogen was kept.  In the late study, all the porogens 
made of 3-DP were infiltrated by 40% PEG. The printed and infiltrated porogen are 
shown in Figure 4.4. 
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Figure 4.4: Pictures of (A) Printed plaster porogen (B) PEG infiltrated porogen 
4.3 Fabrication of Bone Scaffolds 
4.3.1 Scaffold Fabrication 
PCL pellets were weighed using a standard balance, as well as a calculated amount of 
CaP powder based upon how much PCL was measured and the desired ratio of the 
composition. Then the two weighed materials were mixed in a glass beaker.  Pure PCL, 
90/10 and 80/20 PCL–CaP were melted at 75°C in the oven. The melted composites were 
stirred for half an hour by using an ultrasonic probe to ensure the composition was mixed 
B 
A 
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evenly and any small sample from the beaker would be made up of the desired 
percentage. Half an hour before scheduled injection, the mixtures were subjected to a 
vacuum in order to minimize air bubbles in our scaffolds. After that the melted material 
was injected into the infiltrated porogens using disposable 1ml syringe by pressing the 
injection tool tightly onto the porogen. The injected porogens were cooled at room 
temperature.  The excess solidified material was cleaned using a razor blade. Cavex 
GreenClean Alginate and Plaster Remover solution was prepared by measuring two 
scoops of biodegradable Cavex powder in 500ml lukewarm water. Porogen material was 
removed by submerging the injected porogens in the mixed solution.  Each injected 
porogen was immersed in 50ml filled tube and placed in a rotator with a setting 
temperature of 40°C. The solution was changed every 24 hours. After 5 days of 
immersion, the scaffolds were taken out from the tubes and air dried. The resultant 
scaffolds then were washed in DI water for 20 min. Then the scaffolds were collected for 
future tests. 
4.3.2 Femur Head Fabrication 
To further explore the compatibility of making complicated scaffolds using the 
structured porogen method by 3-DP, a femur head was fabricated by casting PCL into the 
plaster mold. The same mold CAD model was used from our previous study (section 
3.3.2), which has a negative shape of reconstructed femur head. Figure 4.5 shows a 
picture of the plaster femur head mold and Figure 4.6 shows the fabricated femur head by 
3-DP. Comparing with the femur head fabricated through DDP in Chapter 3, the time for 
finishing the whole femur head mold is much less than using DDP, because the resolution 
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of DDP is better than 3-DP and it takes more time to print the mold. And without 
infiltration there is a fused plaster shell left on the fabricated femur head.  
 
Figure 4.5: 3-D printed plaster femur head mold 
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Figure 4.6: Injected PCL femur head 
4.4 SEM Images of Fabricated Porogens and Scaffolds 
To further characterize the microstructures of fabricated porogens and scaffolds, 
SEM images were taken. Porogens and scaffold structures were prepared for 
characterization by SEM according to standard protocol. Porogen, infiltrated porogen and 
resultant scaffold were air-dried and sputter coated with Au/Pd for a period of 60 seconds. 
Cell-seeded scaffolds were fixed in 2.5 % aqueous gluteraldehyde for 1 hour at room 
temperature then overnight at 4ºC, dehydrated through graded alcohols (15%, 30%, 50%, 
75%, 85%, 95% and 100%), dried with a critical point dryer (SPI supplies). All Samples 
were then examined with a scanning electron microscope (Environmental SEM-FEG), 
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both using an acceleration voltage of 10.0 kV. Figures 4.7 shows the SEM images of 
porogen, infiltrated porogen, resultant scaffolds. The pores on the scaffolds were 
observed. The pores on infiltrated porogen are more regular shape comparing with the 
porogen without any treatment. The infiltration not only helped to improve the 
mechanical strength of the porogen, but also helped to improve the quality of the 
resultant scaffolds. Figure 4.8 shows the measurements of infiltrated porogen and 
resultant scaffold. The image of infiltrated porogen (Figure 4.8 A) shows that the printed 
porogen has an average of 605.8±40.74µm struts. This is different with the designed 
400µm. This difference may be due to the binder migration on the loose powder.  The top 
image of the resultant scaffold (Figure 4.8B) shows the pore size on the scaffold was 
421.5± 29.7µm, which is close to the designed scaffolds with 400µm pores.  The Figure 
4.9 shows the close-up pore of the scaffolds.  The resultant scaffolds are well-
interconnected and highly opened. The pores provide high surface to volume ratio for cell 
attachment and nutrient transfer.       
4.5 Toxicity Test 
During the porogen material removal process the reaction of Cavex plaster remover 
and plater might bring some unknown reactant into the scaffolds, therefore a toxicity test 
was perfomed in this part of study. The toxicity of PCL scaffold has been tested using 
extraction assays. Extracts have been prepared by incubating sterilized scaffolds for 5 
days in culture mediums. Briefly, the fabricated PCL scaffolds were soaked and shaken 
in 50ml tubes with DI water on a rotator for three days. The DI water was changed every 
day. Then the PBS was added to the tubes and the scaffolds have been washed through in 
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PBS overnight. After that the scaffolds were sterilized with 70% ethanol for 30 minutes 
twice at room temperature, and washed 3 times with sterile PBS. Then the scaffolds have 
been left in the hood for two hours to let them completely dry. After that, the sterilized 
scaffolds were soaked in the two kinds of mediums for 5 days without changing the 
medium. Then the extracts were collected and stored in the refrigerator for future cell 
culture.   
Confluent Osteoblast cell line (7F2) isolated from mouse bone marrow (ATCC, 
CRL-12557) and endothelial hybridoma (EAhy 926) cells which were a friendly gift from 
C.J. Edgell (University of North Carolina, Chapel Hill) to Dr.Lelkes’s lab have been 
cultured in culture mediums containing extract. 7F2 are routinely maintained in Alpha 
minimum essential medium without ribonucleosides and deoxyribonucleosides with 10% 
fetal bovine serum (Hyclone), 2.0mM L-glutamine, 1.0mM sodium pyruvate (VWR) at 
37°C in a 5% CO2 incubator. EAhy926 cells are routinely maintained in Dulbecco’s 
Modification of Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS, Hyclone) 
and 0.5% Penicillin-Streptomycin at 37°C in a 5% CO2 incubator.   
 Cell viability has been continuously quantified by Alamar BlueTM assay. 7F2 and 
EAhy 926 have also been cultured in standard medium without extract as controls. Cells 
have been cultured in 24 well plate for 4 days (n=3 wells for each cell in each kind of 
medium). The Alamar BlueTM assay was performed every two days. The result shown in 
Figure 4.10 indicates that the 7F2 and EAhy 926 cells did not experience any significant 
cellular dysfunction due to the degradation product of PCL scaffolds. ANOVA test for 
independent variables was used to check for differences between results obtained for 
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different mediums which showed no significant between the controls with the testing 
mediums.         
 
 
 
Figure 4.7: SEM images of (A) Porogen (B) Infiltrated porogen (C) PCL-CaP 
composite scaffold from 3-D structured plaster porogen 
B 
C 
A 
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Figure 4.8:  Measurements of (A) infiltrated porogen (B) resultant scaffold 
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Figure 4.10: Toxicity testing result for PCL scaffolds 
4.6 Biocompatibility Test 
In vitro test was used to examine biological properties of the bio-composite scaffolds 
for their potential use in bone tissue engineering.   
4.6.1 Endothelial Cell Line 
Because bone is a highly vascularized tissue, endothelial hybridoma (EAhy 926) 
cells were used to assess the biocompatibility of the bio-composite scaffolds. These cells 
are routinely maintained in Dulbecco’s Modification of Eagle’s medium (DMEM) with 
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10% fetal bovine serum (FBS, Hyclone) and 0.5% Penicillin-Streptomycin at 37°C in a 
5% CO2 incubator.  
The fabricated PCL, 90/10 and 80/20 scaffolds were soaked and shaken in 50ml tubes 
with DI water on a rotator for three days. The DI water was changed every day. Then the 
PBS was added to the tubes and the scaffolds have been washed through in PBS 
overnight. After that the scaffolds were sterilized with 70% ethanol for 30 minutes twice 
at room temperature, and washed 3 times with sterile PBS. Then the scaffolds have been 
left in the hood for two hours to let them completely dry. The dried scaffolds were then 
incubated with 0.1mg/ml fibronectin solution (BD science) in DMEM overnight at 37°C 
on an orbital shaker to facilitate ECM protein adsorption and enhanced cellular 
attachment. Some researchers have showed that the seeding efficiency of endothelial cells 
can be significantly improved by precoating PTFE graft with fibronectin [Seeger and 
Klingman, 1985 and Ramalanjaona, Kempczinski, Rosenman, Douville and Siberstein, 
1986].   
 Scaffolds were then seeded with a suspension of 0.5 million EAhy 926 cells/ml for 
three hours on the orbital shaker. Following seeding, scaffolds were transferred to 6-well 
plates, allowed to equilibrate for 24 hours in the described cell culture medium. 
Subsequently, the samples were fixed in 10% buffered formalin (Fisher) for 30 minutes at 
room temperature. Then the scaffolds were washed using PBS for three times and stored 
in PBS at 4°C until cytological staining. For staining, the samples were washed once 
more with PBS and incubated with PBS containing 2µg/mL Hoechst 
33258(Bisbenzimide, Sigma), a nuclear stain and rhodamine phalloidin, a cytoskeleton 
stain. 
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Figure 4.11 shows the overlay of bisbenzimide and rhodamine phalloidin staining of 
EAhy 926 cells cultured on PCL, 90/10 and 80/20 PCL-CaP composite scaffolds for 24 
hours. From Figures 4.11 A, C and E we can see that the cells attached on the scaffold. 
Figures 4.11 B, D and F show the cells started to spread. Figure 4.12 shows the cells 
growing after 48 hours post-seeding and they are in healthy state. From Figures 4.12A, C 
and E the increasing cell number are observed over a 48 hour culture period confirming 
that EAhy 926 cells attached, grew, and did not experience significant limitations in 
cellular function in plaster-molded scaffolds.  Figures 4.12 B, D and F show the cells are 
confluent. Staining for nuclei and cytoskeletal filaments of EAhy 926 cells seeded onto 
plaster-molded PCL scaffolds demonstrates cell attachment and growth over a 48 hour 
culture period. Furthermore, we also notice the cell number increased from PCL scaffolds 
to 90/10 and 80/20 PCL-CaP scaffolds, which proves that the CaP can help cell 
attachment and growth.  
4.6.2 Osteoblast Cell Line 
The cytocompatibility of the scaffolds was also assessed using Osteoblast cell line 
(7F2) used previousely on toxicity test. These cells are routinely maintained in Alpha 
minimum essential medium without ribonucleosides and deoxyribonucleosides with 10% 
fetal bovine serum (Hyclone), 2.0mM L-glutamine, 1.0mM sodium pyruvate (VWR) at 
37°C in a 5% CO2 incubator. For cell culture studies, the scaffolds were sterilized with 
75% ethanol for 1 hour at room temperature and left in the hood for two hours to let them 
completely dry. Following that, they were rinsed in sterile PBS three times.  
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Figure 4.11: Overlay of bisbenzimide and rhodamine phalloidin staining of EAhy 
926 cells cultured on PCL, 90/10 and 80/20 PCL-CaP composite scaffolds for 24 
hours (A) PCL scaffold showed the cells attached on the scaffold, 5X (B) PCL 
scaffold (20X) showed the cells started to spread (C) 90/10 scaffold showed the cells 
attached on the scaffold, 5X (D) 90/10 scaffold (10X) showed the cells started to 
spread (E) 80/20 scaffold showed the cells attached on the scaffold, 5X (F) 80/20 
scaffold (20X) showed the cells started to spread 
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Figure 4.12: Overlay of bisbenzimide and rhodamine phalloidin staining of EAhy 
926 cells cultured on PCL, 90/10 and 80/20 PCL-CaP composite scaffolds for 48 
hours (A) PCL scaffold, 5X (B) PCL scaffold (10X) showed the cells are confluent (C) 
90/10 scaffold showed the cells attached on the scaffold, 5X (D) 90/10 scaffold (20X) 
showed the cells confluent (E) 80/20 scaffold showed the cells attached on the 
scaffold, 5X (F) 80/20 scaffold (10X) showed the cells confluent 
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The initial contact of osteoblasts with implant surfaces is very important for 
osseointegration of implants. Osseointegration and initial adhesion of osteoblast can be 
improved by precoating of its surface with collagen type I [Geissler, Hempel, Wolf, 
Scharnweber, Worch and Wenzel, 2000 and Aurelie, Robinson, Kenneth and Russell, 
2005]. So the scaffolds were then incubated with 20µg/ml collagen type I (BD 
Biosciences) overnight at 37°C to enhance cellular attachment. Scaffolds were then 
transferred to 24-well plates and seeded with a suspension of 1 million 7F2 cells/ml for 3 
hours on an orbital shaker (Belly Dancer, Stovall).  
Following seeding, the initial level of cell seeding was assessed by the Alamar 
BlueTM (Biosource) assay. In order to evaluate cell growth on the various scaffolds the 
Alamar BlueTM assay was performed again on the same samples at day 4 post-seeding. 
Subsequently, the samples were fixed in 10% neutral buffered formalin (Fisher) for 1 
hour at room temperature and stored in PBS at 4°C until cytological staining. For staining, 
the samples were washed once more with PBS and incubated with PBS containing 
2µg/mL Hoechst 33258 (Bisbenzimide, Sigma), a nuclear stain and 1µg/mL rhodamine 
phalloidin, a cytoskeleton stain. 
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Figure 4.13: Overlay of bisbenzimide and rhodamine phalloidin staining of 7F2 cells 
cultured on PCL, 90/10 and 80/20 PCL-CaP composite scaffolds (5X) (A) PCL  
scaffold, day 1 (B) PCL scaffold, day 4 (C) 90/10 scaffolds day 1 (D) 90/10 scaffolds 
day 4 (E) 80/20 scaffold, day 1 (F) 80/20 scaffold, day 4  
C 
A B 
D 
E F 
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Figure 4.14: Overlay of bisbenzimide 
and rhodamine phalloidin staining of 
7F2 cells cultured on PCL, 90/10 and 
80/20 PCL-CaP composite scaffolds after 
4 days of post-seeding (A) PCL  scaffold, 
20X (B) 90/10 scaffold, 10X (C) 80/20 
scaffold, 10X 
Alamar Blue Assay for 7F2 on Scaffolds
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Figure 4.15: Normalized increase in Alamar Blue™ readings over the 4 day in vitro 
culture period following the initial 24 hour seeding period for 400μm pore size pure 
PCL, 90/10 and 80/20 PCL-CaP scaffolds.  
C 
B A 
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Figure 4.16: SEM images of  7F2 
growing onto the different scaffolds (A) 
osteoblast on PCL scaffold (B) rather 
smooth PCL scaffold (C) osteoblast on 
90/10 scaffold (D) rough 90/10 scaffod 
(E) osteoblast growing into the pores, 
80/20 scaffold, after 4 days post 
seeding (F) rougher 80/20 scaffold (G) 
spreading 7F2 on 80/20 scaffold 
A B
C D
E F
G 
 132
 
In the case of 3-D scaffolds of PCL, 90/10 and 80/20 PCL–CaP, 7F2 cells are able to 
attach as evidenced by fluorescent staining with Hoechst 33258 and rhodamine phalloidin 
(Figure 4.13). These images indicate attachment onto the porous regions and struts of 
both 90/10(Figure 4.13C) and 80/20 PCL–CaP composite scaffolds (Figure 4.13E). For 
the PCL scaffolds, the osteoblasts only attach and grow preferentially in the regions 
around pores (Figure 4.13A). Differences in cellular attachment are observed between the 
PCL scaffold, 90/10 and 80/20 PCL-CaP scaffolds based on the nuclear and cytoskeletal 
staining. Figures 4.13A, C and E show that the there were more osteoblasts attached onto 
the 80/20 and 90/10 PCL-CaP scaffolds than PCL scaffolds. The initial seeding of 
osteoblasts improves with the increasing contents of CaP in those scaffolds.  Figures 
4.13B, D and F show that osteoblasts grew well in the scaffolds after 4 days of in vitro 
culture. Figure 4.14 shows that the osteoblasts proliferated and they were confluent after 
4 days of post seeding on 90/10 (4.14B) and 80/20 (4.14C) composite scaffolds. After 
four days osteoblasts cultured on the bio-composites scaffolds exhibit enhanced growth 
with increasing contents of CaP in the scaffolds.   
Metabolic activity as measured by Alamar Blue™ at 96 hours post-seeding was 
normalized to the Alamar Blue™ readings taken immediately following the 3 hour 
seeding period. The Alamar BlueTM results also reveal growth of osteoblasts on all kinds 
of scaffolds (Figure 4.15) with some differences between materials. The normalized cell 
proliferation data indicates a close cell growth on pure PCL and 90/10 PCL–CaP 
scaffolds (1.41 for PCL scaffolds and 1.49 for 90/10 PCL-CaP scaffolds). By contrast, 
cell growth on the 80/20 scaffolds is significantly enhanced (n=3, p<0.05). The AB data 
is confirmed qualitatively by the observed increase in the density of Hoechst 33258–
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stained nuclei following 4 days of post-seeding culture in vitro on the various scaffolds 
(Figure 4.13 and 4.14).   
The morphology of 7F2 cells growing on PCL and 80/20 PCL–CaP composite 
scaffolds was examined by SEM. As seen in Figure 4.16 the cells flattened on the rather 
smooth PCL surface (Figure 4.16A). We note that after 4 days post-seeding cells were 
visibly growing into the interior pore structures (Figure 4.16E). The staining results and 
the SEM images of the scaffolds after one day post-seeding indicate that osteoblasts like 
to attach to the rough surfaces; osteoblasts grow better around the pores. It is observed 
that the rough morphology of bio-composite scaffolds promote the cell attachment and 
cell growth. The osteoblasts grow better on the rough surfaces (like 80/10 scaffolds). The 
biocompatibility testing results indicate that the highly porous and interconnected 
structure of bio-composite scaffolds could benefit cell growth.  The bio-composite 
scaffolds support the growth of osteoblasts and endothelial cells. 
4.7 Biodegradation study 
 
Biodegradable polymer implants may provide a viable alternative to metal implants 
bone grafting. After scaffold grafting, it is critical that our scaffolds be able to withstand 
applied forces until the bone has completely healed.  One of the potential difficulties with 
degradable implants is the possible low mechanical integrity due to fast scaffold 
degradation, leaving a hole in the problematic bone. Therefore, material evaluation must 
consider mechanical properties as well as the degradation rates. As the scaffolds degrade, 
they will lose strength and mass and we will monitor this by simulating the natural 
degradation process.  
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The degradation rate of biodegradable polymers is related to many factors: 
hydrophilicity promotes degradation, while high crystallinity, melting temperature, glass 
transition temperature, and molecular weight help to slow down degradation [Fambri, 
Migliaresi, Kesenci and Piskin, 2002]. Processing conditions can affect the degradation 
characteristics of a material. Also humidity will accelerate the degradation process of a 
biodegradable polymer; therefore it is vital to maintain dryness of the polymer [Klein et 
al., 1983].  
PCL is a kind of polyesters. Degradation of PCL happens by random hydrolysis of its 
ester linkages. Ester linkages are easily affected by hydrolysis. The rate of hydrolysis can 
be adjusted by the crystallinity and hydrophilicity of the monomer components of the 
polymer chain. In this part of study rates of degradation for PCL, 90/10, 80/20 PCL-CaP 
composite materials were determined. Two sets of tests were performed. 
4.7.1 Static Degradation Test 
The PCL/CaP cylinder specimens were created using structured porogen method by 
3-D printer (Figure 4.17). As a carrier, CaP was chosen for its osteoconductivity and 
bioactivity. The porogen has an injection port which will allow the 3ml syringe to inject 
the biomaterials into the porogen. There were two vents on the bottom of the porogen to 
let the trapped air come out. The aim of this static biodegradation test was to observe the 
rate of degradation for the different cylinder compositions when submerged in a 
physiological fluid and placed in an incubator for an extended period of time.  Before the 
simulated biodegradation process, the weight of each cylinder was measured using an 
accurate balance (American Scientific Products, 2400DR, ±1mg). After that the cylinders 
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were sterilized and the physiological fluid was prepared.  All preparations were done 
using aseptic techniques in a laminar flow hood.  First, the cylinders were sterilized by 
submerging each of them in ethanol for 10 minute, letting them air dry for 10 min, and 
placing them in 15 ml test tubes.  A total of six test tubes were prepared containing 
individual cylinders. The 90/10 and 80/20 cylinders (n=3) were exposed to physiological 
fluid for two weeks.  Second, the PBS with a 10% Penicillin-Streptomycin (v/v) mixture 
was prepared.  Penicillin-Streptomycin was added because it is an antibiotic which helps 
prevent the growth of fungus and bacteria in our samples over the test period.  The 
physiological fluid was then added to each test tube containing the sterilized cylinders 
until they were all completely submerged (10ml).  Last, all the test tubes were labeled 
and placed in an incubator at 37°C and left to degrade for their allotted time periods.   
 
 
Figure 4.17: Designed cylinder mold 
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The solutions were not changed during the incubation intervals. Following the end of 
the two week phase, the cylinders were taken out and vacuum dried for 48h. The dried 
specimens were weighed again to determine the biodegradation rate. The results were 
compared with the initial weight; therefore the weight loss was calculated. The total mass 
loss was normalized with respect to the initial weight.  The result was listed in Table 4.1. 
The degradation rate of 80/20 is slightly higher than 90/10 (they are not significant 
different). The results also show the normalized weight loss was very small, 0.642% of 
90/10 PCL-CaP and 0.758% of 80/20 PCL-CaP composite materials degraded in two 
weeks under the static condition, supporting the notion that PCL has a long degradation 
time. 
Table 4.1: Static biodegradation test results 
Sample 90/10-1 90/10-2 90/10-3 80/20-1 80/20-2 80/20-3 
Before (g) 2.210 2.202 2.276 2.226 2.256 2.238 
After (g) 2.196 2.190 2.259 2.211 2.231 2.226 
Mass loss (g) 0.014 0.012 0.017 0.015 0.025 0.012 
Normalized 
Mass loss 0.633 0.545 0.747 0.674 1.064 0.536 
Mean±STD 0.642±0.101% 0.758±0.274% 
 
4.7.2 Degradation Test under Agitation 
It is necessary for a polymeric bone scaffold to degrade at a rate that will slowly 
transfer load to the healing bone. Since it takes up to few years for PCL to completely 
resorb [Ali et al., 1993], it is clear that an implant fabricated from this material will 
support a bone for its entire duration of healing. In vitro experiments can simulate the 
degradation of polymeric implants within the body. Some researchers utilized PBS 
solutions to mimic the body's environment [Middleton and Tipton, 2000]. However, these 
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experiments were performed in real time which lasted up to two years. We have 
performed a degradation experiment by placing cylinders of PCL, 90/10 and 80/20 PCL-
CaP in vials of both a physiological fluid, which will decompose the structure by 
hydrolysis, and in a mixture of blood proteins, which will emulate factors inside the body. 
We removed the cylinders at different time points, and analyzed their molecular weight 
and its distribution using High Performance Liquid Chromatography (HPLC, Waters, 
USA, see Figure 4.18) equipped with a refractive index detector. We used THF 
(tetrahydrofuran) as our HPLC solvent. For a given volume of solvent flow, molecules of 
different size travel different path lengths within the column. The smaller ones travel 
greater distances than the larger molecules due to permeation into the molecular maze. 
Hence, the large molecules are eluted first from the column, followed by smaller and 
smaller molecules. HPLC measurements were carried out at 25°C and at a flow rate of 
0.8 ml/min. Polystyrene standards (Polyscience Co.) were used for calibration.  
Melted PCL, 90/10 and 80/20 PCL-CaP mixtures were degassed and sucked into 1ml 
syringes. The filled syringes were cooled at ambient temperature and cut into certain 
length (length is at least 2 times of the diameter for future mechanical testing). The top 
and bottom of syringes were cut off where most of the air bubbles were trapped. Before 
the biodegradation test, the initial weight of each individual cylinder was measured using 
a balance (America Scientific Products, Mettler 2400DR, and precision: ±0.001g).  Then 
all of the cylinders made of pure PCL, 90/10 and 80/20 CaP/PCL, having similar weight 
and dimension of approximately 0.2-0.35g and 12-14mm long, respectively, were 
sterilized by submerging each of them in ethanol for 10 minutes, letting them air dry for 
20 min. The sterilized cylinders made of each different material were immersed into 
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ependorf tubes containing DMEM and DMEM with 10% (v/v) FBS (Hyclone). Last, all 
the ependorf tubes were labeled and placed on an orbital shaker (Belly dancer, Stovall 
Life Science) in a 5% CO2 incubator at 37°C for periods up to 6 weeks.  The medium was 
changed every two days. At the predetermined periods of time, the specimens were taken 
out and vacuum dried for 4 days. The dried specimens were weighted to determine the 
biodegradation rate. The total mass loss was normalized with respect to the initial weight. 
The molecular weight has also been measured using HPLC. Each kind of samples 
have been weighted and dissolved in THF (ratio=2mg samples/1ml THF). The dissolved 
samples have been filtered using 0.45µm PTFE (Hydrophobic fluoropore) syringe driven 
filter unit (Mellex). The filtered samples were injected into the HPLC. Figure 4.18 shows 
the HPLC used in our test. Data from the HPLC curve was imported into Excel. The 
calibration curve was drawn using exponential curve fitting (Figure 4.19).  Figure 4.20 
shows the HPLC curve for PCL sample in DMEM removed at week 6. The peak 
maximum time (which is the time when the peak appears) was used to determine the 
number average molecular weight-Mn for each specimen. And the weight average 
molecular weight was also calculated using the HPLC curve. The detailed molecular 
weights of PCL in DMEM and in DMEM with 10% FBS can be found in Table A-4 and 
A-5 in Appendix. The results of decrease in molecular weight over time are presented in 
Figure 4.21, which shows that the molecular weight decreases consistently from week-2 
(27.46) to week-4 (26.75) and to week-6 (26.65) (all molecular weights in KDa) for the 
cylinders placed in DMEM. While for the cylinders placed in DMEM with 10% FBS the 
molecular weight decreases from week-2 27.05 to week-4 26.76 and to week-6 26.53. 
The results suggest that the cylinders may degrade slightly faster in DMEM with 10% 
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FBS than in regular DMEM (they were not significant different). The change is small, 
about 6% of PCL degrade in 6 weeks which supports the fact that the PCL has a long 
degradation time (around two years).  The HPLC tests have also been performed on 
90/10 and 80/20 cylinders (data not shown here). But since CaP was not soluble in THF, 
interpretation of the results of these experiments is difficult. 
 
Figure 4.18: The picture of (A) HPLC system (B) waters 2410 refractive index 
detector (C) waters 2487 dual λ absorbance detector (D) waters 515 HPLC pump 
A B  
C D 
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HPLC Calibration Curve (Flow Rate =0.8ml/min)
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Figure 4.19: HPLC calibration curve (Polystyrene standards) 
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Figure 4.20: HPLC curve, PCL sample removed at Week 6 
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Figure 4.21: Molecular weight change over time 
The total weight changes of the cylinders after submerging in a DMEM solution and 
DMEM with 10% of FBS at 37°C for periods up to 6 weeks are represented with respect 
to incubation time in Figure 4.22. For all cylinders, the weight steadily decreases with 
incubation time. The detailed test results for all the samples in different medium removed 
at different time can be found in Tables A 6-11 in Appendix. The results show that the 
samples containing higher CaP amount showed higher weight loss.  The total weight loss 
was normalized with respect to the initial weight, and is represented in Figure 4.23. The 
in vitro biodegradation of the composite materials in the DMEM and DMEM with 10% 
serum increases linearly with incubation time and the rate differed with the CaP/PCL 
ratio (the degradation rate of 80/20 was significant different with 90/10 and pure PCL, 
P<0.05); the higher CaP amount caused the increased biodegradation.  Comparing the 
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results of degradation with agitation with the results of static degradation tests, the 
specimens degrade slower under the static condition.  
Weight Loss vs Time (in DMEM)
0
0.002
0.004
0.006
0.008
0.01
0.012
0.014
0.016
Week 2 Week 4 Week 6 
Time
W
ei
gh
t L
os
s 
(g
)
Pure PCL in DMEM
90/10 in DMEM
80/20 in DMEM
 
Weight Loss vs Time (in DMEM with 10% FBS)
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Figure 4.22: Degradation test results (weight loss) 
A
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0
1
2
3
4
5
6
Week 2 Week 4 Week 6 
Time
N
or
m
al
iz
ed
 W
ei
gh
t L
os
s 
(%
)
Pure PCL in DMEM
90/10 in DMEM
80/20 in DMEM
 
Degradation Test Results (in DMEM with 10%FBS)
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Figure 4.23: Degradation test results (normalized weight loss) 
 144
 
Stress-strain curve of 90/10 after 2 weeks of degradation
 (in DMEM with 10%FBS)
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Figure 4.24: Stress-stain curve of 90/10 after 2 weeks in DMEM with 10% FBS 
Following the removal and the mass measurement of cylinder samples, compression 
tests were performed using the Tinius Olsen H25KT machine.  Each cylinder was 
measured for length, then placed individually into the instrument and compressed at a 
rate of 1mm/min until failure. Data in the form of force as a function of piston position 
was collected and analyzed. Figure 4.24 shows a stress-strain curve of 90/10 cylinder 
after soaking in DMEM with 10% of FBS for two weeks. Figures 4.25 and 4.26 compare 
UCS and CM of various materials after 6 weeks of degradation test in DMEM and 
DMEM with 10% FBS. The results suggest that the general trend of decreasing in UCS 
and CM with time. We also observe that the 80/20 PCL-CaP material not only lost weight 
faster than the other two kinds of materials, it also lost its mechanical properties faster. 
The in vitro degradation test affects the UCS more than CM.  
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Comparison of CM after 6 weeks of degradation test (in DMEM)
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Figure 4.25: Comparison of CM after 6 weeks of degradation tests (A) in DMEM (B) 
in DMEM with 10% FBS) 
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Comparison of CM after 6 weeks of degradation test 
(in DMEM with 10% FBS)
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Comparison of UCS after 6 weeks of degradation test 
(in DMEM with 10% FBS)
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Figure 4.26: Comparison of UCS after 6 weeks of degradation tests (A) in DMEM 
(B) in DMEM with 10% FBS) 
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We expected to see a decrease in strength with the increase in time, but the opposite 
is observed for pure PCL specimens.  The CM for the PCL samples increases from week 
0 to week 2, and then slowly decreases with time.  This increase in mechanical properties 
is similar to the findings of Timmer [Timmer, 2003]. In their study it was discovered that 
the compressive properties increased during the initial stages of the degradation study.  
Specifically, the compressive modulus and yield strength were greater at 12 weeks than at 
their initial value. It is believed that this observed strengthening is due to the continued 
crosslinking of unreacted bonds within the network.  
4.8 Conclusion 
In this part of study, we established a structured porogen injection molding 
manufacturing process to fabricated bone scaffolds using 3-DP and demonstrated 
efficient, reproducible fabrication of porous PCL and PCL–CaP composite scaffolds. 
With more material choices this technique gave us the flexibility to make more kinds of 
scaffolds. 
Bone growth behavior varied with the kind of biomaterials used. In vitro 
cytocompatibility has been demonstrated for both our PCL and PCL–CaP scaffolds made 
by 3-D printer. The fabricated scaffolds using 3-DP are biocompatible. An in vitro 
biodegradability study has been performed which suggested us that with the increasing 
content of CaP the material degraded faster. By adding CaP into the implant, cell growth 
and the degradation rate were improved. This is in agreement with other authors [Oonishi, 
Hench, Wilson, Sugihara, Tsuji, Kushitani and Iwaki, 1999, Daculsi, 1998].The post 
degradation mechanical test has been done. An interesting result showed that the 
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compressive properties of PCL increased during the initial stages of the degradation study 
which is beneficial for in vivo bone grafts.  
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CHAPTER 5: POROGEN- BASED METHOD STUDY USING A NEWLY 
DEVELOPED SUCROSE MACHINE 
The commercially available SFF systems we used previously are all using non-
biocompatible materials such as thermal plastic wax (Solidscpe INC), plaster (z-corp), 
photoresin (3D system INC)  etc., and the porogen dissolving process is hard and time 
consuming. Most importantly, porogen materials cannot be completely cleaned up; and 
their residues will stay with final scaffolds and will have negative effects on scaffold’s 
bioactivities. To overcome the above mentioned problems we have designed and 
developed a novel biomaterial-sucrose deposition system and used this system to 
fabricate bone scaffold porogens.  
5.1 Porogen Material Study  
The most important task of this part of study was to develop a versatile SFF based 
fabrication system that can deposit biocompatible and easy-washing clean material for 
porogen build.  Sucrose is one of the most abundant carbohydrates found in nature and is 
a major component of the food chain [Sturgeon, 2003]. Sucrose has the empirical formula 
C12H22O11 and a molecular weight of 342.30.  Sucrose is easy to clean, because it is 
highly soluble in water, and is also somewhat soluble in alcohol and other polar solvents. 
The saturated solutions of sucrose in water and ethanol at 20ºC are 67.09 and 0.90 
percent by weight, respectively.  However, it is generally insoluble in non-polar solvents. 
It is slightly soluble in methanol and insoluble in ether dioxine and chloroform. This 
selective solubility in different solvents provides a convenient processing manipulation, 
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and will enable a polymer composite solution to be injected into the porous sucrose 
structure without destroying its structural integrity. The sucrose skeleton can be removed 
by using water leaching after the composite solidifies.  At room temperature, sucrose is a 
monoclinic crystal.  It melts at 185ºC, and decomposes when heated above 200 ºC 
[Yudkin, Edelman and Hough, 1971]. Due to its natural biocompatibility, sucrose has 
found broad applications in tissue engineering [Ma, Wang, He and Chen, 2001 and Li, 
Tuli, Okafor, Derfoul, Danielson, Hall and Tuan 2005]. Therefore in this study, we have 
selected a modified sucrose to build the negative skeleton.  
5.1.1 Sucrose Mixture and the Functions of Each Component 
In this study, we evaluated our modified sucrose as a porogen material in terms of its 
bioresorbability, fluidity, and manufacturability. For this, we first melt the porogen 
material until it reached a semi-liquid state and then extruded it through a nozzle on the 
substrate or underlying layer to form one layer of the part. To extrude the porogen 
material, a sucrose mixture was developed, which consists of sucrose, honey, alum and 
butter. This mixture has met the requirements for our porogen material. Alum (Aluminum 
Sulfate Al2 (SO4)3) can reduce the melting temperature of the mixture. Honey can also 
reduce the melting temperature and increase the hardness and the viscosity of the mixture. 
Butter was also added to work as lubricant.  
 151
 
5.1.2 Sucrose Solution Preparation Process  
Water and sucrose were heated together to 100°C until almost no water was left, and 
then honey and butter were added. The mixture was reheated to 85°C, and then alum was 
added.  In this study, it has been found that the melting temperature of the modified 
sucrose mixture  reduces to around 80ºC, where the material still has low viscosity and 
good fluidity, and is easily extruded from the nozzle to form fine fibers. The deposited 
sucrose fibers solidify at room temperature.  
5.1.3 Porogen Material Rheology Study 
5.1.3.1 Sucrose Rheology 
Viscosity is the most important flow property, which represents the resistance to flow. 
The measurement of viscosity can help to develop a better product, predict its end 
product performance and predict the physical properties of a product during and after 
processing [Vlachopoulos, 2006 and Prentice, 1995]. The viscosity is defined as the ratio 
of the applied shear stress and the shear rate given in Equation 5.1. 
.γ
τη ==
ShearRate
sShearStres                                             (5.1) 
Poise (dynes-s/cm2) is a frequently used unit for viscosity. For a Newtonian fluid, the 
shear stress is proportional to the shear rate. So its viscosity is a constant. But then the 
viscosity of a non-Newtonian fluid changes with the imposed strain rate. Figure 5.1 
shows a typical shear stress-shear rate relation for Newtonian and non-Newtonian liquids. 
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Liquids with high molecular weight which include polymer melts and solutions of 
polymers are usually non-Newtonian. For non-Newtonian liquids, the viscosities are not 
constant; they are the function of the temperature, pressure, and shear rate which are 
being applied. When the viscosity decreases with increasing shear rate, the fluid is called 
shear-thinning. On the other hand, if the viscosity increases as the fluid is subjected to a 
higher shear rate, the fluid is called shear-thickening. Shear-thinning phenomenon is 
more common than shear thickening [Subramanian]. Many shear-thinning fluids 
demonstrate Newtonian behavior at low and high end shear rates.  For those kinds of 
fluids, when the viscosity is plotted against log shear rate, we can see the curve in Figure 
5.2 [Subraimanian]. The regions where the viscosity is just about constant are known as 
Newtonian regions. The region between these Newtonian regions is called power-law 
region [Shankar, 2007 and Subraimanian]. Researchers investigating the flow of non-
Newtonian fluids often use the power-law relation [Massoudi and Phuoc, 2004, Tij, 2001 
and Buschow, 2006] which can be described by Equations 5.2 and 5.3: 
.
nK γτ =                                                               (5.2) 
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τη                                                         (5.3) 
where K is called the consistency index and n is the power law index. It can be noticed 
that when n=1 and K=η the Newtonian fluid is recovered. For shear thinning material 
n<1 and if n>1 the fluid is shear thickening.  
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Source: www.geosci.usyd.edu.au/users/prey/teaching/Granite/Granite.html 
Figure 5.1: Shear stress-shear rate relation for Newtonian and non-Newtonian 
liquids  
 
Figure 5.2: Viscosity measurements for Newtonian and Non-Newtonian liquids from 
a log viscosity versus log shear rate graph 
(www.clarkson.edu/subramanian/ch301/notes/nonnewtonian.pdf) 
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The most important factors for non-Newtonian polymer melt flow are the temperature 
and shear rate dependence of viscosity [Chien, Jong and Chen, 2005]. So the temperature 
dependence of the viscosity must be taken into account along with the shear rate-
dependence [Bernnet, 2001]. The viscosity thus can be written as follows: 
)()(
.
0 γηη ⋅= TH                                               (5.4) 
where H(T) is the Arrhenius relation and )(
.
0 γη  is the viscosity at a reference temperature 
Tα. The Arrhenius relation can be written as: 
)]11(exp[)(
00 TTTT
TH −−−= α
α                                (5.5) 
where α is the “activation energy for flow” and Tα is the reference temperature for which 
H(T)=1[Bernnet, 2001]. 
5.1.3.2 Viscosity Measurement  
Sucrose mixture was prepared as described in section 5.1.2. Because the temperature 
of the sucrose material affects its viscosity and the viscosity affects the velocity of the 
flow, we studied the rheological behavior of the sucrose material at different 
temperatures, for the quality control of our porogen structure.  A temperature-controlled 
cone-plate rheometer (TA Instruments RFS II; Figure 5.3) has been used to determine the 
viscosity of sucrose mixture at different temperature (110, 120, and 135°C). The 
rheometer was configured with the Peltier plate temperature control and recirculating 
bath temperature control option. Both environmental control systems can also be easily 
exchanged, if necessary. Our modified sucrose material was placed in between of the 
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cone and plate. A motor was connected to the cone and applied rotational force to the 
testing sucrose mixture. As the sucrose mixture creates resistance to flow, the 
corresponding rotation of the lower plate was measured. The resistance to flow was 
calculated as shear stress (force divided by area) divided by shear rate (rotational speed).  
 
Figure 5.3: RFII rheometer 
Table 5.1: Viscosity of various sucrose mixtures 
 
 
 
Mixing Sucrose (g) Alum (g) Honey (g) Butter (g) Water (g) Viscosity (cP) 
1 25 1.25 1 0.25 5 5100 
2 25 1.25 0 0.25 10 2200 
3 25 2 0 0.25 50 270 
4 25 0.25 0 0.25 75 40 
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The viscosity of our porogen material was measured for shear rates changed from 220 
to 2200 s-1. Table 5.1 shows that with changing the ratio of each component of sucrose 
mixture, we could get different viscosity result. The water contents had the biggest effect 
on the viscosity results.  With the ratio of sucrose, honey, alum, and butter setting to 
90:4:5:1 by weight, we performed the rheology test. Tables 5.2, 5.3 and 5.4 show the test 
results for sucrose porogen material at different temperatures of 110, 120, and 135°C. It 
is clear that the viscosity of melted sucrose decreases with increasing shear rate. This 
behavior was referred as shear thinning and can be generally modeled with a power law 
relation. Our data suggested that the viscosity is highly dependent on the temperature. 
The testing data has been collected and analyzed using Matlab to determine the 
parameters- α, K, and n for power law fitting of the data.  
 
Table 5.2: Rheology test for sucrose solution, temp=110°C 
Strain Rate (1/S) Stress(Pa) Viscosity (Pa.s) Torque (N.m) 
541.17 2321.240481 4.2893 72.618 
630.96 2890.11228 4.5805 90.415 
735.64 3601.104928 4.8952 112.66 
857.7 3548.81952 4.1376 111.02 
1000 3701.9 3.7019 115.81 
1165.9 3922.55396 3.3644 122.72 
1359.4 3975.97312 2.9248 124.38 
1584.9 3543.04395 2.2355 110.84 
1847.9 3606.91601 1.9519 112.84 
2154.4 3510.5948 1.6295 109.83 
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Table 5.3: Rheology test for sucrose solution, temp=120°C 
Strain Rate (1/S) Stress(Pa) Viscosity (Pa.s) Torque (N.m) 
707.95 3632.562 5.1311 113.64 
794.33 4152.519 5.2277 129.91 
891.25 4518.727 5.0701 141.37 
1000 4037.9 4.0379 126.32 
1122 3949.216 3.5198 123.55 
1258.9 4731.45 3.7584 148.02 
1412.5 4772.414 3.3787 149.31 
1584.9 4530.278 2.8584 141.73 
1778.3 4473.847 2.5158 139.96 
1995.3 3937.126 1.9732 123.17 
2238.7 4247.709 1.8974 132.89 
Table 5.4: Rheology test for sucrose solution, temp=135°C 
Strain Rate (1/S) Stress(Pa) Viscosity (Pa.s) Torque(N.m) 
184.79 239.838941 1.2979 7.5029 
215.44 285.738072 1.3263 8.9393 
251.19 356.086944 1.4176 11.14 
292.86 374.743656 1.2796 11.724 
341.45 342.303625 1.0025 10.709 
398.11 348.3780988 0.87508 10.899 
464.16 449.3718624 0.96814 14.058 
541.17 704.982159 1.3027 22.054 
630.96 284.7648672 0.45132 8.9086 
735.64 326.1239248 0.44332 10.203 
857.7 386.230887 0.45031 12.083 
1000 444.27 0.44427 13.899 
1165.9 507.224795 0.43505 15.868 
1359.4 575.23011 0.42315 17.995 
1584.9 668.384028 0.42172 20.91 
1847.9 698.931217 0.37823 21.865 
 
From the experimental data, after the least square fitting have been performed, we 
know that: 
)13598.0(.
2.4361)(
−
×= γη TH                                                    (5.6) 
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where α=634.9ºC, T0=56.67ºC, Tα=135ºC (Figure 5.4). 
This viscosity test results are important for us for controlling the parameter 
settings and to improve the quality of our fabricated porogen. 
 
Figure 5.4: Data points and curve fitting for viscosity of sucrose mixture 
⎥⎦
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5.1.4 Flow Rate Measurement 
To optimize the nozzle moving speed and estimate the manufactured part building 
volume, we need to know the dispensed material flow rate. Experiments were conducted 
to measure the flow rate of the sucrose mixture at various parameters to understand the 
controllability of deposition of sucrose mixture and to improve the quality of the printed 
porogen. We measured the mass of the deposited solution on a balance and then divided 
it by the measuring time as shown in Equation 5.8. First the mass flow rate was 
calculated then volumetric flow rate was calculated by dividing the mass flow rate by the 
solution density as shown in Equation 5.9. The nozzle tips were approximately 1cm 
above the Petri dish surface. All the experiments used the same nozzle tip with an inner 
diameter (ID) of 500 µm. 
)dgram/seconin (   
.
time
massm =                                        (5.8) 
second)mililiter/(in   
.
ρ
mQ =                                      (5.9) 
Where 
.
m  is mass flow rate, Q is the volumetric flow rate, and ρ is the density. The 
density of the solution is calculated by using Equation 5.10 as shown below.  
mlg
volume
mass
V
m /===ρ                                       (5.10) 
The experimental set up is schematically shown in Figure 5.5. An air supply that is 
adjustable was connected to the reservoir, where the sucrose mixture was delivered to the 
microvalve for deposition. The deposited sucrose mixture was collected into a Petri dish 
that was placed on a balance for measuring the mass of the sucrose mixture over a 
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specific interval of time (20 seconds in our test) to calculate the mass flow rate as 
expressed by Equation 5.8. The volumetric flow rate was then determined by dividing the 
mass flow rate by the density of the sucrose mixture (1446 kg/m3) as described in 
Equation 5.9.   The density of the sucrose mixture was measured by weighing a filled 3 
cc syringe. Then Equation 5.10 was used to calculate the density of sucrose mixture. 
Three measurements were performed and the average density was taken into the flow rate 
calculation.  
The flow rate was measured with controller pressure (the so called pressure of the 
controller actually is the pressure used to control the microvalve through controller) of 80 
psi, temperature of 100°C and the reservoir pressure of 50 psi.  The mass flow rate 
measurements were recorded five times and the average was taken as the final value. An 
average volumetric flow rate of 1.21×10-6ml/s was calculated using Equation 5.9.  
 
   
Figure 5.5: Experimental set-up for measurement of flow rate 
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Supply 
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5.2 Fabrication System Design 
The fabrication system design started with the nozzle jet system selection and 
installation, which includes the nozzle, the reservoir and the heating element of the 
nozzle and reservoir. We have studied and developed a SFF-based manufacturing system 
to build our sucrose skeleton which serves as the bone scaffold porogen, and then to 
extrude and cast the polymer-ceramic composite into the sucrose porogen to form bone 
scaffolds with predefined structures and sufficient mechanical strength. The schematic of 
the SFF-based porogen fabrication system is shown in Figure 5.6. The control signal is 
sent from the host computer to move the nozzle in x-y directions based on the tool path, 
which was mounted on the moving stage. Air supply was connected with two regulators 
to provide compressed air for both the porogen material and the valve controller. The 
porogen material reservoir was wrapped in a band heater (Omega Engineering INC, 
Stamford, CT) which was controlled by a temperature controller (Omega). A custom-
made copper needle tip was installed on the microvalve which can be heated up to the 
same temperature as the microvalve. The heated porogen material was then dispensed on 
the working stage which can move in z-direction.   
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Figure 5.6: Diagram of RP system components 
5.2.1 Build Platform 
This SFF-based porogen fabrication system used two DC motors to move the nozzle 
in the x and y axis (Pittman, Harleysville, PA) and a stepper motor moves the nozzle in 
the z axis (Pittman). The motion in the x-y plane is driven with isochronous toothed belts. 
The z axis is driven with a lead screw.   
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5.2.2 Nozzle Jet System (Nozzle selection) 
There are several constraints in the selection of the nozzle jet system.  In order to 
simulate the channels in bone which contain the marrow, the nozzle must be able to 
generate small droplets. In addition, the reservoir, the nozzle, and the connecting tube 
must be able to withstand the temperature needed to melt the porogen material (85ºC).  
There are two types of nozzles which can dispense small droplets as we require: the 
piezoelectric nozzle and the air-driven needle valve.   
5.2.2.1 Piezoelectric microvalve 
Initially a piezoelectric microvalve was used in our study (MJ-SF-01-50, Microfab 
Technologies, Inc., Plano, TX). This microvalve had an inner nozzle diameter of 50µm, 
total length of 34mm, and body diameter of 12mm (Figure 5.7). The piezoelectric 
microvalve can dispense different kind of microdrops, range from solvents, water-based 
fluids, inks solder to polymers. The dispensing fluid properties affect the performance of 
the microvalve significantly. The microvalve used in this study successfully dispenses 
fluids with surface tensions in the range of 0.02-0.5 N/m (Microfab user manual). This 
microvalve can also generate drop sizes ranging from 10-500 picoliters. A holding 
pressure is always needed to keep the fluid held just at tip of the nozzle. Once a holding 
pressure is applied to a fluid, the piezoelectric nozzle frequency can be optimized which 
allows the fluid to deposit in microdrops. The mechanical vibration induced by the 
piezoelectric component causes instability which helps the fluid stream to break into 
individual droplets. The droplet size and dispensing rate can be controlled by the 
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frequency of the piezoelectric microvalve and the voltage applied and is directly related 
to viscosity and surface tension of the fluid.  
 
Figure 5.7: Piezoelectric actuator nozzle (Microfab) used in our initial nozzle 
selction testing 
The piezoelectric dispense valve was wrapped in heat tape (OMEGA) to maintain the 
temperature of the sucrose solution at about 85ºC. A cement-on thermocouple (OMEGA) 
was placed between the heat tape and the valve to monitor the temperature. A pre-heated 
aluminum reservoir with self-heating tube was used to deliver the sucrose solution. The 
whole system was kept at 85 ºC to maintain the fluidity of the sucrose solution. The 
reservoir has inner dimensions of 6”x 3”x 2”. A heating element was used to keep the 
temperature of the porogen material constant. Fiberglass insulation was attached onto the 
sidewalls of the reservoir to prevent the heat leakage. Two cement-on thermocouples 
(OMEGA) were installed on the self heating tube and the reservoir to monitor the 
temperatures. In order to install the piezoelectric valve onto the nozzle rack, a nozzle 
holder was designed and incorporated into the system. A reservoir holder was designed to 
hold the reservoir on the side frame of the machine (see Figure 5.8.for detailed pictures). 
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Figure 5.9 shows the integrated system. Although the system worked well on alcohol, it 
cannot dispense the viscous sucrose solution since it can only dispense a solution with 
viscosity ≤40cP. In our preliminary tests we established that a sucrose solution with such 
low viscosity can not solidify quickly enough for layer by layer fabrication. 
 
 
 
Figure 5.8: Detailed pictures of the integrated piezoelectric system 
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Figure 5.9: Our designed SFF system with integrated piezoelectric nozzle, reservoir 
and heating tube. 
5.2.2.2 HP 7x Pressure-Driven Valve 
Due to the high viscosity of our porogen material, we therefore integrated an air 
pressure driven dispensing valve (EFD Inc., East Providence, RI) into our system, which 
can dispense high viscous materials up to 100,000 cP. We first chose the HP 7x (Figure 
5.10) dispense system with the maximum pressure up to 700 psi from EFD.  The HP 7x 
dispensing tool makes it easy to apply very thick fluids like silicones, medical-grade 
adhesives and epoxies through small dispense tips with less time. It features a unique 
design that increases the pressure inside a disposable syringe reservoir by a 7 to 1 ratio. 
Up to 700 psi (48.2 bars) of air pressure can be applied to the 3cc syringe reservoir within 
the HP 7x. Its lightweight aluminum handpiece is very easy to mount.  A custom-
 167
 
designed stainless steel barrel was designed to replace the disposable syringe (Figure 
5.11A). A nozzle heater with inner diameter of 1.0 inch was used to heat the barrel 
(Figure 5.11B). A copper sleeve was made to allow the tight fit between the nozzle heater 
and stainless steel barrel which was also used as a fixture to mount the nozzle onto the 
moving stage (Figure 5.11C and D). Replaceable needle tips were designed with different 
size ranging from 75µm to 400µm (Figure 5.11E and F), which were made by Electrical 
discharge machining (EDM).  Cement thermocouples (Omega) were used to monitor the 
temperature of the HP 7x nozzle. However, after a numerous tests, we found that in our 
hands it is difficult to get continuous flow with good quality using HP 7x.  
 
 
Figure 5.10: Schematic drawing of HP7x 
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Figure 5.11: (A) Custom-designed syringe barrel (B) Nozzle heater (C & D) 
Different views of copper sleeve and fixture (E & F) Different views of replaceable 
needle tip   
5.2.2.3 Pressure-Driven Microvalve 
The 741MD-SS valve (EFD INC) was then selected as needle valve in this study, 
which has an adjustable needle stroke with a unique calibration feature that allows the 
user to maintain exact deposit size of low to high viscosity fluids with exceptional control. 
This system is ideal for automated assembly processes that require small dispensing tips 
ranging in size from 22 to 33 gauges (User Manual). The unique design of the 741MD-SS 
needle valve ensures extremely fine deposit control. The stainless steel shutoff needle 
seats in the hub of the dispensing tip rather than the valve body. This design minimizes 
C 
E 
A B 
D 
F 
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dead fluid volume by having fluid cutoff occur as close as possible to the dispensing 
orifice. Because the needle seat is part of the dispense tip itself, the seat can be renewed 
by simply replacing the tip. The dispense valve is a normally closed, fail-safe air-operated 
needle valve. It requires 70psi (4.8 bar) air pressure (User Manual). This air pressure retracts the 
piston and needle, lifting the needle off the seat inside the dispensing tip, and allowing fluid flow 
through the tip. Once the cycle is complete, air pressure is exhausted, which will cause the piston 
spring to return the needle back to its original position, and stop fluid flow. A picture of 
721MD-SS microvalve is shown in Figure 5.12.   
A commercially available 10cc polypropelene syringe barrel (EFD) was used as 
material container to deliver melted sucrose solution (Figure 5.13A), which was 
pressurized to a constant pressure. The syringe barrel was wrapped in heat tape (OMEGA 
Engineering, INC, Stamford, CT) to maintain the constant temperature of the sucrose 
solution (Figure 5.13B) and the temperature is controlled by a controller. Fiberglass 
insulation was attached onto the sidewalls of the syringe to prevent heat leakage. A 
nozzle heater with inner diameter of 0.5 in was used to keep the nozzle temperature 
(same kind of nozzle heater as seen in Figure 5.13B).  The whole system was kept at 
90ºC to maintain the fluidity and good manufacturability of the sucrose solution. Two 
thermocouples (OMEGA) were placed between the heat tape and the syringe, the nozzle 
heater and the microvalve to monitor the temperature (Figure 5.13C).  A custom made 
copper needle tip was used to replace the disposable needle tip which is shown in Figure 
5.8D. The inner diameter of the needle tip was 500µm. Commercial available stainless 
steel needle tips (EFD) also have been purchased and modified in this study size ranging 
from 24 gauge (ID 30 gauge) to 31 gauge (ID 38 gauge)  (Figure 5.13). The metal needle 
tips will keep the sucrose solution to the same temperature as the reservoir.  Before 
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dispensing, the molten porogen solution was drawn into a 10cc syringe, a 0.45µm syringe 
driven filter was used to filter sucrose particles to preventing the future clogging. In order 
to install the microvalve onto the nozzle rack of the fabrication system, a nozzle holder 
was designed and incorporated into the system (Figure 5.13F). The nozzle holder was 
mounted onto the moving stage.  
 
 
Figure 5.12: Schematic view of 741MD-SS microvalve 
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Figure 5.13: (A) 5cc syringe barrel (B) Heating tape (C) Thermocouple (D) Copper 
Needle tip (E) Modified stainless steel needle tip (F)EFD dispense nozzle holder   
 
Figure 5.14: The picture of SFF system integrated with EFD 741 microvalve  
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 172
 
5.2.3 Electronic System Control 
The control system was divided into three major parts: the temperature control, the 
motor control, and the EFD dispenser control. Figure 5.15 shows the computer control 
flow diagram.   Fig. 5.16 shows a graphical user interface of the software. First, reverse 
engineering software was used to reconstruct a 3-D model from CT or MRI data of multi-
planar images, and then to generate STL file.  The STL model was then sliced to a set of 
sequential cross sections with certain interval.  A computer file was created which will be 
used to control the SFF machine to make the bone scaffold.  Tool path was sending to 
motion controller to control the movement of the working stage and the dispenser.  
 
Figure 5.15: Computer control flow diagram 
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Figure 5.16: User friendly interfaces software to print sucrose porogen 
5.2.3.1 Temperature Control 
To maintain temperature of the nozzle jet system at the setting temperature, 
CN8501TC temperature controllers (Omega) were used for each heating element 
(Omega).  The current rate of these controllers is 5 Amps, which is lower than the heating 
elements allowed current.  Therefore, 10-Amps relays were used to prevent overload.  
Figure 5.17 shows the connection diagram. 
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Figure 5.17: Our desined temperature control system diagram 
5.2.3.2 Motor Control 
Our porogen fabrication system uses two DC motors (Pittman 9433J490 and Pittman 
8322S003) to move the nozzle in the x and y directions respectively. A tech80 model 
5639 motion controller (ACS Motion Control) was used to control the x-y moving stage. 
A model 6409 motor amplifier was connected to motion controller. Then the signals were 
sent out to x-y motors.  For the z axis a microcontroller controls a stepper motor (Superior 
Electric, Bristol, CT) via a motor controller (Parker Hannifin - Compumotor Division, 
Rohnert Park, CA), see Figure 5.18. 
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Figure 5.18: Motor control diagram 
5.2.3.3 EFD Dispenser Control 
An AVR Microcontroller (Atmel AT90S8515) (Figure 5.19) and VALVEMATE 
7000 controller (EFD) were used to control the valve. By choosing the proper reservoir 
pressure, needle stroke and valve open time from valve controller, the desired deposit 
size of the droplet can be achieved.   
Compressed air was utilized as extrusion force to extrude the porogen material under 
high pressure from the reservoir in this study. Then the nozzle jet dispenses it onto the 
substrate. The nozzle jet was attached to the nozzle rack which can be moved in the x-y 
plane. When one layer is finished, the working table will move down a certain distance in 
z direction and the machine will repeat the same process to build the next layer. In this 
way, a three-dimensional sucrose skeleton was built based on the CAD model. The entire 
system was coordinated and controlled by a central computer unit. 
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5.3 Variable Analysis and Quality Control 
In order to improve the dimensional accuracy of the printed porogen and to evaluate 
the input factors, on the flow rate of the microprinting and strut size of printed porogen, 
design of experiments (DOE) a “structured, organized method for determining the 
relationship between different factors affecting a process and the output of that process” 
was used [http://www.isixsigma.com/dictionary/Design_of_Experiments_-_DOE-
41.htm]. 
5.3.1 Variable Analysis of Flow Rate 
Eight-run fractional experiments were conducted on the flow rate of the micronozzle 
system. Its nominal parameters were listed in table 5.5. Three factors representing the 
most important setting for this machine (pressure of the controller, and temperature and 
pressure of the reservoir) were selected to be investigated in this sensitivity design 
because they are all closely related to the flow rate of the nozzle.  
Table 5.5: Factors for flow rate analysis design 
Factor Nominal values 
Pressure of the Controller (psi) 80 
Temperature (°C) 100 
Pressure of the Reservoir (psi) 40 
 
The variable setting for flow rate is listed in Table 5.6. The resultant varied flow rates 
associated with the three selected factors, controller pressure, temperature and reservoir 
pressure, are listed in Table 5.7.  DATAPLOT [Fong, Filliben, deWit and Bernstein, 
2006] software package was used to analyze the variation of the flow rate associated with 
different parameter settings.  
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Table 5.6: List of variable setting for 8-run factorial experiment  
 
 
1 
Pc= Controller Pressure (psi) 
2 
T=Temperature (°C) 
3 
Pr= Reservoir 
 Pressure (psi) 
Effect  ±10 psi ±10°C ±10 psi 
 
5.3.2 Variable Analysis Results of Flow Rate 
The variation of the flow rate from the eight-run experiments, as well as that from the 
central run with nominal values, is summarized in Table 5.7. With the 10-step DOE 
analysis, factor and interaction effects were estimated in least square sense. According to 
our data, the main factor effect of reservoir pressure topped the rank list of factors. This 
means that the reservoir pressure was dominant to determine the flow rate. The second 
most important factor is the temperature of sucrose mixture. The pressure of the 
micronozzle controller had almost no effect on the flow rate.   
Figure 5.19 shows the ordered data plot for the eight experiment runs. From this 
figure we also can see the best setting was to use a higher temperature, higher reservoir 
pressure and controller pressure, if we want to maximize the flow rate. If we want to 
minimize the flow rate the best setting was using lower temperature, smaller reservoir 
pressure and controller pressure. We can also see that the X3 is the most important factor 
since the four largest flow rates (1.141, 1.245, 1.66, and 1.763) have factor X3 at +1, and 
the four smallest flow rates (0.795, 0.91 and 1) have  factor X3 at -1. Figure 5.20 shows 
the scatter plot, which also can tell us factor X3 is the most important factor, X2 is the 
lesser important factor and X1 is the least important factor because X1 has too much 
overlap to be important with respect to location.  
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 Plotted on the left of Figure 5.21 are the main effects of all three factors. And the 
halfnormal probability plot of the absolute values of effects was displayed on the right. 
From it we generated a list of ranked factor: the factor X3-pressure of the reservoir 
dominated among the three factors. As shown in Figure 5.22, a rank list of main factors 
and their interactions was obtained. The effects of X3 and X2 are listed at the top. The 
contour plot is shown in Figure 5.23 further confirms that the pressure of reservoir 
(Horizontal axis)  is the most important factor in the experiments and the temperature of 
the sucrose mixture is the second most important factor in the experiment (Vertical axis). 
Figure 5.23 also shows us the best setting for the experiment: to maximize the flow rate, 
the higher temperature and higher pressure should be used (+X2, +X3); to minimize the 
flow rate, the lower temperature and lower pressure should be used (-X2, -X3).  Figure 
5.24 also shows us the block plot, Youden plot, effects plot and cumulative residual SD 
plot which can also tell us the ranked list of factors and separate the factors into important 
and unimportant categories: 
Important: X3, X2, X23 
Unimportant: the remainder 
Table 5.7: Eight run factorial design results 
 
 
 
 
 
 
 
Run 
1 
Pc= Controller 
Pressure  
2 
T=Temperature  
3 
Pr= Reservoir 
Pressure  
Flow   
Rate 
(10-6ml/s) 
Run 0 0 0 0 1.21 
Run 1 -1 -1 -1 0.795 
Run 2 +1 -1 -1 0.795 
Run 3 -1 +1 -1 1.00 
Run 4 +1 +1 -1 0.93 
Run 5 -1 -1 +1 1.141 
Run 6 +1 -1 +1 1.245 
Run 7 -1 +1 +1 1.66 
Run 8 +1 +1 +1 1.763 
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With a two-level five-factor fractional orthogonal design of experiments, the variation 
due to parameter setting in the flow rate analysis of a micronozzle system was evaluated. 
The sensitivity analysis using DATAPLOT made it possible to locate two dominant 
factors which had the greatest impact on the flow rate of the micronozzle.  
 
 
Figure 5.19: Ordered Data Plot-Most important factor and best setting 
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Figure 5.20: Scatter Plot 
 
 
 
 
Figure 5.21: Factor effects 
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Figure 5.22: Interactive effects matrix and rank list of main factors and interactions 
 
Figure 5.23: Contour plots of factors X2 and X3 
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Figure 5.24: (A) Block plots (B) Youden Plot (C) Effects plot (D) Cumulative 
residual standard deviation plot  
5.3.3 Variable Analysis of Strut Size 
The microvalve system deposits sucrose mixture onto substrate to form sucrose strut, 
which would then be oriented to form layers of porogen. The size of the strut is the most 
important factor to control the quality of porogen. The size of the strut is a function of 
many process parameters which include the pressures of the controller and reservoir, 
temperature of the system and the speed of the nozzle. 
A B
C D
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Eight-run fractional experiments were conducted on the strut size analysis. Its 
nominal parameters are listed in table 5.8. Four factors representing the most important 
setting for the size of the printed strut (pressure of the controller, temperature and 
pressure of the reservoir and the speed of the nozzle) were selected to be investigated. 
 
5.3.4 Variable Analysis Result of Strut Size 
The variable setting of the four selected factors for strut sizes variable analysis was 
listed in Table 5.9.  The strut sizes from the eight-run experiments are summarized in 
Table 5.10. Following the same steps and procedures for flow rate analysis, factor and 
interaction effects were estimated. According to our data, the main factor effect of motor 
speed topped the rank list of factors. This means that the motor speed was dominant to 
determine the strut size. The lesser important factors are the pressures of controller and 
reservoir.  
Figure 5.25 shows the ordered data plot for the eight experimental runs. From this 
figure we can see the best setting was to use a higher motor speed, lower temperature of 
the system and smaller reservoir pressure and controller pressure, since we would like to 
get the strut size as small as possible. In our case we can not use very high motor speed 
when making the porogen, since the machine will start to vibrate under the high speed 
which will make the quality of the printed porogen worse. We can also see that X4 is the 
most important factor since the four largest strut size (550, 625, 650 and 750µm) have 
factor X4 at -1, and the four smallest strut size (200, 250, 305 and 375µm) have factor X3 
at +1. Figure 5.26 shows the scatter plot, which also can tell us factor X4 is the most 
important factor, the other factors are all the lesser important factors. Plotted in Figure 
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5.27 are the main effects of all four factors. From a list of ranked factor was achieved and 
the factor, X4-motor speed dominated among the four factors. Figure 5.28 also shows us 
the block plot, effects plot, cumulative residual SD (standard deviation) plot and the 
contour plot for the strut size which can also tell us the ranked list of factors and separate 
the factors into important and unimportant categories. 
With a two-level four-factor fractional orthogonal design of experiments, the resultant 
variation of strut size due to parameter setting in the strut size analysis of a micronozzle 
system was evaluated. The sensitivity analysis using DATAPLOT made it possible to 
locate the dominant factor which had the greatest impact on the strut size of the printed 
structure. The variable analysis suggested that the reservior pressure is the most 
important input factor for flow rate and the motor speed is the dominant factor for strut 
size. Resullts of variable analysis for flow rate and strut size gave us valuable information 
which can be used to improve the quality of our printed structure.  
Table 5.8: Factors for analysis design for strut size analysis 
Factor Nominal 
values 
Pressure of the Controller (psi) 80 
Temperature (°C) 100 
Pressure of the Reservoir (psi) 40 
Motor Speed (m/s) 0.2 
 
 
Table 5.9: List of variable setting for 8-run factorial experiment 
 
 
1 
Pc= Pressure 
of the 
Controller 
(psi) 
2 
T=Temperature 
(°C) 
3 
Pr=Pressure of 
the Reservoir 
(psi) 
4  
V=Motor Speed 
(m/s)  
Effect ±10 psi ±10°C ±10 psi ±0.1 
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Table 5.10: Eight run factorial design results for strut size 
 
Run 
1 
Pc= 
Pressure  
of the 
Controller 
(psi) 
2 
T=Temperature 
(°C) 
3 
Pr=Pressure 
of the 
Reservoir 
(psi) 
4 
V=Motor  
Speed 
(m/s) 
 
Strut 
Size 
(µm) 
Run 1 -1 -1 -1 +1 200 
Run 2 +1 -1 -1 -1 550 
Run 3 -1 +1 -1 -1 625 
Run 4 +1 +1 -1 +1 250 
Run 5 -1 -1 +1 +1 305 
Run 6 +1 -1 +1 -1 650 
Run 7 -1 +1 +1 -1 750 
Run 8 +1 +1 +1 +1 375 
 
 
Figure 5.25: Ordered data plot for strut size test 
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Figure 5.26: Scatter plot of strut size test 
 
Figure 5.27: Main effect plots for strut size tests 
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Figure 5.28: (A) Block plot (B) Effect plot (C) Cumulative residual plot (D) contour 
plot for strut size tests 
5.4 Structured Scaffold and Porogen Design for Our Sucrose SFF Machine 
In order to test the machinability of our SFF machine a scaffold was designed with 
fully interconnected voids to enable the injection of scaffold material with a syringe. By 
using a syringe, a pressure could be applied to the scaffold material to help overcome the 
frictional forces resisting material flow through the porogen. Three-dimensional models 
of the scaffolds and corresponding porogens were created using Pro/Engineer and saved 
as STL files required by the fabrication system.  
A B 
C D 
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5.4.1 Fabrication of Scaffolds  
 The designed porogen structures have been fabricated based on the CAD design. 
Figure 5.29A shows the CAD model of design porogen. The designed distance between 
each strut from center to center is 1000μm. The target strut diameter is 500μm, therefore 
the spacing between strut is 500μm in both horizontal and vertical direction. Based on the 
DOE result, a motor speed of 0.1m/s, pressure of the controller of 30 psi, pressure of the 
reservoir of 90psi and temperature of 90°C were set to fabricate the designed porogen. 
Figure 5.29B shows an image of representative porogen structures fabricated based on 
CAD design. A sucrose porogen with approximately 600μm struts and 400μm spacing 
between the struts can be made using this SFF machine.  20 layers of sucrose mixture 
were printed on the platform. It takes about 30 minutes to complete the whole porogen. 
Since the sucrose mixture solidified right after it attached the substrate at room 
temperature, therefore there is no external cooling needed. The fabricated porogen was 
stored in a sealed Petri dish and placed into the freezer until the injection. 
Following the fabrication of sucrose porogen, PCL scaffolds were fabricated as 
described in Chapter 3. Briefly, the PCL and porogen were first placed in an oven at a 
temperature of 70º C. During heating the PCL was occasionally agitated by hand and 
visually inspected for solid particles. After one hour the PCL and porogen were removed 
from the oven. The molten PCL was then quickly packed into a syringe and injected into 
the porogen by inserted the needle into the bottom of the porogen. Excess PCL was 
removed with a spatula. The PCL was then allowed to cool to room temperature. Once at 
room temperature, the filled porogen was placed in DI water to separate the sucrose 
porogen material from the PCL. The DI water in the water bath was removed and 
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replenished with new water for a minimum of three times. The PCL scaffold was then 
allowed to air-dry at room temperature. 
Followed by the removal of sucrose porogen, PCL scaffolds can beobtained. The 
smallest strut size on the scaffold is about 250µm and the porogen diameter varies from 
250µm -500µm. From our fabricated scaffold we notice that some parts of the injected 
scaffolds have been collapsed due to the melt of the porogen (about 30%). So when 
injecting the scaffolds, the temperature of the scaffold material is critical and must be 
carefully monitored.  Solvent casting of the scaffolds has been tested using PLGA in 
acetone and PCL in acetic acid. The structure can be generated without any problem, but 
they were very fragile for bone scaffolding (image not shown here).  
5.4.2 Femur Head Fabrication 
To further test the compatibility of making complicated scaffolds using the structured 
porogen method by our designed sucrose fabrication system, a femur head was fabricated 
by casting PCL into the sucrose mold. The same mold CAD model was used from our 
previous study, which has a negative shape of reconstructed femur head. Figure 5.30 
shows the picture of the sucrose femur head mold and Figure 5.31 shows the fabricated 
femur head by our sucrose machine. Because the sucrose mold absorbs the moisture very 
quickly, so the printed sucrose femur head mold has been injected immediately after the 
fabrication. Unlike the fabricated femur head by DDP and 3-DP, there is no sucrose 
residue left on the fabricated femur head made by our sucrose machine, because sucrose 
is easily dissolved in water. 
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Figure 5.29: (A) CAD design of sucrose porogen (B) Fabricated sucrose porogen 
 
 
 
1mm
A 
B 
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Figure 5.30: Fabricated sucrose femur head mold 
 
 
Figure 5.31: Various views of the injected PCL femur head using sucrose machine 
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5.5 Biocompatibility 
As we expected that the sucrose porogen made scaffold give us a much better 
biocompitability. To prove this, the following biocompatibility test has been done using 
the same methods and during the same experiments as the 3DP scaffolds (section 4.6). 
Briefly, the scaffolds have been washed thoroughly and sterilized with 70% ethanol for 
30 minutes twice at room temperature, and washed 3 times with sterile PBS. After that 
the scaffolds have been air dried in the hood for two hours. The dried scaffolds were then 
incubated with 10μg/ml Fibronectin in DMEM overnight at 37°C on an orbital shaker. 
Scaffolds were then seeded with a suspension of 0.5 million EAhy 926 cells/ml for three 
hours on an orbital shaker. Following seeding and after 48 hours culture, the samples 
were fixed in 10% buffered formalin for 15 minutes at room temperature. Then the 
scaffolds were washed using PBS for three times. Then the samples were washed once 
more with PBS and incubated with PBS containing 2µg/mL Hoechst 33258 a nuclear 
stain and rhodamine phalloidin for 30 minutes. After that the samples were washed using 
PBS for three times. 
The microscope images show the cell growing after 48 hours post-seeding in Figure 
5.32. Figure 5.32A shows the nuclei of EAhy 926 cells cultured on sucrose molded PCL 
scaffolds. We noticed that the cell attached to the scaffold. Figure 5.32B shows an 
overlay of bisbenzimide and rhodamine phalloidin staining of EAhy 926 cells cultured on 
sucrose molded PCL scaffold. Figure 5.32C shows the cells are confluent.  Staining for 
nuclei and cytoskeletal filaments of EAhy 926 cells seeded onto sucrose-molded PCL 
scaffolds demonstrated cell attachment and growth over a 48 hour culture period.  
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Figure 5.32: Fluorescent stains of cells growing on PCL scaffolds. (A) Bisbenzimide 
stain showing nuclei of EAhy 926 cells cultured on sucrose molded PCL scaffolds 
after 48 hours post-seeding, 5× (B)Overlay of bisbenzimide and rhodamine 
phalloidin staining of EAhy 926 cells cultured on PCL scaffolds for 48 hours,  10X 
(C) Cells are confluent on the sucrose molded PCL scaffold after 48 hours of seeding, 
20X  
The biocompatibility of the scaffolds was also assessed using Osteoblast cell line as 
described in chapter 4. Briefly, 7F2 cells were seeded on the scaffolds coated with 
20µg/ml collagen type I with a suspension of 1 million 7F2 cells/ml for 3 hours in on an 
orbital shaker (Belly Dancer, Stovall). Following seeding, the initial level of cell seeding 
was assessed by the Alamar BlueTM (Biosource) assay. In order to evaluate cell growth 
on the PCL scaffolds the Alamar BlueTM assay was performed again on the same samples 
at day 2, 4 and 6 post-seeding. Subsequently, the samples were fixed in 10% neutral 
A 
B C 
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buffered formalin (Fisher) for 1 hour at room temperature and stored in PBS at 4°C until 
cytological staining. For staining, the samples were washed once more with PBS and 
incubated with PBS containing 2µg/mL Hoechst 33258 (Bisbenzimide, Sigma), a nuclear 
stain and 1µg/mL rhodamine phalloidin, a cytoskeleton stain. 
The results show that 7F2 cells were able to attach to the PCL scaffolds as evidenced 
by fluorescent staining with Hoechst 33258 and rhodamine phalloidin (Figure 5.33A). 
Figure 5.33B shows that osteoblasts grew well and they were confluent after 4 days of 
post seeding on PCL scaffolds. The morphology of 7F2 cells growing on PCL scaffolds 
was examined by SEM (Figure 5.34). As seen in Figure 5.34A the cells flatten on the 
surface. We note that after 4 days post-seeding cells were everywhere over the whole 
surface. Metabolic activity measured by Alamar Blue™ revealed growth of osteoblasts 
on PCL scaffolds (Figure 5.35). The result indicatee the continuous growing and 
proliferation of the 7F2 cells on the PCL scaffolds. 
 
 
Figure 5.33: Overlay of bisbenzimide and rhodamine phalloidin staining of 7F2 cells 
cultured on PCL scaffolds (A) day 2, showed the initial attachment, 5X (B) day 4, 
showed the cells were confluent, 10X 
A B 
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Figure 5.34: SEM images of 7F2 growing onto the PCL scaffolds (A) Flattened 7F2 
cells on PCL scaffold, Scale bar = 20 μm (B) day 1 (C) day 4 
A B 
C 
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Figure 5.35: Normalized fluorescence of PCL scaffold 
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Figure 5.36: Comparison of Alamar Blue metabolic activity results for sucrose 
molded PCL scaffolds and plaster molded PCL/CaP scaffolds 
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The comparison of Alamar Blue metabolic activity results for sucrose molded PCL 
scaffolds and Plaster molded PCL/CaP scaffolds is shown in Figure 5.36. We found that 
the metabolic activity on sucrose molded PCL scaffolds grew much faster than on plaster 
molded PCL scaffolds and even can be faster than that on PCL/CaP composite scaffolds 
which proves that the residues of sucrose do not have effect on cellular function and the 
environment is benigh. This further confirms that it is necessary to design a SFF machine 
which can print biocompatible porogen materials. 
5.6 Conclusion 
Sucrose material has been selected and studied as the porogen material. The viscosity 
of the sucrose mixture has been tested and analyzed. The data has been curve fitted to 
find the parameters of power law. The flow rate measurement of sucrose machine has 
been carried out. The input factor induced variation in the flow rate and strut size of the 
microprinting system has been analyzed. The result showed that the reservoir pressure 
was the most dominant factor to determine the flow rate and the motor moving speed was 
the most dominant factor to determine the strut size. This is very important to improve 
the quality control of our fabrication system.  
A new SFF-based manufacturing system for casting custom-built sucrose bone 
scaffold porogens has been developed. The implementation of the EFD pressure-based 
extrusion will allow for the use of sucrose solutions with viscosity high enough to 
achieve solidification in an acceptable time frame for layer by layer fabrication. 
The fabrication process for PCL scaffolds has been developed and tested using the 
newly developed porogen system. The resultant scaffolds demonstrate the defined porous 
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structure designed into the sucrose porogens. Complex femur head has been fabricated.  
Biocompatibility of the resultant scaffold was tested in vitro. The sucrose molded 
PCL scaffolds were biocompatible, the cell were attached and showed better metabolic 
activity and evidence of proliferation compared with the plaster molded PCL scaffolds.
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CHAPTER 6: CONCLUSION AND FUTURE WORK 
6.1 Conclusion 
In this study, a novel structured porogen fabrication method for design and 
manufacturing of bone scaffolds and replacements has been developed. This process 
demonstrated highly efficient, reproducible fabrication of porous scaffolds. This research 
integrated biomaterials study, solid freeform fabrication technology, tissue engineering 
and biotesting into one system.  Molten Poly (ε-caprolactone) and the composite of Poly 
(ε-caprolactone) and calcium phosphate were selected as the injected biomaterials for the 
fabrication process.  This research was focused on the development of an engineering 
technique for manufacturing PCL and PCL-CaP composite tissue scaffolds by using the 
structured porogen-based manufacturing process. An SFF-based manufacturing system to 
build a sucrose skeleton which serves as the bone scaffold porogen was designed and 
presented. 
To study and develop this approach, the first part of the thesis included the 
development of a viable structured porogen-based manufacturing method using a DDP 
system. The mechanical properties of bulk PCL and PCL-CaP composite materials and 
their scaffolds were characterized. To our knowledge, this is the first time the tensile 
properties of PCL scaffolds have been tested and reported, due to the complicated testing 
procedures and the difficulty to make the long tensile testing scaffolds. In vitro 
cytocompatibility has been demonstrated for both our PCL and PCL–CaP scaffolds. With 
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fully interconnected porous structure, these scaffolds may be suitable for specific tissue 
engineering applications, such as replacement of trabecular bone, etc.  
In the second part of this study, a structured porogen-based fabrication process using 
3-DP was developed. This technique gave us more flexibility to make various scaffolds 
with more material selections. The cell-scaffold interaction was carefully investigated.  
The degradation behavior of the PCL and PCL-CaP composite materials has been studied. 
And the post-degradation mechanical properties have also been determined.  
The third part of the thesis included the development of a new SFF-based 
manufacturing system for custom-built sucrose deposition. Three nozzle systems were 
tested on the fabrication system. The selected nozzle system was then set to further 
variable study on flow rate and the strut diameter. The most dominant factors for 
controlling the quality of the fabricated scaffolds have been determined. A structured 
porogen-based fabrication process to manufacture PCL scaffolds has been developed and 
tested using the newly developed SFF machine.  In addition, endothelial hybridoma cells 
(EAhy 926) and Osteoblasts (7F2) have been cultured on the fabricated PCL scaffolds for 
validating the biocompatibility of the scaffolds.  Cell viability studies have proven that 
the fabricated scaffolds are able to maintain the EAhy 926 cells and 7F2 in a healthy state 
and grow. These results have demonstrated that the structured porogen-based fabrication 
method is capable to biomanufacturing bone tissue scaffolds. The results also showed 
that the structured porogen-based fabrication method can be used on various SFF 
machines which suggested that the structured porogen-based fabrication method might be 
a universal method on more commercially available machines.  
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6.2 Contribution 
This study developed a structured porogen-based fabrication method using the DDP, 
3-DP and custom-designed SFF manufacturing systems. By indirect building, the 
resolution of our fabricated scaffolds can be improved at least 2-fold as compared to 
directly built scaffolds made by the same kind of SFF machine. This fabrication method 
gave us the ability to use multiple biomaterials for injection molding with a single 
ubiquitous porogen. By using the bio-composite material of calcium phosphate and Poly 
(ε-caprolactone), the mechanical strength and bioactivity have been improved 
dramatically. The structured porogen-based fabrication method also provided the ability 
to make complex structures which has the exact shape and similar predefined internal 
structure of the bone tissue with sufficient mechanical strength. A new custom designed 
SFF system has been developed. By combining this novel fabrication method with new 
bio-composite materials, the bone manufacturing technology can be highly advanced. 
This research will help to build knowledge and lead to novel solutions in fabricating 
polymeric scaffolds in bone tissue engineering applications.  This research has the 
potential to advance scientific knowledge, enhance our manufacturing industry 
competitiveness and benefit our nation’s health and economy. More specifically, this 
research involves both fundamental scientific research and experimental engineering 
studies. Research on new bio-composite materials, new SFF system design and 
integration and system control of the machine has been conducted. The notion of 
combining materials to form a composite scaffold has been investigated extensively, 
There has not been, however, a similar methodology to the one described in this 
manuscript for bone scaffolds fabrication. 
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6.3 Future Work 
The structured porogen-based fabrication method is capable to make complex and 
highly porous structure. Although the preliminary development of the scaffolds presented 
in this manuscript has demonstrated the great potential of this approach to scaffold 
development, the research is not totally complete yet. The study to fabricate more 
complex structure such as trabecular bone should be finished.  
The mechanical properties of the fabricated scaffolds, although sufficient for handling 
and shaping of the scaffolds, are not as strong as would be considered ideal for a  weight-
bearing defect. More material studies should be conducted to develop composite 
materials with higher mechanical strength, such as fiber reinforced composite using 
electrospinning and PLGA/CaP composite etc. 
This fabrication method gave us the ability to make more bioactive scaffolds with 
much more flexibility. The composite scaffold is an ideal platform to deliver drugs, bone 
growth factors to promote more rapid bone healing, antibiotics to reduce the potential for 
infection at the site of injury, or angiogenic factors to promote vascularization within the 
defect site. Calcium phosphate has been used in other forums for drug delivery 
applications due to its high affinity for proteins [Kim, 2004].  This capacity to deliver 
proteins should be fully investigated. As mentioned, the potential of this composite 
material as a platform for drug or factor delivery needs to be explored. The CPC scaffolds 
with embedded growth factor (such as BMP2) and drug should be fabricated. The cell-
scaffolds interaction of the scaffolds should be carried out. An interesting research on the 
bio-composite scaffolds with CaP microsphere embedded with drug could be finished. 
Studies examining the loading and delivery of factors and other proteins will allow for 
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the full potential of this composite material. Such refined bioactive scaffolds would be 
perfect when implanting into the body with suitable geometry and regenerate tissue 
constructs at the proper locations. With the addition of factors to the scaffold healing will 
be substantially improved. 
The mechanical performance of the scaffolds fabricated by 3-DP and the newly 
developed SFF sucrose system should be investigated. The long term degradation test of 
porous scaffolds and in vivo degradation test should be carried out to understand the 
degradation behavior of the bone grafts. Future work may include a study to develop an 
equation to determine the degradation rate and mechanical strength after degradation 
given known values of geometry and porosity of the scaffolds.  
The in vivo animal test of fabricated scaffolds should be performed to further validate 
the scaffolds support the new bone ingrowth and remodeling on animal models such as 
rabbit and goat.   
 An FEA analysis on the scaffold to compute the effective elastic modulus would be 
beneficial. The failure analysis of the scaffolds should be done to validate and further 
understand the mechanical behavior of the porous scaffolds. The porosity is a major 
factor on the effective mechanical properties of the scaffolds and therefore the effect of 
the porosity should be measured.     
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APPENDIX 
Table A-1:  Compression test result of various materials: PCL, 90/10 and 80/20 
PCL-CaP 
 
Cylinder CM (MPa) UCS (MPa) 
100  275  12.4  
90-10 341 19.5 
80-20 425 24.8 
 
Table A-2:  Compression test result of scaffolds made of various materials tested by 
Instron 5543 
600µm scaffolds CM (MPa) UCS(MPa) 
100 43.97±3.15 2.777±0.26 
90-10 46.6±6.49 3.21±0.53 
80-20 61.4±3.44 3.702±0.207 
 
Table A-3: Compression test results for various scaffolds tested by Tinius Olsen 
H25KT 
 
Material UTS (MPa) E (MPa) Yield Stress 
(MPa) 
PCL 3.150±0.557 45.672±3.798 2.573±0.727 
90/10 3.523±0.662 57.166±8.091 3.049±0.716 
80/20 4.107±0.959 71.511±1.995 3.703±0.871 
 
Table A-4: HPLC results for PCL (in DMEM) 
Degradation time (weeks) Mn Molecular weight (g/mol) 
Week 2 25485 27460 
Week 4 24658 26753 
Week 6 23989 26645 
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Table A-5: HPLC results for PCL (in DMEM with 10%FBS) 
Degradation time (weeks) Mn Molecular weight (g/mol) 
Week 2 25347 27048 
Week 4 25347 26695 
Week 6 23339 26533 
 
Table A-6: Samples in DMEM removed at Week 2 
PCL 90/10 80/20 
     Sample 1 2 3 4 1 2 3 4 1 2 3 
Before (g) 0.317 0.227 0.297 0.266 0.306 0.245 0.237 0.238 0.349 0.214 0.302 
After (g) 0.316 0.226 0.296 0.265 0.300 0.240 0.233 0.233 0.341 0.208 0.295 
Mass Loss (g) 0.001 0.001 0.001 0.001 0.006 0.005 0.004 0.005 0.008 0.006 0.007 
Normalized 
Mass Loss (%) 0.315 0.440 0.337 0.376 1.960 2.041 1.688 2.101 2.292 2.804 2.318 
Mean±STD 0.367±0.055 1.948±0.182 2.471±0.288 
 
Table A-7: Samples in DMEM with 10% serum removed at Week 2  
 
Table A-8: Samples in DMEM removed at Week 4 
PCL 90/10 80/20 
    Sample 1 2 3 1 2 3 1 2 3 
Before (g) 0.272 0.326 0.227 0.314 0.312 0.247 0.309 0.388 0.254 
After (g) 0.266 0.320 0.221 0.304 0.303 0.239 0.298 0.375 0.244 
Mass Loss (g) 0.006 0.006 0.006  0.100 0.009 0.008 0.011 0.013 0.010 
Normalized 
Mass Loss 2.206 1.840 2.643 3.185 2.885 3.239 3.560 3.351 3.937 
Mean±STD 2.230±0.402 3.103±0.190 3.616±0.297 
 
Table A-9: Samples in DMEM with 10% FBS removed at Week 4 
PCL 90/10 80/20 
     Sample 1 2 3 1 2 3 1 2 3 
Before (g) 0.303 0.298 0.295 0.286 0.289 0.277 0.353 0.348 0.287 
After (g) 0.294 0.288 0.287 0.275 0.277  0.266 0.339 0.332 0.274 
Mass Loss (g) 0.009 0.010 0.008 0.011 0.012 0.011 0.014 0.016 0.013 
Normalized 
Mass Loss 2.970 3.356 2.711 3.846 4.152 3.971 3.966 4.597 4.530 
Mean±STD 3.012±0.325 3.990±0.154 4.364±0.347 
PCL 90/10 80/20 
Sample 1 2 3 4 1 2 3 4 1 2 3 4 
Before (g) 0.257 0.306 0.282 0.295 0.304 0.290 0.283 0.280 0.378 0.290 0.294 0.205 
After (g) 0.256 0.305 0.281 0.294 0.296 0.283 0.276 0.274 0.369 0.282 0.286 0.198 
Mass Loss (g) 0.001 0.001 0.001 0.001 0.008 0.007 0.007 0.006 0.009 0.008 0.008 0.007 
Normalized 
Mass Loss (%) 0.389 0.327 0.355 0.339 2.632 2.414 2.473 2.143 2.381 2.759 2.721 3.414 
Mean±STD 0.353±0.027 2.416±0.204 2.819±0.432 
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Table A-10: Samples in DMEM removed at Week 6 
PCL 90/10 80/20 
Sample 1 2 3 1 2 3 1 2 3 
Before (g) 0.263 0.247 0.229 0.348 0.265 0.282 0.331 0.249 0.263 
After (g) 0.254 0.239 0.221 0.335 0.255 0.270 0.317 0.236 0.249 
Mass Loss (g) 0.009 0.008 0.007 0.013 0.010 0.012 0.015 0.013 0.014 
Normalized 
Mass Loss 3.422 3.239 3.057 3.736 3.774 4.255 4.532 5.220 5.323 
Mean±STD 3.239±0.183 3.921±0.289 5.025±0.430 
Table A-11: Samples in DMEM with 10% FBS removed at Week 6 
PCL 90/10 80/20 
     Sample 1 2 3 1 2 3 1 2 3 
Before (g) 0.294 0.263 0.257 0.322 0.281 0.286 0.324 0.283 0.295 
After (g) 0.282 0.252 0.247 0.307 0.278 0.262 0.306 0.267 0.280 
Mass Loss (g) 0.012 0.011 0.010 0.015 0.013 0.014 0.018 0.016 0.015 
Normalized 
Mass Loss 4.082 4.183 3.891 4.658 4.626 4.895 5.556 5.654 5.085 
Mean±STD 4.052±0.148 4.726±0.147 5.431±0.304 
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